rocketchoo2的个人主页 - 老虎社区

rocketchoo2

rocketchoo2

暂无个人介绍

IP属地：未知

41关注

4粉丝

0主题

0勋章

2021-07-23

$Gaotu Techedu Inc.(GOTU)$Can't even describe how I feel now. :( X 10000000

2021-11-18

Finally!!! Its time for it to shine!

Novavax shares jumped 5% in premarket trading<blockquote>Novavax股价在盘前交易中上涨5%</blockquote>

2021-12-19

Nova!!!!

Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir跻身医疗保健股涨幅之列，辉瑞(Pfizer)创下十年来最佳涨幅</blockquote>

2021-06-04

$Tiger Brokers(TIGR)$Thank you. Thank you.

2021-12-27

Yes pleaseeeeeee.

Plug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla<blockquote>普拉格能源的交易就像一只故事股票，闻起来像早期的特斯拉</blockquote>

2021-11-30

Vaccine stock rally tonight 🔥🙏💉

Moderna CEO says vaccines likely less effective against Omicron<blockquote>Moderna首席执行官表示疫苗对奥密克戎病毒的效果可能较差</blockquote>

2021-06-23

$Stem Inc.(STEM)$[财迷] [财迷] [财迷]

2021-11-19

Holding on....especially with the opening of themeparks in the near future.

Disney Stock: Jim Cramer Says Selling Now Is Shortsighted<blockquote>迪士尼股票：吉姆·克莱默表示现在出售是短视的</blockquote>

2021-09-09

$Tiger Brokers(TIGR)$waiting for report to be released tmr. Hang in there! [吃瓜]

2021-12-19

Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?

Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3574086622886620","uuid":"3574086622886620","gmtCreate":1614185144348,"gmtModify":1622818829225,"name":"rocketchoo2","pinyin":"rocketchoo2","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":41,"tweetSize":21,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.05%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":696300104,"gmtCreate":1640612840415,"gmtModify":1640612840516,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Yes pleaseeeeeee.","listText":"Yes pleaseeeeeee.","text":"Yes pleaseeeeeee.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696300104","repostId":"1111088353","repostType":4,"repost":{"id":"1111088353","kind":"news","pubTimestamp":1640610579,"share":"https://www.laohu8.com/m/news/1111088353?lang=zh_CN&edition=full","pubTime":"2021-12-27 21:09","market":"us","language":"en","title":"Plug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla<blockquote>普拉格能源的交易就像一只故事股票，闻起来像早期的特斯拉</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111088353","media":"Seeking Alpha","summary":"Summary\n\nThe stock of Plug Power enjoyed some great appreciation during the last years, which seems ","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>The stock of Plug Power enjoyed some great appreciation during the last years, which seems hard to explain when purely looking at the fundamentals.</li>  <li>The stock performance of almost 2,000% over the last 5 years is an illustration of the increased momentum of the hydrogen market.</li>  <li>Plug Power shows some important parallels with Tesla, on which I will elaborate in this article.</li>  <li>If the sentiment can remain positive while growth continues, short-term fundamentals might not matter much.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80405c7f3988b402597ce18944c15c47\" tg-width=\"1536\" tg-height=\"683\" width=\"100%\" height=\"auto\"><span>http://www.fotogestoeber.de/iStock via Getty Images</span></p><p><blockquote><ul><li>普拉格能源的股票在过去几年中大幅升值，如果纯粹从基本面来看，这似乎很难解释。</li><li>过去5年近2,000%的股票表现说明了氢市场的增长势头。</li><li>普拉格能源与特斯拉有一些重要的相似之处，我将在本文中详细阐述。</li><li>如果在增长持续的同时，市场情绪能够保持积极，那么短期基本面可能并不重要。</li></ul><p class=\"t-img-caption\"><span>http://www.fotogestoeber.de/iStock来自Getty Images</span></p></blockquote></p><p> How can a company in a niche sector which has continuously burned cash over the years have a market capitalization of over $17B? Plug Power (PLUG) is a pure-play hydrogen company that has yet to run a profit. Still, the stock has returned a total of almost 2,000% over the last 5 years.</p><p><blockquote>一家多年来不断烧钱的利基行业公司，市值怎么可能超过170亿美元？普拉格能源（PLUG）是一家纯粹的氢能公司，尚未盈利。尽管如此，该股在过去5年中的总回报率仍接近2,000%。</blockquote></p><p> In this article, I will investigate the promises and expectations behind Plug Power and compare the stock to another stock with large promises: Tesla (TSLA).</p><p><blockquote>在本文中，我将调查普拉格能源背后的承诺和期望，并将该股票与另一只具有巨大承诺的股票：特斯拉（TSLA）进行比较。</blockquote></p><p> <b>Great stock performance, but a lofty valuation</b></p><p><blockquote><b>股票表现出色，但估值很高</b></blockquote></p><p> Plug Power has behaved somewhat like a battleground stock during the last couple of years. Ever since the&nbsp;2014 hydrogen rally, Plug Power has remained a stock that lured investors who believe in the technology, but also attracted quite some short-sellers, judged by its current short interest of almost 10 percent.</p><p><blockquote>过去几年，普拉格能源的表现有点像战场股票。自2014年氢能反弹以来，普拉格能源一直是一只吸引相信该技术的投资者的股票，但从其目前近10%的空头兴趣来看，也吸引了相当多的卖空者。</blockquote></p><p> More recently, the stock has experienced a huge liftoff, most likely fueled by the announcement of the&nbsp;Build Back Better Plan&nbsp;of president Biden. Since then, Plug Power's stock more or less came back to earth again, even though it is still trading at a very high price to sales ratio.</p><p><blockquote>最近，该股经历了大幅上涨，很可能是拜登总统宣布的重建更好计划推动的。从那时起，普拉格能源的股票或多或少又回到了现实，尽管它的市销率仍然非常高。</blockquote></p><p> Please review the following charts for illustration of these metrics:</p><p><blockquote>请查看以下图表，了解这些指标的说明：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3664f73c0fc1fcd1b2673c8df4701be5\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Plug Power development of share price, short interest, and price to sales ratio during the last 10 years. (source: YCharts)</i></p><p><blockquote><i>过去10年股价、空头权益和市销率的普拉格能源发展。（来源：YCharts）</i></blockquote></p><p> A true story stock</p><p><blockquote>真实故事股票</blockquote></p><p>   A story stock refers to a company's shares whose value reflects expected outperformance, the culmination of some new innovation, or favorable press coverage, rather than its market value being solely based on fundamentals like assets and income (Source:Investopedia)  A story can be a powerful backbone of stock performance. Though the hydrogen market is still somewhat of a niche, the story of Plug is one of great expectations.</p><p><blockquote>故事股票是指一家公司的股票，其价值反映了预期的优异表现、一些新创新的高潮或有利的新闻报道，而不是其市值仅基于资产和收入等基本面（来源：Investopedia）故事可以是股票表现的强大支柱。尽管氢市场在某种程度上仍然是一个利基市场，但Plug的故事却令人充满期待。</blockquote></p><p> Hydrogen is indeed a promising market. Let us explore the&nbsp;potential benefits and promises&nbsp;of hydrogen:</p><p><blockquote>氢确实是一个前景广阔的市场。让我们探索氢的潜在好处和前景：</blockquote></p><p> <ul>  <li>Green hydrogen can help to decarbonize multiple sectors in which it is difficult to reduce emissions, like long-haul transport, chemical industry, and iron and steel production.</li>  <li>Green hydrogen can contribute to improvements in air quality and energy security.</li>  <li>Hydrogen can be produced using a multitude of sources, such as renewables, nuclear energy, natural gas, oil, and even coal. Transportation can be done using pipelines or in liquefied form. It can be transformed into electricity very easily.</li>  <li>Hydrogen can play an important role in coping with the variable outputs of renewable energy sources. Wind and solar energy output are not always in sync with electricity demand, and hydrogen can be used as a store or energy in times when renewable energy production outpaces demand. These storages can be used in times when renewable energy output is lower than demand, and can be saved for days, weeks, or even months, and can even be transported over long distances if needed.</li>  <li>Clean hydrogen is currently used in an expanding number of projects worldwide, and it seems to be a matter of time before the technology is scaled up and costs are brought down.</li>  <li>Currently, hydrogen is mostly used in oil refining processes and for the production of fertilizers. Sectors in which it is still hardly used, like transport, buildings, and power generation seem large untapped markets.</li> </ul> As such, hydrogen could play an important supporting role in the renewable energy transition, supplying markets that are difficult or impractical to reach for batteries.</p><p><blockquote><ul><li>绿色氢可以帮助长途运输、化学工业和钢铁生产等难以减排的多个行业脱碳。</li><li>绿色氢能有助于改善空气质量和能源安全。</li><li>氢气可以使用多种来源生产，例如可再生能源、核能、天然气、石油甚至煤炭。运输可以使用管道或液化形式进行。它可以很容易地转化为电能。</li><li>氢可以在应对可再生能源的可变输出方面发挥重要作用。风能和太阳能输出并不总是与电力需求同步，当可再生能源产量超过需求时，氢可以用作储存或能源。这些存储可以在可再生能源输出低于需求的时候使用，可以保存几天、几周甚至几个月，如果需要，甚至可以长距离运输。</li><li>清洁氢目前在全球越来越多的项目中使用，该技术的扩大和成本的降低似乎只是时间问题。</li><li>目前，氢气主要用于炼油过程和化肥生产。交通、建筑和发电等仍然很少使用它的行业似乎是巨大的未开发市场。</li></ul>因此，氢可以在可再生能源转型中发挥重要的支持作用，供应电池难以或不切实际的市场。</blockquote></p><p> Plug Power has a focused strategy, is already an established business in the hydrogen market, and has a large growing number of commercial relationships. This might mean that the company has the potential to become one of the first pure-play hydrogen companies which&nbsp;could transition&nbsp;from a story stock to a large positive cash flow company.</p><p><blockquote>普拉格能源拥有专注的战略，已经是氢市场的成熟企业，并且拥有大量不断增长的商业关系。这可能意味着该公司有潜力成为首批纯氢公司之一，可以从故事股票转型为大型正现金流公司。</blockquote></p><p></p><p> The commercial relationships and collaborations which Plug is undertaking are among the most important future drivers of growth for the company, among which are collaborations with&nbsp;Airbus(OTCPK:EADSF),Phillips66(PSX),Acciona(OTCPK:ACXIF),BAE Systems(OTCPK:BAESF),Baker Hughes(BKR), and&nbsp;Brookfield Renewable(BEP).</p><p><blockquote>Plug正在开展的商业关系和合作是公司未来最重要的增长动力之一，其中包括与空中客车公司(OTCPK：EADSF)、Phillips66(PSX)、Acciona(OTCPK：ACXIF)、BAE Systems(OTCPK：BAESF)、贝克休斯(BKR)和布鲁克菲尔德可再生能源公司(BEP)的合作。</blockquote></p><p> <b>Parallels with early-stage Tesla</b></p><p><blockquote><b>与早期特斯拉的相似之处</b></blockquote></p><p> I think it is very interesting to compare Plug Power with Tesla. This seems to make sense since they were both one of the largest first movers in big markets: EV for Tesla and hydrogen for Plug. Tesla also was (and might still be) a good example of a story stock, with their large promises of electrifying the automotive sector.</p><p><blockquote>我认为将普拉格能源与特斯拉进行比较是非常有趣的。这似乎是有道理的，因为他们都是大市场中最大的先行者之一：电动汽车代表特斯拉，氢能代表插电式汽车。特斯拉也是（并且可能仍然是）故事股票的一个很好的例子，他们在汽车行业电气化方面有着巨大的前景。</blockquote></p><p> Let us look at the share price development, short percentage, and PS ratio of Tesla during the period from 2010 to the end of 2019:</p><p><blockquote>让我们看看2010年至2019年底期间特斯拉的股价发展、空头百分比和PS比率：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d9911b4514f3c0a566dffcd28c188e1c\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Tesla's development of share price, short interest, and price to sales ratio between 2010 and the end of 2019. (source: YCharts)</i></p><p><blockquote><i>2010年至2019年底特斯拉股价、空头权益和市销率的发展情况。（来源：YCharts）</i></blockquote></p><p> There are some noticeable differences between the share price development of Plug Power and an earlier-stage Tesla. First of all, from 2012 to 2019, the percentage of Tesla's stock sold short has consistently oscillated around 20%. Plug Power is already under 10% and has moved around 15% for the largest part of the last couple of years. But the biggest difference between the two stocks is probably that the price to sales ratio of Tesla has trended down quickly between 2010 and the end of 2019. Since Plug Power's price to sales ratio is heavily influenced by its recent outlier, let us take a look at a graph comparing the two between 2010 and September of this year:</p><p><blockquote>普拉格能源的股价发展与早期特斯拉有一些明显的差异。首先，从2012年到2019年，特斯拉股票被卖空的比例一直在20%左右振荡。普拉格能源已经低于10%，并且在过去几年的大部分时间里一直在15%左右波动。但两只股票最大的区别可能是，特斯拉的市销率在2010年至2019年底期间呈快速下降趋势。由于普拉格能源的市销率受到近期异常值的严重影响，让我们看一下2010年至今年9月两者的比较图表：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d46be5e658002b2f45b8c5ca43559b93\" tg-width=\"635\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Tesla and Plug Power development price to sales ratio between 2010 and September 2021. (source: YCharts)</i></p><p><blockquote><i>2010年至2021年9月期间特斯拉和普拉格能源开发的市销率。（来源：YCharts）</i></blockquote></p><p> These two ratios look to have a lot more in common. But as we can already see, after the end of 2019, Tesla's price to sales ratio went sharply up again. The reason for this was, of course, the almost unprecedented skyrocketing of the Tesla stock starting from the end of 2019. This is illustrated in the following graph of what happened to Tesla shares from September 2019 until now:</p><p><blockquote>这两个比率看起来有更多的共同点。但正如我们已经看到的，2019年底后，特斯拉的市销率再次大幅上升。其原因当然是特斯拉股价从2019年底开始几乎史无前例的暴涨。下图显示了从2019年9月至今特斯拉股票的情况：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d29232b1b3d9ff99e1edb6e4eac33901\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Development of Tesla share price, short interest, and price to sales ratio between September 2019 and now. (source: YCharts)</i></p><p><blockquote><i>2019年9月至今特斯拉股价、空头利息和市销率的发展。（来源：YCharts）</i></blockquote></p><p> As the stock price of Tesla skyrocketed, the short percentage went down sharply and the PS ratio went up.</p><p><blockquote>随着特斯拉股价暴涨，空头百分比大幅下降，PS比率上升。</blockquote></p><p> The million-dollar question is of course, could this happen to Plug Power as well? Technically, if we look solely at the metrics of Plug compared with the metrics of Tesla just before the stock price exploded, the P/S ratio of Plug is still much too high to expect that the stock could go in the same direction in short order. I also believe that fundamentally, Plug would need to experience some serious growth for the stock to be able to regain its recent upward momentum.</p><p><blockquote>当然，最重要的问题是，这种情况也会发生在普拉格能源身上吗？从技术上讲，如果我们仅将Plug的指标与股价爆炸前特斯拉的指标进行比较，Plug的市盈率仍然太高，无法预期该股在短期内会朝着同样的方向发展。我还认为，从根本上讲，Plug需要经历一些大幅增长，该股才能恢复近期的上涨势头。</blockquote></p><p> Another similarity between Plug and Tesla is that negative earnings surprises have been many at Plug recently, this happened to Tesla as well&nbsp;in 2019. At the time, Tesla's stock price was not negatively impacted by those surprises. Currently, the market seems to shake off Plug Power's results as well, though the stock did drop by more than 50% since last year.</p><p><blockquote>Plug和特斯拉之间的另一个相似之处是，最近Plug的盈利出现了很多负面意外，2019年特斯拉也发生了这种情况。当时，特斯拉的股价并未受到这些意外的负面影响。目前，市场似乎也摆脱了普拉格能源的业绩，尽管该股自去年以来确实下跌了50%以上。</blockquote></p><p> <b>Currently, expectations still beat metrics</b></p><p><blockquote><b>目前，预期仍然超过指标</b></blockquote></p><p> Like Tesla, Plug's share price seems to be governed more by growth expectations than by current stock metrics. This<i>could</i>mean that Plug would be able to go in the same direction as Tesla if enough investors remain convinced that their business model is profitable for the future and if growth can be expected to continue. Also, as for Tesla, in the long term, fundamental metrics will need to correspond with their lofty valuations. This means that the companies will need to deliver on their expectations.</p><p><blockquote>与特斯拉一样，Plug的股价似乎更多地取决于增长预期，而不是当前的股票指标。这个<i>可以</i>这意味着，如果有足够多的投资者仍然相信他们的商业模式在未来是有利可图的，并且可以预期增长将继续下去，那么Plug将能够朝着与特斯拉相同的方向发展。此外，对于特斯拉来说，从长远来看，基本面指标需要与其高估值相对应。这意味着公司需要实现他们的期望。</blockquote></p><p> <b>These are some very large ifs.</b></p><p><blockquote><b>这些都是非常大的假设。</b></blockquote></p><p> Of course, the hydrogen market is different from the EV market. Since the energy density of hydrogen is very high, it will likely be able to compete in markets where batteries still have issues, like long-haul transport. On the other hand, on an energy efficiency level, batteries have some large benefits over hydrogen for smaller transport purposes. On aggregate, I am skeptical about hydrogen being able to be a strong competitor in the EV space, but it will likely play a large role in other modes of transport, as in energy storage.</p><p><blockquote>当然，氢市场不同于电动汽车市场。由于氢的能量密度非常高，它很可能能够在电池仍然存在问题的市场中竞争，例如长途运输。另一方面，在能源效率水平上，对于较小的运输目的，电池比氢气有一些很大的好处。总的来说，我对氢能否成为电动汽车领域的强有力竞争对手持怀疑态度，但它可能会在其他交通方式中发挥重要作用，例如在储能方面。</blockquote></p><p></p><p> Plug Power has been trading like a stock for believers, which shows some strong parallels with Tesla. Theoretically, the stock could follow the same direction as Tesla did, but this is anyone's guess and I believe it would take more growth to continue its upward momentum.</p><p><blockquote>普拉格能源的交易就像信徒的股票一样，这与特斯拉有一些很强的相似之处。理论上，该股可能会遵循与特斯拉相同的方向，但这是任何人的猜测，我相信需要更多的增长才能继续其上涨势头。</blockquote></p><p> Plug Power is a promising business, but the company had some bad results recently. This did not impact the stock much during the last 2 years. In the short term, the stock price seems to be most impacted by sentiment and not by fundamentals. This makes it a wonderful stock for traders, but as a long-term investor, I am staying on the sidelines.</p><p><blockquote>普拉格能源是一项有前途的业务，但该公司最近业绩不佳。在过去的两年里，这对股票没有太大影响。短期内，股价似乎受情绪影响最大，而不是基本面。这使得它成为交易者的绝佳股票，但作为长期投资者，我仍持观望态度。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Plug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla<blockquote>普拉格能源的交易就像一只故事股票，闻起来像早期的特斯拉</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPlug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla<blockquote>普拉格能源的交易就像一只故事股票，闻起来像早期的特斯拉</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-27 21:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>The stock of Plug Power enjoyed some great appreciation during the last years, which seems hard to explain when purely looking at the fundamentals.</li>  <li>The stock performance of almost 2,000% over the last 5 years is an illustration of the increased momentum of the hydrogen market.</li>  <li>Plug Power shows some important parallels with Tesla, on which I will elaborate in this article.</li>  <li>If the sentiment can remain positive while growth continues, short-term fundamentals might not matter much.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80405c7f3988b402597ce18944c15c47\" tg-width=\"1536\" tg-height=\"683\" width=\"100%\" height=\"auto\"><span>http://www.fotogestoeber.de/iStock via Getty Images</span></p><p><blockquote><ul><li>普拉格能源的股票在过去几年中大幅升值，如果纯粹从基本面来看，这似乎很难解释。</li><li>过去5年近2,000%的股票表现说明了氢市场的增长势头。</li><li>普拉格能源与特斯拉有一些重要的相似之处，我将在本文中详细阐述。</li><li>如果在增长持续的同时，市场情绪能够保持积极，那么短期基本面可能并不重要。</li></ul><p class=\"t-img-caption\"><span>http://www.fotogestoeber.de/iStock来自Getty Images</span></p></blockquote></p><p> How can a company in a niche sector which has continuously burned cash over the years have a market capitalization of over $17B? Plug Power (PLUG) is a pure-play hydrogen company that has yet to run a profit. Still, the stock has returned a total of almost 2,000% over the last 5 years.</p><p><blockquote>一家多年来不断烧钱的利基行业公司，市值怎么可能超过170亿美元？普拉格能源（PLUG）是一家纯粹的氢能公司，尚未盈利。尽管如此，该股在过去5年中的总回报率仍接近2,000%。</blockquote></p><p> In this article, I will investigate the promises and expectations behind Plug Power and compare the stock to another stock with large promises: Tesla (TSLA).</p><p><blockquote>在本文中，我将调查普拉格能源背后的承诺和期望，并将该股票与另一只具有巨大承诺的股票：特斯拉（TSLA）进行比较。</blockquote></p><p> <b>Great stock performance, but a lofty valuation</b></p><p><blockquote><b>股票表现出色，但估值很高</b></blockquote></p><p> Plug Power has behaved somewhat like a battleground stock during the last couple of years. Ever since the&nbsp;2014 hydrogen rally, Plug Power has remained a stock that lured investors who believe in the technology, but also attracted quite some short-sellers, judged by its current short interest of almost 10 percent.</p><p><blockquote>过去几年，普拉格能源的表现有点像战场股票。自2014年氢能反弹以来，普拉格能源一直是一只吸引相信该技术的投资者的股票，但从其目前近10%的空头兴趣来看，也吸引了相当多的卖空者。</blockquote></p><p> More recently, the stock has experienced a huge liftoff, most likely fueled by the announcement of the&nbsp;Build Back Better Plan&nbsp;of president Biden. Since then, Plug Power's stock more or less came back to earth again, even though it is still trading at a very high price to sales ratio.</p><p><blockquote>最近，该股经历了大幅上涨，很可能是拜登总统宣布的重建更好计划推动的。从那时起，普拉格能源的股票或多或少又回到了现实，尽管它的市销率仍然非常高。</blockquote></p><p> Please review the following charts for illustration of these metrics:</p><p><blockquote>请查看以下图表，了解这些指标的说明：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3664f73c0fc1fcd1b2673c8df4701be5\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Plug Power development of share price, short interest, and price to sales ratio during the last 10 years. (source: YCharts)</i></p><p><blockquote><i>过去10年股价、空头权益和市销率的普拉格能源发展。（来源：YCharts）</i></blockquote></p><p> A true story stock</p><p><blockquote>真实故事股票</blockquote></p><p>   A story stock refers to a company's shares whose value reflects expected outperformance, the culmination of some new innovation, or favorable press coverage, rather than its market value being solely based on fundamentals like assets and income (Source:Investopedia)  A story can be a powerful backbone of stock performance. Though the hydrogen market is still somewhat of a niche, the story of Plug is one of great expectations.</p><p><blockquote>故事股票是指一家公司的股票，其价值反映了预期的优异表现、一些新创新的高潮或有利的新闻报道，而不是其市值仅基于资产和收入等基本面（来源：Investopedia）故事可以是股票表现的强大支柱。尽管氢市场在某种程度上仍然是一个利基市场，但Plug的故事却令人充满期待。</blockquote></p><p> Hydrogen is indeed a promising market. Let us explore the&nbsp;potential benefits and promises&nbsp;of hydrogen:</p><p><blockquote>氢确实是一个前景广阔的市场。让我们探索氢的潜在好处和前景：</blockquote></p><p> <ul>  <li>Green hydrogen can help to decarbonize multiple sectors in which it is difficult to reduce emissions, like long-haul transport, chemical industry, and iron and steel production.</li>  <li>Green hydrogen can contribute to improvements in air quality and energy security.</li>  <li>Hydrogen can be produced using a multitude of sources, such as renewables, nuclear energy, natural gas, oil, and even coal. Transportation can be done using pipelines or in liquefied form. It can be transformed into electricity very easily.</li>  <li>Hydrogen can play an important role in coping with the variable outputs of renewable energy sources. Wind and solar energy output are not always in sync with electricity demand, and hydrogen can be used as a store or energy in times when renewable energy production outpaces demand. These storages can be used in times when renewable energy output is lower than demand, and can be saved for days, weeks, or even months, and can even be transported over long distances if needed.</li>  <li>Clean hydrogen is currently used in an expanding number of projects worldwide, and it seems to be a matter of time before the technology is scaled up and costs are brought down.</li>  <li>Currently, hydrogen is mostly used in oil refining processes and for the production of fertilizers. Sectors in which it is still hardly used, like transport, buildings, and power generation seem large untapped markets.</li> </ul> As such, hydrogen could play an important supporting role in the renewable energy transition, supplying markets that are difficult or impractical to reach for batteries.</p><p><blockquote><ul><li>绿色氢可以帮助长途运输、化学工业和钢铁生产等难以减排的多个行业脱碳。</li><li>绿色氢能有助于改善空气质量和能源安全。</li><li>氢气可以使用多种来源生产，例如可再生能源、核能、天然气、石油甚至煤炭。运输可以使用管道或液化形式进行。它可以很容易地转化为电能。</li><li>氢可以在应对可再生能源的可变输出方面发挥重要作用。风能和太阳能输出并不总是与电力需求同步，当可再生能源产量超过需求时，氢可以用作储存或能源。这些存储可以在可再生能源输出低于需求的时候使用，可以保存几天、几周甚至几个月，如果需要，甚至可以长距离运输。</li><li>清洁氢目前在全球越来越多的项目中使用，该技术的扩大和成本的降低似乎只是时间问题。</li><li>目前，氢气主要用于炼油过程和化肥生产。交通、建筑和发电等仍然很少使用它的行业似乎是巨大的未开发市场。</li></ul>因此，氢可以在可再生能源转型中发挥重要的支持作用，供应电池难以或不切实际的市场。</blockquote></p><p> Plug Power has a focused strategy, is already an established business in the hydrogen market, and has a large growing number of commercial relationships. This might mean that the company has the potential to become one of the first pure-play hydrogen companies which&nbsp;could transition&nbsp;from a story stock to a large positive cash flow company.</p><p><blockquote>普拉格能源拥有专注的战略，已经是氢市场的成熟企业，并且拥有大量不断增长的商业关系。这可能意味着该公司有潜力成为首批纯氢公司之一，可以从故事股票转型为大型正现金流公司。</blockquote></p><p></p><p> The commercial relationships and collaborations which Plug is undertaking are among the most important future drivers of growth for the company, among which are collaborations with&nbsp;Airbus(OTCPK:EADSF),Phillips66(PSX),Acciona(OTCPK:ACXIF),BAE Systems(OTCPK:BAESF),Baker Hughes(BKR), and&nbsp;Brookfield Renewable(BEP).</p><p><blockquote>Plug正在开展的商业关系和合作是公司未来最重要的增长动力之一，其中包括与空中客车公司(OTCPK：EADSF)、Phillips66(PSX)、Acciona(OTCPK：ACXIF)、BAE Systems(OTCPK：BAESF)、贝克休斯(BKR)和布鲁克菲尔德可再生能源公司(BEP)的合作。</blockquote></p><p> <b>Parallels with early-stage Tesla</b></p><p><blockquote><b>与早期特斯拉的相似之处</b></blockquote></p><p> I think it is very interesting to compare Plug Power with Tesla. This seems to make sense since they were both one of the largest first movers in big markets: EV for Tesla and hydrogen for Plug. Tesla also was (and might still be) a good example of a story stock, with their large promises of electrifying the automotive sector.</p><p><blockquote>我认为将普拉格能源与特斯拉进行比较是非常有趣的。这似乎是有道理的，因为他们都是大市场中最大的先行者之一：电动汽车代表特斯拉，氢能代表插电式汽车。特斯拉也是（并且可能仍然是）故事股票的一个很好的例子，他们在汽车行业电气化方面有着巨大的前景。</blockquote></p><p> Let us look at the share price development, short percentage, and PS ratio of Tesla during the period from 2010 to the end of 2019:</p><p><blockquote>让我们看看2010年至2019年底期间特斯拉的股价发展、空头百分比和PS比率：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d9911b4514f3c0a566dffcd28c188e1c\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Tesla's development of share price, short interest, and price to sales ratio between 2010 and the end of 2019. (source: YCharts)</i></p><p><blockquote><i>2010年至2019年底特斯拉股价、空头权益和市销率的发展情况。（来源：YCharts）</i></blockquote></p><p> There are some noticeable differences between the share price development of Plug Power and an earlier-stage Tesla. First of all, from 2012 to 2019, the percentage of Tesla's stock sold short has consistently oscillated around 20%. Plug Power is already under 10% and has moved around 15% for the largest part of the last couple of years. But the biggest difference between the two stocks is probably that the price to sales ratio of Tesla has trended down quickly between 2010 and the end of 2019. Since Plug Power's price to sales ratio is heavily influenced by its recent outlier, let us take a look at a graph comparing the two between 2010 and September of this year:</p><p><blockquote>普拉格能源的股价发展与早期特斯拉有一些明显的差异。首先，从2012年到2019年，特斯拉股票被卖空的比例一直在20%左右振荡。普拉格能源已经低于10%，并且在过去几年的大部分时间里一直在15%左右波动。但两只股票最大的区别可能是，特斯拉的市销率在2010年至2019年底期间呈快速下降趋势。由于普拉格能源的市销率受到近期异常值的严重影响，让我们看一下2010年至今年9月两者的比较图表：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d46be5e658002b2f45b8c5ca43559b93\" tg-width=\"635\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Tesla and Plug Power development price to sales ratio between 2010 and September 2021. (source: YCharts)</i></p><p><blockquote><i>2010年至2021年9月期间特斯拉和普拉格能源开发的市销率。（来源：YCharts）</i></blockquote></p><p> These two ratios look to have a lot more in common. But as we can already see, after the end of 2019, Tesla's price to sales ratio went sharply up again. The reason for this was, of course, the almost unprecedented skyrocketing of the Tesla stock starting from the end of 2019. This is illustrated in the following graph of what happened to Tesla shares from September 2019 until now:</p><p><blockquote>这两个比率看起来有更多的共同点。但正如我们已经看到的，2019年底后，特斯拉的市销率再次大幅上升。其原因当然是特斯拉股价从2019年底开始几乎史无前例的暴涨。下图显示了从2019年9月至今特斯拉股票的情况：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d29232b1b3d9ff99e1edb6e4eac33901\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Development of Tesla share price, short interest, and price to sales ratio between September 2019 and now. (source: YCharts)</i></p><p><blockquote><i>2019年9月至今特斯拉股价、空头利息和市销率的发展。（来源：YCharts）</i></blockquote></p><p> As the stock price of Tesla skyrocketed, the short percentage went down sharply and the PS ratio went up.</p><p><blockquote>随着特斯拉股价暴涨，空头百分比大幅下降，PS比率上升。</blockquote></p><p> The million-dollar question is of course, could this happen to Plug Power as well? Technically, if we look solely at the metrics of Plug compared with the metrics of Tesla just before the stock price exploded, the P/S ratio of Plug is still much too high to expect that the stock could go in the same direction in short order. I also believe that fundamentally, Plug would need to experience some serious growth for the stock to be able to regain its recent upward momentum.</p><p><blockquote>当然，最重要的问题是，这种情况也会发生在普拉格能源身上吗？从技术上讲，如果我们仅将Plug的指标与股价爆炸前特斯拉的指标进行比较，Plug的市盈率仍然太高，无法预期该股在短期内会朝着同样的方向发展。我还认为，从根本上讲，Plug需要经历一些大幅增长，该股才能恢复近期的上涨势头。</blockquote></p><p> Another similarity between Plug and Tesla is that negative earnings surprises have been many at Plug recently, this happened to Tesla as well&nbsp;in 2019. At the time, Tesla's stock price was not negatively impacted by those surprises. Currently, the market seems to shake off Plug Power's results as well, though the stock did drop by more than 50% since last year.</p><p><blockquote>Plug和特斯拉之间的另一个相似之处是，最近Plug的盈利出现了很多负面意外，2019年特斯拉也发生了这种情况。当时，特斯拉的股价并未受到这些意外的负面影响。目前，市场似乎也摆脱了普拉格能源的业绩，尽管该股自去年以来确实下跌了50%以上。</blockquote></p><p> <b>Currently, expectations still beat metrics</b></p><p><blockquote><b>目前，预期仍然超过指标</b></blockquote></p><p> Like Tesla, Plug's share price seems to be governed more by growth expectations than by current stock metrics. This<i>could</i>mean that Plug would be able to go in the same direction as Tesla if enough investors remain convinced that their business model is profitable for the future and if growth can be expected to continue. Also, as for Tesla, in the long term, fundamental metrics will need to correspond with their lofty valuations. This means that the companies will need to deliver on their expectations.</p><p><blockquote>与特斯拉一样，Plug的股价似乎更多地取决于增长预期，而不是当前的股票指标。这个<i>可以</i>这意味着，如果有足够多的投资者仍然相信他们的商业模式在未来是有利可图的，并且可以预期增长将继续下去，那么Plug将能够朝着与特斯拉相同的方向发展。此外，对于特斯拉来说，从长远来看，基本面指标需要与其高估值相对应。这意味着公司需要实现他们的期望。</blockquote></p><p> <b>These are some very large ifs.</b></p><p><blockquote><b>这些都是非常大的假设。</b></blockquote></p><p> Of course, the hydrogen market is different from the EV market. Since the energy density of hydrogen is very high, it will likely be able to compete in markets where batteries still have issues, like long-haul transport. On the other hand, on an energy efficiency level, batteries have some large benefits over hydrogen for smaller transport purposes. On aggregate, I am skeptical about hydrogen being able to be a strong competitor in the EV space, but it will likely play a large role in other modes of transport, as in energy storage.</p><p><blockquote>当然，氢市场不同于电动汽车市场。由于氢的能量密度非常高，它很可能能够在电池仍然存在问题的市场中竞争，例如长途运输。另一方面，在能源效率水平上，对于较小的运输目的，电池比氢气有一些很大的好处。总的来说，我对氢能否成为电动汽车领域的强有力竞争对手持怀疑态度，但它可能会在其他交通方式中发挥重要作用，例如在储能方面。</blockquote></p><p></p><p> Plug Power has been trading like a stock for believers, which shows some strong parallels with Tesla. Theoretically, the stock could follow the same direction as Tesla did, but this is anyone's guess and I believe it would take more growth to continue its upward momentum.</p><p><blockquote>普拉格能源的交易就像信徒的股票一样，这与特斯拉有一些很强的相似之处。理论上，该股可能会遵循与特斯拉相同的方向，但这是任何人的猜测，我相信需要更多的增长才能继续其上涨势头。</blockquote></p><p> Plug Power is a promising business, but the company had some bad results recently. This did not impact the stock much during the last 2 years. In the short term, the stock price seems to be most impacted by sentiment and not by fundamentals. This makes it a wonderful stock for traders, but as a long-term investor, I am staying on the sidelines.</p><p><blockquote>普拉格能源是一项有前途的业务，但该公司最近业绩不佳。在过去的两年里，这对股票没有太大影响。短期内，股价似乎受情绪影响最大，而不是基本面。这使得它成为交易者的绝佳股票，但作为长期投资者，我仍持观望态度。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4476789-plug-power-stock-promising-business-parallels-with-tesla\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLUG":"普拉格能源"},"source_url":"https://seekingalpha.com/article/4476789-plug-power-stock-promising-business-parallels-with-tesla","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111088353","content_text":"Summary\n\nThe stock of Plug Power enjoyed some great appreciation during the last years, which seems hard to explain when purely looking at the fundamentals.\nThe stock performance of almost 2,000% over the last 5 years is an illustration of the increased momentum of the hydrogen market.\nPlug Power shows some important parallels with Tesla, on which I will elaborate in this article.\nIf the sentiment can remain positive while growth continues, short-term fundamentals might not matter much.\n\nhttp://www.fotogestoeber.de/iStock via Getty Images\nHow can a company in a niche sector which has continuously burned cash over the years have a market capitalization of over $17B? Plug Power (PLUG) is a pure-play hydrogen company that has yet to run a profit. Still, the stock has returned a total of almost 2,000% over the last 5 years.\nIn this article, I will investigate the promises and expectations behind Plug Power and compare the stock to another stock with large promises: Tesla (TSLA).\nGreat stock performance, but a lofty valuation\nPlug Power has behaved somewhat like a battleground stock during the last couple of years. Ever since the 2014 hydrogen rally, Plug Power has remained a stock that lured investors who believe in the technology, but also attracted quite some short-sellers, judged by its current short interest of almost 10 percent.\nMore recently, the stock has experienced a huge liftoff, most likely fueled by the announcement of the Build Back Better Plan of president Biden. Since then, Plug Power's stock more or less came back to earth again, even though it is still trading at a very high price to sales ratio.\nPlease review the following charts for illustration of these metrics:\nData by YCharts\nPlug Power development of share price, short interest, and price to sales ratio during the last 10 years. (source: YCharts)\nA true story stock\n\n A story stock refers to a company's shares whose value reflects expected outperformance, the culmination of some new innovation, or favorable press coverage, rather than its market value being solely based on fundamentals like assets and income (Source:Investopedia)\n\nA story can be a powerful backbone of stock performance. Though the hydrogen market is still somewhat of a niche, the story of Plug is one of great expectations.\nHydrogen is indeed a promising market. Let us explore the potential benefits and promises of hydrogen:\n\nGreen hydrogen can help to decarbonize multiple sectors in which it is difficult to reduce emissions, like long-haul transport, chemical industry, and iron and steel production.\nGreen hydrogen can contribute to improvements in air quality and energy security.\nHydrogen can be produced using a multitude of sources, such as renewables, nuclear energy, natural gas, oil, and even coal. Transportation can be done using pipelines or in liquefied form. It can be transformed into electricity very easily.\nHydrogen can play an important role in coping with the variable outputs of renewable energy sources. Wind and solar energy output are not always in sync with electricity demand, and hydrogen can be used as a store or energy in times when renewable energy production outpaces demand. These storages can be used in times when renewable energy output is lower than demand, and can be saved for days, weeks, or even months, and can even be transported over long distances if needed.\nClean hydrogen is currently used in an expanding number of projects worldwide, and it seems to be a matter of time before the technology is scaled up and costs are brought down.\nCurrently, hydrogen is mostly used in oil refining processes and for the production of fertilizers. Sectors in which it is still hardly used, like transport, buildings, and power generation seem large untapped markets.\n\nAs such, hydrogen could play an important supporting role in the renewable energy transition, supplying markets that are difficult or impractical to reach for batteries.\nPlug Power has a focused strategy, is already an established business in the hydrogen market, and has a large growing number of commercial relationships. This might mean that the company has the potential to become one of the first pure-play hydrogen companies which could transition from a story stock to a large positive cash flow company.\nThe commercial relationships and collaborations which Plug is undertaking are among the most important future drivers of growth for the company, among which are collaborations with Airbus(OTCPK:EADSF),Phillips66(PSX),Acciona(OTCPK:ACXIF),BAE Systems(OTCPK:BAESF),Baker Hughes(BKR), and Brookfield Renewable(BEP).\nParallels with early-stage Tesla\nI think it is very interesting to compare Plug Power with Tesla. This seems to make sense since they were both one of the largest first movers in big markets: EV for Tesla and hydrogen for Plug. Tesla also was (and might still be) a good example of a story stock, with their large promises of electrifying the automotive sector.\nLet us look at the share price development, short percentage, and PS ratio of Tesla during the period from 2010 to the end of 2019:\nData by YCharts\nTesla's development of share price, short interest, and price to sales ratio between 2010 and the end of 2019. (source: YCharts)\nThere are some noticeable differences between the share price development of Plug Power and an earlier-stage Tesla. First of all, from 2012 to 2019, the percentage of Tesla's stock sold short has consistently oscillated around 20%. Plug Power is already under 10% and has moved around 15% for the largest part of the last couple of years. But the biggest difference between the two stocks is probably that the price to sales ratio of Tesla has trended down quickly between 2010 and the end of 2019. Since Plug Power's price to sales ratio is heavily influenced by its recent outlier, let us take a look at a graph comparing the two between 2010 and September of this year:\nData by YCharts\nTesla and Plug Power development price to sales ratio between 2010 and September 2021. (source: YCharts)\nThese two ratios look to have a lot more in common. But as we can already see, after the end of 2019, Tesla's price to sales ratio went sharply up again. The reason for this was, of course, the almost unprecedented skyrocketing of the Tesla stock starting from the end of 2019. This is illustrated in the following graph of what happened to Tesla shares from September 2019 until now:\nData by YCharts\nDevelopment of Tesla share price, short interest, and price to sales ratio between September 2019 and now. (source: YCharts)\nAs the stock price of Tesla skyrocketed, the short percentage went down sharply and the PS ratio went up.\nThe million-dollar question is of course, could this happen to Plug Power as well? Technically, if we look solely at the metrics of Plug compared with the metrics of Tesla just before the stock price exploded, the P/S ratio of Plug is still much too high to expect that the stock could go in the same direction in short order. I also believe that fundamentally, Plug would need to experience some serious growth for the stock to be able to regain its recent upward momentum.\nAnother similarity between Plug and Tesla is that negative earnings surprises have been many at Plug recently, this happened to Tesla as well in 2019. At the time, Tesla's stock price was not negatively impacted by those surprises. Currently, the market seems to shake off Plug Power's results as well, though the stock did drop by more than 50% since last year.\nCurrently, expectations still beat metrics\nLike Tesla, Plug's share price seems to be governed more by growth expectations than by current stock metrics. Thiscouldmean that Plug would be able to go in the same direction as Tesla if enough investors remain convinced that their business model is profitable for the future and if growth can be expected to continue. Also, as for Tesla, in the long term, fundamental metrics will need to correspond with their lofty valuations. This means that the companies will need to deliver on their expectations.\nThese are some very large ifs.\nOf course, the hydrogen market is different from the EV market. Since the energy density of hydrogen is very high, it will likely be able to compete in markets where batteries still have issues, like long-haul transport. On the other hand, on an energy efficiency level, batteries have some large benefits over hydrogen for smaller transport purposes. On aggregate, I am skeptical about hydrogen being able to be a strong competitor in the EV space, but it will likely play a large role in other modes of transport, as in energy storage.\nPlug Power has been trading like a stock for believers, which shows some strong parallels with Tesla. Theoretically, the stock could follow the same direction as Tesla did, but this is anyone's guess and I believe it would take more growth to continue its upward momentum.\nPlug Power is a promising business, but the company had some bad results recently. This did not impact the stock much during the last 2 years. In the short term, the stock price seems to be most impacted by sentiment and not by fundamentals. This makes it a wonderful stock for traders, but as a long-term investor, I am staying on the sidelines.","news_type":1,"symbols_score_info":{"PLUG":0.9}},"isVote":1,"tweetType":1,"viewCount":2941,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698145843,"gmtCreate":1640327029733,"gmtModify":1640327659820,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Another great yr for pfizer!?","listText":"Another great yr for pfizer!?","text":"Another great yr for pfizer!?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698145843","repostId":"1110395878","repostType":4,"repost":{"id":"1110395878","kind":"news","pubTimestamp":1640310818,"share":"https://www.laohu8.com/m/news/1110395878?lang=zh_CN&edition=full","pubTime":"2021-12-24 09:53","market":"us","language":"en","title":"Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.<blockquote>辉瑞的Covid药丸获得批准。投资者开始关注该股。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1110395878","media":"Barrons","summary":"The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over","content":"<p>The Covid-19 pill is here, and it couldn’t have come at a better time.</p><p><blockquote>新冠肺炎药丸来了，来得正是时候。</blockquote></p><p> The pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.</p><p><blockquote>随着奥密克戎变种席卷美国，疫情在过去两周变得更加黑暗。随着大多数广泛使用的疗法因该变种的突变而变得无用，病例数迅速攀升，医生和公共卫生官员越来越担心。</blockquote></p><p> The Food and Drug Administration’s authorization of&nbsp;Pfizer’s&nbsp;(ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.</p><p><blockquote>美国食品和药物管理局周三批准辉瑞公司（股票代码：PFE）的Covid-19药物Paxlovid带来了一些希望。这种药丸仅适用于高危人群，最初供应有限，但它将拯救生命。</blockquote></p><p> The authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.</p><p><blockquote>此次授权对辉瑞来说是一次非同寻常的政变，这是辉瑞公司在疫情的第二次授权。FactSet的数据显示，分析师预计辉瑞公司将在2022年销售价值217亿美元的该药物，不过该公司现在表示明年将生产1.2亿个疗程的该药物，比之前的预测多4000万个疗程，这可能会推高这些估计。</blockquote></p><p> As <i>Barron’s</i> argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.</p><p><blockquote>作为<i>巴伦周刊</i>去年11月，Paxlovid的成功进一步证明，该公司在2019年决定摆脱除创新生物制药业务以外的所有业务是明智的。</blockquote></p><p> Investors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the&nbsp;S&amp;P 500&nbsp;index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&amp;P 500 has climbed just 1.6%.</p><p><blockquote>投资者一直迟迟没有买入重组后的辉瑞，但今年年底他们很快就赶上了。在今年11月之前的12个月里，辉瑞的股价落后于标准普尔500指数，尽管它推出了新冠肺炎疫苗。然而，自11月初以来，辉瑞股价大幅上涨。此后，该股上涨了36.4%，而标普500仅上涨了1.6%。</blockquote></p><p> And the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like&nbsp;Eli Lilly&nbsp;(LLY), which trades at 31.7 times earnings, and&nbsp;Johnson &amp; Johnson&nbsp;(JNJ), at 16.1 times earnings.</p><p><blockquote>FactSet的数据显示，该股仍然相对便宜，未来12个月预期市盈率仅为9.8倍，低于礼来公司(LLY)和强生公司(JNJ)等同行，市盈率为31.7倍。市盈率为16.1倍。</blockquote></p><p> The good news for Pfizer this week was matched by less-good news for&nbsp;Merck&nbsp;(MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.</p><p><blockquote>本周辉瑞的好消息与默克（MRK）的坏消息相匹配。尽管其Covid-19药物molnupiravir的早期数据导致疫苗股走低，默克公司股价走高，但此后该药物的光芒已经消失，因为更新的数据表明它的效果不如最初看起来的那么好，而且安全问题仍然存在。</blockquote></p><p> The FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.</p><p><blockquote>FDA于周四发布了molnupiravir的紧急使用授权，一天前它发布了Paxlovid的紧急使用授权，但条款要严格得多。该授权允许molnupiravir仅在其他Covid-19治疗方法（如Paxlovid）不可用或临床不合适时使用。该机构也不建议在怀孕期间使用该药物，并建议服用莫努匹韦的男性在怀孕后至少三个月内应采取避孕措施。</blockquote></p><p> Earlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.</p><p><blockquote>早些时候对莫努匹拉韦可能成为长期收入驱动力的希望正在消失。这种失望提醒人们默克在本十年结束前面临的挑战：失去Keytruda的专利保护，Keytruda是一种癌症药物，约占其收入的三分之一。默克一直在努力填补这一空白。莫努匹拉韦似乎不会对这一努力做出重大贡献。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.<blockquote>辉瑞的Covid药丸获得批准。投资者开始关注该股。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.<blockquote>辉瑞的Covid药丸获得批准。投资者开始关注该股。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-12-24 09:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The Covid-19 pill is here, and it couldn’t have come at a better time.</p><p><blockquote>新冠肺炎药丸来了，来得正是时候。</blockquote></p><p> The pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.</p><p><blockquote>随着奥密克戎变种席卷美国，疫情在过去两周变得更加黑暗。随着大多数广泛使用的疗法因该变种的突变而变得无用，病例数迅速攀升，医生和公共卫生官员越来越担心。</blockquote></p><p> The Food and Drug Administration’s authorization of&nbsp;Pfizer’s&nbsp;(ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.</p><p><blockquote>美国食品和药物管理局周三批准辉瑞公司（股票代码：PFE）的Covid-19药物Paxlovid带来了一些希望。这种药丸仅适用于高危人群，最初供应有限，但它将拯救生命。</blockquote></p><p> The authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.</p><p><blockquote>此次授权对辉瑞来说是一次非同寻常的政变，这是辉瑞公司在疫情的第二次授权。FactSet的数据显示，分析师预计辉瑞公司将在2022年销售价值217亿美元的该药物，不过该公司现在表示明年将生产1.2亿个疗程的该药物，比之前的预测多4000万个疗程，这可能会推高这些估计。</blockquote></p><p> As <i>Barron’s</i> argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.</p><p><blockquote>作为<i>巴伦周刊</i>去年11月，Paxlovid的成功进一步证明，该公司在2019年决定摆脱除创新生物制药业务以外的所有业务是明智的。</blockquote></p><p> Investors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the&nbsp;S&amp;P 500&nbsp;index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&amp;P 500 has climbed just 1.6%.</p><p><blockquote>投资者一直迟迟没有买入重组后的辉瑞，但今年年底他们很快就赶上了。在今年11月之前的12个月里，辉瑞的股价落后于标准普尔500指数，尽管它推出了新冠肺炎疫苗。然而，自11月初以来，辉瑞股价大幅上涨。此后，该股上涨了36.4%，而标普500仅上涨了1.6%。</blockquote></p><p> And the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like&nbsp;Eli Lilly&nbsp;(LLY), which trades at 31.7 times earnings, and&nbsp;Johnson &amp; Johnson&nbsp;(JNJ), at 16.1 times earnings.</p><p><blockquote>FactSet的数据显示，该股仍然相对便宜，未来12个月预期市盈率仅为9.8倍，低于礼来公司(LLY)和强生公司(JNJ)等同行，市盈率为31.7倍。市盈率为16.1倍。</blockquote></p><p> The good news for Pfizer this week was matched by less-good news for&nbsp;Merck&nbsp;(MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.</p><p><blockquote>本周辉瑞的好消息与默克（MRK）的坏消息相匹配。尽管其Covid-19药物molnupiravir的早期数据导致疫苗股走低，默克公司股价走高，但此后该药物的光芒已经消失，因为更新的数据表明它的效果不如最初看起来的那么好，而且安全问题仍然存在。</blockquote></p><p> The FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.</p><p><blockquote>FDA于周四发布了molnupiravir的紧急使用授权，一天前它发布了Paxlovid的紧急使用授权，但条款要严格得多。该授权允许molnupiravir仅在其他Covid-19治疗方法（如Paxlovid）不可用或临床不合适时使用。该机构也不建议在怀孕期间使用该药物，并建议服用莫努匹韦的男性在怀孕后至少三个月内应采取避孕措施。</blockquote></p><p> Earlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.</p><p><blockquote>早些时候对莫努匹拉韦可能成为长期收入驱动力的希望正在消失。这种失望提醒人们默克在本十年结束前面临的挑战：失去Keytruda的专利保护，Keytruda是一种癌症药物，约占其收入的三分之一。默克一直在努力填补这一空白。莫努匹拉韦似乎不会对这一努力做出重大贡献。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110395878","content_text":"The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.\nThe Food and Drug Administration’s authorization of Pfizer’s (ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.\nThe authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.\nAs Barron’s argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.\nInvestors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the S&P 500 index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&P 500 has climbed just 1.6%.\nAnd the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like Eli Lilly (LLY), which trades at 31.7 times earnings, and Johnson & Johnson (JNJ), at 16.1 times earnings.\nThe good news for Pfizer this week was matched by less-good news for Merck (MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.\nThe FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.\nEarlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1978,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698142420,"gmtCreate":1640326890164,"gmtModify":1640327613911,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Yes. Continue to rallllllyyyyy","listText":"Yes. Continue to rallllllyyyyy","text":"Yes. Continue to rallllllyyyyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698142420","repostId":"1183390970","repostType":4,"repost":{"id":"1183390970","kind":"news","pubTimestamp":1640313641,"share":"https://www.laohu8.com/m/news/1183390970?lang=zh_CN&edition=full","pubTime":"2021-12-24 10:40","market":"us","language":"en","title":"Apple Stock: Wall Street Lines Up Behind $3 Trillion Bull Case<blockquote>苹果股票：华尔街支持3万亿美元的牛市</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1183390970","media":"TheStreet","summary":"Wall Street continues to support the bull case on Apple stock. We review the most recent sell-side t","content":"<p>Wall Street continues to support the bull case on Apple stock. We review the most recent sell-side takes and assess if now is the time to buy the dip in AAPL.</p><p><blockquote>华尔街继续支持苹果股票的牛市。我们回顾了最近的卖方观点，并评估现在是否是逢低买入AAPL的时候。</blockquote></p><p> Apple stock&nbsp;has bounced up and down in the past couple of weeks and now trades around $8 per share below&nbsp;my recent “trim the position” price point. But lack of momentum has not fazed Wall Street analysts, who increasingly believe that Apple will reach a market cap above $3 trillion within the next 12 months.</p><p><blockquote>苹果股票在过去几周上下反弹，目前每股交易价格比我最近的“削减头寸”价格点低约8美元。但缺乏动力并没有困扰华尔街分析师，他们越来越相信苹果的市值将在未来12个月内达到3万亿美元以上。</blockquote></p><p> Today, the Apple Maven scans through the most recently published sell-side reports and assesses the ever-stronger bull case on shares of the Cupertino company.</p><p><blockquote>今天，苹果专家浏览了最近发布的卖方报告，并评估了库比蒂诺公司股票日益强劲的牛市理由。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b8dea165a4c3f8375b37ab1560d20bec\" tg-width=\"1240\" tg-height=\"930\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple's store in New York, NY.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：纽约州纽约市的苹果商店。</span></p></blockquote></p><p> <b>Wall Street moves up the bar</b></p><p><blockquote><b>华尔街名列前茅</b></blockquote></p><p> Because Apple stock rallied as strongly as it did in late November and early December, something unique happened: despite Wall Street having a consensus “strong buy” rating on shares, the average target price had fallen below AAPL’s market value.</p><p><blockquote>由于苹果股价像11月底和12月初一样强劲反弹，发生了一些独特的事情：尽管华尔街一致对该股给予“强力买入”评级，但平均目标价已跌破AAPL的市值。</blockquote></p><p> One of two things could have happened: either analysts would need to downgrade their views based on stretched valuations, or raise their price targets to catch up. The latter ended up happening, which suggests confidence in further upside opportunity.</p><p><blockquote>可能会发生两种情况之一：要么分析师需要根据过高的估值下调他们的观点，要么提高他们的价格目标以迎头赶上。后者最终发生了，这表明对进一步上涨机会的信心。</blockquote></p><p> Last week,we pointed out that a wave of analysts&nbsp;had made their case for AAPL at a $3 trillion market cap or above. On the buy side, Gene Munster from Loup Ventures even called for $4 trillion fair value on the back of opportunities in metaverse and autonomous vehicles.</p><p><blockquote>上周，我们指出，一波分析师认为AAPL的市值为3万亿美元或以上。在买方方面，Loup Ventures的Gene Munster甚至呼吁，基于元宇宙和自动驾驶汽车的机会，公允价值为4万亿美元。</blockquote></p><p> The most recent report&nbsp;came in&nbsp;from Citi, on December 22. Analyst Jim Suva raised his price target by $30 to $200, citing a few positive developments ahead: (1) resilient demand for products and services in the current fiscal year; and (2) the mixed reality opportunity not fully reflected in the stock price.</p><p><blockquote>最近的一份报告来自花旗于12月22日发布。分析师Jim Suva将目标价上调30美元至200美元，并列举了未来的一些积极进展：(1)本财年对产品和服务的弹性需求；(2)混合现实机会未充分反映在股价中。</blockquote></p><p> The bottom line is that Wall Street is looking past the short-term headwinds that have pushed AAPL share price from $180 two weeks ago to the high $160s recently. Bearish pressures, it seems, have served as a catalyst to buy Apple stock cheaper, according to analysts.</p><p><blockquote>最重要的是，华尔街正在忽视将AAPL股价从两周前的180美元推高至最近160美元的短期阻力。分析师表示，看跌压力似乎成为低价购买苹果股票的催化剂。</blockquote></p><p> <b>Is it time to buy AAPL?</b></p><p><blockquote><b>是时候购买AAPL了吗？</b></blockquote></p><p> Late last week,I offered a plan of action&nbsp;for those looking to buy the dip in Apple stock. First, I still think that AAPL is a good addition to a growth portfolio that does not have any exposure to it. Otherwise, I believe that investors should:</p><p><blockquote>上周晚些时候，我为那些希望逢低买入苹果股票的人提供了一个行动计划。首先，我仍然认为苹果公司是没有任何风险敞口的成长型投资组合的一个很好的补充。否则，我认为投资者应该：</blockquote></p><p> <ul>  <li>Consider accumulating AAPL if the stock underperforms the Nasdaq by 5 percentage points — which I estimated could happen at $160 share price.</li>  <li>“Back up the truck” in the more unlikely scenario of a share price dip below $150.</li> </ul> The chart below shows that, premarket on December 22, AAPL had trailed the Nasdaq index by about 2 percentage points since my “trim the position” article. Therefore, the case for buying AAPL is slowly gaining strength, but some underperformance ahead is still not out of question.</p><p><blockquote><ul><li>如果AAPL股票的表现落后纳斯达克5个百分点，请考虑积累AAPL——我估计股价可能会达到160美元。</li><li>在股价跌破150美元的可能性更小的情况下“备份卡车”。</li></ul>下图显示，自我发表“削减头寸”文章以来，12月22日盘前，AAPL落后纳斯达克指数约2个百分点。因此，购买苹果公司的理由正在慢慢增强，但未来表现不佳仍不是不可能的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/67f898e47d3d3dcee96368c621537b62\" tg-width=\"1095\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Figure 2: AAPL and IXIC performance.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图2：AAPL和IXIC性能。</span></p></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: Wall Street Lines Up Behind $3 Trillion Bull Case<blockquote>苹果股票：华尔街支持3万亿美元的牛市</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: Wall Street Lines Up Behind $3 Trillion Bull Case<blockquote>苹果股票：华尔街支持3万亿美元的牛市</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-12-24 10:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Wall Street continues to support the bull case on Apple stock. We review the most recent sell-side takes and assess if now is the time to buy the dip in AAPL.</p><p><blockquote>华尔街继续支持苹果股票的牛市。我们回顾了最近的卖方观点，并评估现在是否是逢低买入AAPL的时候。</blockquote></p><p> Apple stock&nbsp;has bounced up and down in the past couple of weeks and now trades around $8 per share below&nbsp;my recent “trim the position” price point. But lack of momentum has not fazed Wall Street analysts, who increasingly believe that Apple will reach a market cap above $3 trillion within the next 12 months.</p><p><blockquote>苹果股票在过去几周上下反弹，目前每股交易价格比我最近的“削减头寸”价格点低约8美元。但缺乏动力并没有困扰华尔街分析师，他们越来越相信苹果的市值将在未来12个月内达到3万亿美元以上。</blockquote></p><p> Today, the Apple Maven scans through the most recently published sell-side reports and assesses the ever-stronger bull case on shares of the Cupertino company.</p><p><blockquote>今天，苹果专家浏览了最近发布的卖方报告，并评估了库比蒂诺公司股票日益强劲的牛市理由。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b8dea165a4c3f8375b37ab1560d20bec\" tg-width=\"1240\" tg-height=\"930\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple's store in New York, NY.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：纽约州纽约市的苹果商店。</span></p></blockquote></p><p> <b>Wall Street moves up the bar</b></p><p><blockquote><b>华尔街名列前茅</b></blockquote></p><p> Because Apple stock rallied as strongly as it did in late November and early December, something unique happened: despite Wall Street having a consensus “strong buy” rating on shares, the average target price had fallen below AAPL’s market value.</p><p><blockquote>由于苹果股价像11月底和12月初一样强劲反弹，发生了一些独特的事情：尽管华尔街一致对该股给予“强力买入”评级，但平均目标价已跌破AAPL的市值。</blockquote></p><p> One of two things could have happened: either analysts would need to downgrade their views based on stretched valuations, or raise their price targets to catch up. The latter ended up happening, which suggests confidence in further upside opportunity.</p><p><blockquote>可能会发生两种情况之一：要么分析师需要根据过高的估值下调他们的观点，要么提高他们的价格目标以迎头赶上。后者最终发生了，这表明对进一步上涨机会的信心。</blockquote></p><p> Last week,we pointed out that a wave of analysts&nbsp;had made their case for AAPL at a $3 trillion market cap or above. On the buy side, Gene Munster from Loup Ventures even called for $4 trillion fair value on the back of opportunities in metaverse and autonomous vehicles.</p><p><blockquote>上周，我们指出，一波分析师认为AAPL的市值为3万亿美元或以上。在买方方面，Loup Ventures的Gene Munster甚至呼吁，基于元宇宙和自动驾驶汽车的机会，公允价值为4万亿美元。</blockquote></p><p> The most recent report&nbsp;came in&nbsp;from Citi, on December 22. Analyst Jim Suva raised his price target by $30 to $200, citing a few positive developments ahead: (1) resilient demand for products and services in the current fiscal year; and (2) the mixed reality opportunity not fully reflected in the stock price.</p><p><blockquote>最近的一份报告来自花旗于12月22日发布。分析师Jim Suva将目标价上调30美元至200美元，并列举了未来的一些积极进展：(1)本财年对产品和服务的弹性需求；(2)混合现实机会未充分反映在股价中。</blockquote></p><p> The bottom line is that Wall Street is looking past the short-term headwinds that have pushed AAPL share price from $180 two weeks ago to the high $160s recently. Bearish pressures, it seems, have served as a catalyst to buy Apple stock cheaper, according to analysts.</p><p><blockquote>最重要的是，华尔街正在忽视将AAPL股价从两周前的180美元推高至最近160美元的短期阻力。分析师表示，看跌压力似乎成为低价购买苹果股票的催化剂。</blockquote></p><p> <b>Is it time to buy AAPL?</b></p><p><blockquote><b>是时候购买AAPL了吗？</b></blockquote></p><p> Late last week,I offered a plan of action&nbsp;for those looking to buy the dip in Apple stock. First, I still think that AAPL is a good addition to a growth portfolio that does not have any exposure to it. Otherwise, I believe that investors should:</p><p><blockquote>上周晚些时候，我为那些希望逢低买入苹果股票的人提供了一个行动计划。首先，我仍然认为苹果公司是没有任何风险敞口的成长型投资组合的一个很好的补充。否则，我认为投资者应该：</blockquote></p><p> <ul>  <li>Consider accumulating AAPL if the stock underperforms the Nasdaq by 5 percentage points — which I estimated could happen at $160 share price.</li>  <li>“Back up the truck” in the more unlikely scenario of a share price dip below $150.</li> </ul> The chart below shows that, premarket on December 22, AAPL had trailed the Nasdaq index by about 2 percentage points since my “trim the position” article. Therefore, the case for buying AAPL is slowly gaining strength, but some underperformance ahead is still not out of question.</p><p><blockquote><ul><li>如果AAPL股票的表现落后纳斯达克5个百分点，请考虑积累AAPL——我估计股价可能会达到160美元。</li><li>在股价跌破150美元的可能性更小的情况下“备份卡车”。</li></ul>下图显示，自我发表“削减头寸”文章以来，12月22日盘前，AAPL落后纳斯达克指数约2个百分点。因此，购买苹果公司的理由正在慢慢增强，但未来表现不佳仍不是不可能的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/67f898e47d3d3dcee96368c621537b62\" tg-width=\"1095\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Figure 2: AAPL and IXIC performance.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图2：AAPL和IXIC性能。</span></p></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/apple/news/apple-stock-wall-street-lines-up-behind-3-trillion-bull-case\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/news/apple-stock-wall-street-lines-up-behind-3-trillion-bull-case","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183390970","content_text":"Wall Street continues to support the bull case on Apple stock. We review the most recent sell-side takes and assess if now is the time to buy the dip in AAPL.\nApple stock has bounced up and down in the past couple of weeks and now trades around $8 per share below my recent “trim the position” price point. But lack of momentum has not fazed Wall Street analysts, who increasingly believe that Apple will reach a market cap above $3 trillion within the next 12 months.\nToday, the Apple Maven scans through the most recently published sell-side reports and assesses the ever-stronger bull case on shares of the Cupertino company.\nFigure 1: Apple's store in New York, NY.\nWall Street moves up the bar\nBecause Apple stock rallied as strongly as it did in late November and early December, something unique happened: despite Wall Street having a consensus “strong buy” rating on shares, the average target price had fallen below AAPL’s market value.\nOne of two things could have happened: either analysts would need to downgrade their views based on stretched valuations, or raise their price targets to catch up. The latter ended up happening, which suggests confidence in further upside opportunity.\nLast week,we pointed out that a wave of analysts had made their case for AAPL at a $3 trillion market cap or above. On the buy side, Gene Munster from Loup Ventures even called for $4 trillion fair value on the back of opportunities in metaverse and autonomous vehicles.\nThe most recent report came in from Citi, on December 22. Analyst Jim Suva raised his price target by $30 to $200, citing a few positive developments ahead: (1) resilient demand for products and services in the current fiscal year; and (2) the mixed reality opportunity not fully reflected in the stock price.\nThe bottom line is that Wall Street is looking past the short-term headwinds that have pushed AAPL share price from $180 two weeks ago to the high $160s recently. Bearish pressures, it seems, have served as a catalyst to buy Apple stock cheaper, according to analysts.\nIs it time to buy AAPL?\nLate last week,I offered a plan of action for those looking to buy the dip in Apple stock. First, I still think that AAPL is a good addition to a growth portfolio that does not have any exposure to it. Otherwise, I believe that investors should:\n\nConsider accumulating AAPL if the stock underperforms the Nasdaq by 5 percentage points — which I estimated could happen at $160 share price.\n“Back up the truck” in the more unlikely scenario of a share price dip below $150.\n\nThe chart below shows that, premarket on December 22, AAPL had trailed the Nasdaq index by about 2 percentage points since my “trim the position” article. Therefore, the case for buying AAPL is slowly gaining strength, but some underperformance ahead is still not out of question.\nFigure 2: AAPL and IXIC performance.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":2528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693025877,"gmtCreate":1639939479267,"gmtModify":1639939479362,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Bookmark this","listText":"Bookmark this","text":"Bookmark this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693025877","repostId":"2192597562","repostType":4,"isVote":1,"tweetType":1,"viewCount":3003,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693025341,"gmtCreate":1639939247109,"gmtModify":1639939247235,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Please huat nova.&nbsp;","listText":"Please huat nova.&nbsp;","text":"Please huat nova.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693025341","repostId":"2192905514","repostType":4,"repost":{"id":"2192905514","kind":"highlight","pubTimestamp":1639855524,"share":"https://www.laohu8.com/m/news/2192905514?lang=zh_CN&edition=full","pubTime":"2021-12-19 03:25","market":"us","language":"en","title":"Biden to deliver Tuesday speech on Omicron variant amid COVID rise<blockquote>拜登将于周二就新冠疫情上升的奥密克戎变种发表讲话</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2192905514","media":"reuters.com","summary":"(Reuters) - U.S. President Joe Biden will deliver a speech on Tuesday addressing the Omicron variant","content":"<p>(Reuters) - U.S. President Joe Biden will deliver a speech on Tuesday addressing the Omicron variant of the coronavirus, NBC News reported&nbsp;on Saturday, citing a White House official.</p><p><blockquote>（路透社）-美国全国广播公司新闻周六援引一名白宫官员的话说，美国总统乔·拜登将于周二发表演讲，讨论冠状病毒的奥密克戎变种。</blockquote></p><p> Biden is expected to go beyond his \"Winter Plan\" with additional steps to help communities in need, the report said.</p><p><blockquote>报道称，拜登预计将超越他的“冬季计划”，采取额外措施帮助有需要的社区。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biden to deliver Tuesday speech on Omicron variant amid COVID rise<blockquote>拜登将于周二就新冠疫情上升的奥密克戎变种发表讲话</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiden to deliver Tuesday speech on Omicron variant amid COVID rise<blockquote>拜登将于周二就新冠疫情上升的奥密克戎变种发表讲话</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">reuters.com</strong><span class=\"h-time small\">2021-12-19 03:25</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Reuters) - U.S. President Joe Biden will deliver a speech on Tuesday addressing the Omicron variant of the coronavirus, NBC News reported&nbsp;on Saturday, citing a White House official.</p><p><blockquote>（路透社）-美国全国广播公司新闻周六援引一名白宫官员的话说，美国总统乔·拜登将于周二发表演讲，讨论冠状病毒的奥密克戎变种。</blockquote></p><p> Biden is expected to go beyond his \"Winter Plan\" with additional steps to help communities in need, the report said.</p><p><blockquote>报道称，拜登预计将超越他的“冬季计划”，采取额外措施帮助有需要的社区。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">reuters.com</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192905514","content_text":"(Reuters) - U.S. President Joe Biden will deliver a speech on Tuesday addressing the Omicron variant of the coronavirus, NBC News reported on Saturday, citing a White House official.\nBiden is expected to go beyond his \"Winter Plan\" with additional steps to help communities in need, the report said.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":4273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699706015,"gmtCreate":1639886846944,"gmtModify":1639886847065,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Nova!!!!","listText":"Nova!!!!","text":"Nova!!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/699706015","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","kind":"news","pubTimestamp":1639884070,"share":"https://www.laohu8.com/m/news/1122414343?lang=zh_CN&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir跻身医疗保健股涨幅之列，辉瑞(Pfizer)创下十年来最佳涨幅</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p><p><blockquote>标普500的医疗保健股表现优于大盘指数中的所有其他板块，涨幅约为2.5%，主要得益于并购前景。<a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>科技股以及与COVID-19死灰复燃作斗争的股票领涨，而整体指数下跌约1.9%。</blockquote></p><p> Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p><p><blockquote>在过去一周市值超过20亿美元、日均成交量超过10万的股票中，<a href=\"https://laohu8.com/S/ARNA\">Arena制药公司</a>之后上涨约83.8%<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>同意以约6.7 B美元的价格收购该生物技术公司，溢价100%。<a href=\"https://laohu8.com/S/CERN\">塞尔纳</a>也加入了并购推动的涨势，本周上涨约20.7%，有报道称来自<a href=\"https://laohu8.com/S/ORCL\">神谕</a>电子病历公司。</blockquote></p><p> Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p><p><blockquote>疫苗开发商、<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>由于投资者欢迎世界卫生组织批准该公司的COVID-19疫苗，股价上涨约30.5%。当欧洲监管机构的专家小组将于下周审查该疫苗的营销授权时，这家总部位于马里兰州的生物技术公司可能会进一步受益。</blockquote></p><p> <a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p><p><blockquote><a href=\"https://laohu8.com/S/BHVN\">Biohaven制药</a>在该公司宣布NURTEC ODT(rimegepant)在以色列获得批准后，该公司每周上涨约25.2%，使其成为该偏头痛药物在美国以外的首个监管胜利。与此同时，Vir Biotechnology（纳斯达克股票代码：VIR）飙升约23.7%，成为本月第二周涨幅最大的股票之一。本周出现的更多数据证实了该公司与葛兰素史克（纽约证券交易所股票代码：GSK）合作开发的COVID-19疗法具有奥密克戎中和作用。跻身涨幅前五名的还有，<a href=\"https://laohu8.com/S/ROIV\">Roivant科学</a>增加了约22.6%。</blockquote></p><p> Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p><p><blockquote>值得注意的赢家：<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE)本周成为头条新闻，再次提高了COVID-19疫苗的销售指引，因为迅速传播的奥密克戎变种凸显了加强注射的必要性。尽管周五突然结束了连续六天的涨势，<a href=\"https://laohu8.com/S/NWY\">纽约</a>总部位于美国的制药巨头股价上涨约12.7%，创下2009年3月以来的最佳单周涨幅。</blockquote></p><p> Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p><p><blockquote>在本周表现最差的公司中，两家新IPO的生物技术公司Instil Bio（纳斯达克股票代码：TIL）和Exscientia（纳斯达克股票代码：EXAI）脱颖而出，尽管它们在华尔街获得了良好的评级，但分别下跌了19.3%和约13.5%。与此同时，处方药比价平台运营商GoodRx Holdings（纳斯达克股票代码：GDRX）股价下跌约15.6%。</blockquote></p><p> Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p><p><blockquote>上周表现最好的，<a href=\"https://laohu8.com/S/BHG\">光明健康集团</a>，暴跌约13.1%，受到唯一卖出评级的伤害<a href=\"https://laohu8.com/S/GS\">高盛</a>尽管这家投资银行以基本积极的观点开始了对管理式医疗的报道。</blockquote></p><p> Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p><p><blockquote>Allogene Therapeutics（纳斯达克股票代码：ALLO）在ASH介绍实验性同种异体药物1期数据后股价下跌约12.3%<a href=\"https://laohu8.com/S/00699\">车</a>T疗法未能让投资者兴奋，其中包括Cathie Wood的Ark Investment Management，该公司几天后出售了约160万股该生物技术公司的股票。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir跻身医疗保健股涨幅之列，辉瑞(Pfizer)创下十年来最佳涨幅</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir跻身医疗保健股涨幅之列，辉瑞(Pfizer)创下十年来最佳涨幅</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-19 11:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p><p><blockquote>标普500的医疗保健股表现优于大盘指数中的所有其他板块，涨幅约为2.5%，主要得益于并购前景。<a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>科技股以及与COVID-19死灰复燃作斗争的股票领涨，而整体指数下跌约1.9%。</blockquote></p><p> Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p><p><blockquote>在过去一周市值超过20亿美元、日均成交量超过10万的股票中，<a href=\"https://laohu8.com/S/ARNA\">Arena制药公司</a>之后上涨约83.8%<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>同意以约6.7 B美元的价格收购该生物技术公司，溢价100%。<a href=\"https://laohu8.com/S/CERN\">塞尔纳</a>也加入了并购推动的涨势，本周上涨约20.7%，有报道称来自<a href=\"https://laohu8.com/S/ORCL\">神谕</a>电子病历公司。</blockquote></p><p> Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p><p><blockquote>疫苗开发商、<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>由于投资者欢迎世界卫生组织批准该公司的COVID-19疫苗，股价上涨约30.5%。当欧洲监管机构的专家小组将于下周审查该疫苗的营销授权时，这家总部位于马里兰州的生物技术公司可能会进一步受益。</blockquote></p><p> <a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p><p><blockquote><a href=\"https://laohu8.com/S/BHVN\">Biohaven制药</a>在该公司宣布NURTEC ODT(rimegepant)在以色列获得批准后，该公司每周上涨约25.2%，使其成为该偏头痛药物在美国以外的首个监管胜利。与此同时，Vir Biotechnology（纳斯达克股票代码：VIR）飙升约23.7%，成为本月第二周涨幅最大的股票之一。本周出现的更多数据证实了该公司与葛兰素史克（纽约证券交易所股票代码：GSK）合作开发的COVID-19疗法具有奥密克戎中和作用。跻身涨幅前五名的还有，<a href=\"https://laohu8.com/S/ROIV\">Roivant科学</a>增加了约22.6%。</blockquote></p><p> Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p><p><blockquote>值得注意的赢家：<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE)本周成为头条新闻，再次提高了COVID-19疫苗的销售指引，因为迅速传播的奥密克戎变种凸显了加强注射的必要性。尽管周五突然结束了连续六天的涨势，<a href=\"https://laohu8.com/S/NWY\">纽约</a>总部位于美国的制药巨头股价上涨约12.7%，创下2009年3月以来的最佳单周涨幅。</blockquote></p><p> Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p><p><blockquote>在本周表现最差的公司中，两家新IPO的生物技术公司Instil Bio（纳斯达克股票代码：TIL）和Exscientia（纳斯达克股票代码：EXAI）脱颖而出，尽管它们在华尔街获得了良好的评级，但分别下跌了19.3%和约13.5%。与此同时，处方药比价平台运营商GoodRx Holdings（纳斯达克股票代码：GDRX）股价下跌约15.6%。</blockquote></p><p> Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p><p><blockquote>上周表现最好的，<a href=\"https://laohu8.com/S/BHG\">光明健康集团</a>，暴跌约13.1%，受到唯一卖出评级的伤害<a href=\"https://laohu8.com/S/GS\">高盛</a>尽管这家投资银行以基本积极的观点开始了对管理式医疗的报道。</blockquote></p><p> Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p><p><blockquote>Allogene Therapeutics（纳斯达克股票代码：ALLO）在ASH介绍实验性同种异体药物1期数据后股价下跌约12.3%<a href=\"https://laohu8.com/S/00699\">车</a>T疗法未能让投资者兴奋，其中包括Cathie Wood的Ark Investment Management，该公司几天后出售了约160万股该生物技术公司的股票。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARNA":"阿里那","BK4533":"AQR资本管理(全球第二大对冲基金)","CERN":"美国塞纳","BK4007":"制药","BK4550":"红杉资本持仓","ORCL":"甲骨文","PFE":"辉瑞","BK4568":"美国抗疫概念","BK4534":"瑞士信贷持仓"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals  dominated with a ~83.8% rise after Pfizer  agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner  also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle  for the electronic-medical-records company.\nVaccine developer, Novavax  jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical  posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences  added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1,"symbols_score_info":{"ORCL":0.9,"CERN":0.9,"ARNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2324,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699454604,"gmtCreate":1639881638280,"gmtModify":1639881638376,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?","listText":"Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?","text":"Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699454604","repostId":"1109831591","repostType":4,"repost":{"id":"1109831591","kind":"news","pubTimestamp":1639804463,"share":"https://www.laohu8.com/m/news/1109831591?lang=zh_CN&edition=full","pubTime":"2021-12-18 13:14","market":"us","language":"en","title":"Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109831591","media":"Motley Fool","summary":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnso","content":"<p>What happened</p><p><blockquote>发生了什么</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>当日均跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的看法。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师Chris Shibutani周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性推荐。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司开发的Comirnaty冠状病毒疫苗取得了巨大成功，但涩谷对他认为辉瑞的未来有些阴云密布感到担忧<b>BioNTech</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对[辉瑞]的看法归结为，我们估计其当前估值的三分之一左右归因于COVID-19疫苗和治疗[产品]，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预言家认为该股的估值也相当合理。然而，他对公司的潜力持更为乐观的态度。</blockquote></p><p> \"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着[强生]正处于组织多个领域的转型之中……我们看到了可能性——即使是在[强生]规模和范围的组织内——开发更多潜在的颠覆性机会在我们看来，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p><p><blockquote>Shibutani对辉瑞股票的目标价为每股51美元，强生公司的目标价为每股161美元。</blockquote></p><p> Now what</p><p><blockquote>现在怎么办</blockquote></p><p> Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞和强生公司无疑正在进入一些不确定的水域——无论是冠状病毒，还是后者公司显然迫在眉睫的分拆。不过，在我看来，这两家公司在各自疫苗之外的众多产品领域都拥有雄厚的实力，因此投资者不应因高盛的最新评估而过于气馁。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-18 13:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>What happened</p><p><blockquote>发生了什么</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>当日均跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的看法。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师Chris Shibutani周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性推荐。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司开发的Comirnaty冠状病毒疫苗取得了巨大成功，但涩谷对他认为辉瑞的未来有些阴云密布感到担忧<b>BioNTech</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对[辉瑞]的看法归结为，我们估计其当前估值的三分之一左右归因于COVID-19疫苗和治疗[产品]，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预言家认为该股的估值也相当合理。然而，他对公司的潜力持更为乐观的态度。</blockquote></p><p> \"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着[强生]正处于组织多个领域的转型之中……我们看到了可能性——即使是在[强生]规模和范围的组织内——开发更多潜在的颠覆性机会在我们看来，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p><p><blockquote>Shibutani对辉瑞股票的目标价为每股51美元，强生公司的目标价为每股161美元。</blockquote></p><p> Now what</p><p><blockquote>现在怎么办</blockquote></p><p> Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞和强生公司无疑正在进入一些不确定的水域——无论是冠状病毒，还是后者公司显然迫在眉睫的分拆。不过，在我看来，这两家公司在各自疫苗之外的众多产品领域都拥有雄厚的实力，因此投资者不应因高盛的最新评估而过于气馁。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109831591","content_text":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnson & Johnson both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.\n\nSo what\nGoldman Sachs analyst Chris Shibutani initiated coverage on Pfizer and Johnson & Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.\nShibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech BioNTech.\n\"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.\nAs for Johnson & Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.\n\"With [Johnson & Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson & Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.\nLast month, Johnson & Johnson announced plans to spin off its sprawlingconsumer healthcare division.\nShibutani's price target on Pfizer stock is $51 per share, and that for Johnson & Johnson is $161.\nNow what\nPfizer and Johnson & Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.","news_type":1,"symbols_score_info":{"PFE":0.9,"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":3235,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690255150,"gmtCreate":1639672141160,"gmtModify":1639672141253,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Good&nbsp;read!","listText":"Good&nbsp;read!","text":"Good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690255150","repostId":"1121295991","repostType":4,"repost":{"id":"1121295991","kind":"news","pubTimestamp":1639664163,"share":"https://www.laohu8.com/m/news/1121295991?lang=zh_CN&edition=full","pubTime":"2021-12-16 22:16","market":"us","language":"en","title":"Why analysts love Apple right now<blockquote>为什么分析师现在喜欢苹果</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1121295991","media":"Yahoo Finance","summary":"Apple’s  market capitalization is once again closing in on $3 trillion. If and when it hits the mark, which will require shares to reach $182.86, Apple will be in historic territory. And analysts are loving it.This month alone, Katy Huberty of Morgan Stanley, Samik Chatterjee of JPMorgan, and Amit Daryanani of Evercore ISI have raised their price targets on the stock to $200. And on Tuesday BofA Global Research’s Wamsi Mohan upgraded the stock from neutral to buy and raised his price target for ","content":"<p>Apple’s (AAPL) market capitalization is once again closing in on $3 trillion. If and when it hits the mark, which will require shares to reach $182.86, Apple will be in historic territory. And analysts are loving it.</p><p><blockquote>苹果(AAPL)的市值再次逼近3万亿美元。如果达到要求股价达到182.86美元的目标，苹果将处于历史高位。分析师们很喜欢它。</blockquote></p><p> This month alone, Katy Huberty of Morgan Stanley, Samik Chatterjee of JPMorgan, and Amit Daryanani of Evercore ISI have raised their price targets on the stock to $200. And on Tuesday BofA Global Research’s Wamsi Mohan upgraded the stock from neutral to buy and raised his price target for shares to $210.</p><p><blockquote>仅本月，摩根士丹利的Katy Huberty、摩根大通的Samik Chatterjee和Evercore ISI的Amit Daryanani就将该股的目标价提高至200美元。周二，美国银行全球研究部的瓦姆西·莫汉(Wamsi Mohan)将该股评级从中性上调至买入，并将股价目标上调至210美元。</blockquote></p><p> Several factors are spurring analysts to fawn over Apple: Optimism for Apple’s iPhone, its coming products including its rumored AR/VR headset, and the company’s ability to suck in consumers and keep them there through its services business.</p><p><blockquote>有几个因素促使分析师奉承苹果：对苹果iPhone的乐观情绪、其即将推出的产品（包括传闻中的AR/VR耳机），以及该公司通过其服务业务吸引消费者并将他们留在那里的能力。</blockquote></p><p> “We expect Apple to introduce an augmented reality/virtual reality (AR/VR) headset, either by the end of 2022 or early 2023,” Mohan wrote in a recent analyst note. “We view this technology as a game-changer as it will enable many new applications which will require high performance hardware and higher access speeds.”</p><p><blockquote>Mohan在最近的一份分析师报告中写道：“我们预计苹果将在2022年底或2023年初推出增强现实/虚拟现实（AR/VR）耳机。”“我们认为这项技术改变了游戏规则，因为它将支持许多需要高性能硬件和更高访问速度的新应用程序。”</blockquote></p><p> Apple’s AR/VR headset,according to Bloomberg’s Mark Gurman, could cost upwards of $3,000 and be geared to gaming, entertainment, and communications. The headset has been rumored for some time, with Apple filing various patents related to the technology.</p><p><blockquote>据彭博社的Mark Gurman称，苹果的AR/VR耳机价格可能超过3000美元，适用于游戏、娱乐和通信。这款耳机的传闻已经有一段时间了，苹果申请了与该技术相关的各种专利。</blockquote></p><p> “I think what a number of people and investors are thinking about is, ‘Hey, if they move to the glasses, the AR and VR glasses that a lot of people expect to see in '22, that's another opportunity to really build on this incredible ecosystem of device owners, and iOS, and Mac OS holders that really love their devices,’ ” TECHnalysis Research president Bob O’Donnell told Yahoo Finance Live.</p><p><blockquote>“我认为许多人和投资者正在考虑的是，‘嘿，如果他们转向眼镜，很多人期望在22年看到的AR和VR眼镜，这是另一个真正建立在这个基础上的机会TECHnalysis Research总裁Bob O’Donnell告诉雅虎财经直播。</blockquote></p><p> Apple’s Services business, which includes its App Store, is one of the major sticking points the company has going for it. After all, if you own an iPhone, you’re going to buy apps, and when it’s time to get a new phone you’ll likely buy another iPhone to keep those apps.</p><p><blockquote>苹果的服务业务（包括其应用商店）是该公司发展的主要症结之一。毕竟，如果你有一部iPhone，你就会购买应用程序，当需要买一部新手机时，你可能会购买另一部iPhone来保留这些应用程序。</blockquote></p><p> The same idea would apply to the company’s AR/VR headset if Apple can wrangle the kind of third-party developer support it already enjoys on the iPhone.</p><p><blockquote>如果苹果能够争取到它在iPhone上已经享有的第三方开发者支持，同样的想法也适用于该公司的AR/VR耳机。</blockquote></p><p> “We see the potential for more Services monetization relative to iPad as use cases develop beyond gaming and remote servicing and evolve into a whole new way in which the world digitally interacts, which AR/VR experts we've spoken with view as the long-term killer AR/VR application,” Huberty wrote in a Dec. 7 analyst note.</p><p><blockquote>“随着用例超越游戏和远程服务的发展，并演变成一种全新的世界数字交互方式，我们看到了相对于iPad更多服务货币化的潜力，我们采访过的AR/VR专家将其视为长期杀手AR/VR应用，”Huberty在12月7日的分析师报告中写道。</blockquote></p><p> Of course, Apple’s iPhone is still the major driver of Apple’s revenue. And despite the supply chain problems that have upended nearly every industry around the world, Apple seems to be coming out of the crunch.</p><p><blockquote>当然，苹果的iPhone仍然是苹果营收的主要驱动力。尽管供应链问题颠覆了全球几乎所有行业，但苹果似乎正在走出困境。</blockquote></p><p> “Our checks indicate iPhone production is surprising to the upside as Apple hasn't experienced the same level of manufacturing disruptions as in the September quarter,” Huberty wrote. “While upward trending COVID cases are worth monitoring given they could create new production bottlenecks, we view supply upside as a driver of better December quarter iPhone results.”</p><p><blockquote>休伯蒂写道：“我们的检查表明，iPhone产量的增长令人惊讶，因为苹果并未经历与9月份季度相同程度的制造中断。”“虽然呈上升趋势的新冠病例值得监控，因为它们可能会造成新的生产瓶颈，但我们认为供应上升是iPhone 12月季度业绩更好的驱动因素。”</blockquote></p><p> Taken together, it’s clear analysts believe Apple’s new headset and related apps and services business, not to mention the iPhone, will serve as the catalysts that will not only push Apple over the $3 trillion mark, but send the company’s stock even higher.</p><p><blockquote>综上所述，分析师显然认为苹果的新耳机以及相关应用和服务业务（更不用说iPhone）将成为催化剂，不仅将推动苹果突破3万亿美元大关，还将推动该公司股价进一步走高。</blockquote></p><p> “Apple's rise is testament to its strong business model,” Santosh Rao, Manhattan Venture Partners’ head of research, told Yahoo Finance Live. “It's an amazing story.”</p><p><blockquote>Manhattan Venture Partners研究主管Santosh Rao告诉雅虎财经直播：“苹果的崛起证明了其强大的商业模式。”“这是一个惊人的故事。”</blockquote></p><p> “We have the cars coming up down the road, the 5G refresh, and so many other things, the services business, of course, is very strong,” he said. “So overall combined, this is a company that's well situated.”</p><p><blockquote>“我们有汽车上路、5G更新以及许多其他事情，当然，服务业务非常强劲，”他说。“所以总的来说，这是一家处于有利地位的公司。”</blockquote></p><p> Now Apple just has to prove the analysts’ optimism correct.</p><p><blockquote>现在苹果只需要证明分析师的乐观是正确的。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why analysts love Apple right now<blockquote>为什么分析师现在喜欢苹果</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy analysts love Apple right now<blockquote>为什么分析师现在喜欢苹果</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Yahoo Finance</strong><span class=\"h-time small\">2021-12-16 22:16</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Apple’s (AAPL) market capitalization is once again closing in on $3 trillion. If and when it hits the mark, which will require shares to reach $182.86, Apple will be in historic territory. And analysts are loving it.</p><p><blockquote>苹果(AAPL)的市值再次逼近3万亿美元。如果达到要求股价达到182.86美元的目标，苹果将处于历史高位。分析师们很喜欢它。</blockquote></p><p> This month alone, Katy Huberty of Morgan Stanley, Samik Chatterjee of JPMorgan, and Amit Daryanani of Evercore ISI have raised their price targets on the stock to $200. And on Tuesday BofA Global Research’s Wamsi Mohan upgraded the stock from neutral to buy and raised his price target for shares to $210.</p><p><blockquote>仅本月，摩根士丹利的Katy Huberty、摩根大通的Samik Chatterjee和Evercore ISI的Amit Daryanani就将该股的目标价提高至200美元。周二，美国银行全球研究部的瓦姆西·莫汉(Wamsi Mohan)将该股评级从中性上调至买入，并将股价目标上调至210美元。</blockquote></p><p> Several factors are spurring analysts to fawn over Apple: Optimism for Apple’s iPhone, its coming products including its rumored AR/VR headset, and the company’s ability to suck in consumers and keep them there through its services business.</p><p><blockquote>有几个因素促使分析师奉承苹果：对苹果iPhone的乐观情绪、其即将推出的产品（包括传闻中的AR/VR耳机），以及该公司通过其服务业务吸引消费者并将他们留在那里的能力。</blockquote></p><p> “We expect Apple to introduce an augmented reality/virtual reality (AR/VR) headset, either by the end of 2022 or early 2023,” Mohan wrote in a recent analyst note. “We view this technology as a game-changer as it will enable many new applications which will require high performance hardware and higher access speeds.”</p><p><blockquote>Mohan在最近的一份分析师报告中写道：“我们预计苹果将在2022年底或2023年初推出增强现实/虚拟现实（AR/VR）耳机。”“我们认为这项技术改变了游戏规则，因为它将支持许多需要高性能硬件和更高访问速度的新应用程序。”</blockquote></p><p> Apple’s AR/VR headset,according to Bloomberg’s Mark Gurman, could cost upwards of $3,000 and be geared to gaming, entertainment, and communications. The headset has been rumored for some time, with Apple filing various patents related to the technology.</p><p><blockquote>据彭博社的Mark Gurman称，苹果的AR/VR耳机价格可能超过3000美元，适用于游戏、娱乐和通信。这款耳机的传闻已经有一段时间了，苹果申请了与该技术相关的各种专利。</blockquote></p><p> “I think what a number of people and investors are thinking about is, ‘Hey, if they move to the glasses, the AR and VR glasses that a lot of people expect to see in '22, that's another opportunity to really build on this incredible ecosystem of device owners, and iOS, and Mac OS holders that really love their devices,’ ” TECHnalysis Research president Bob O’Donnell told Yahoo Finance Live.</p><p><blockquote>“我认为许多人和投资者正在考虑的是，‘嘿，如果他们转向眼镜，很多人期望在22年看到的AR和VR眼镜，这是另一个真正建立在这个基础上的机会TECHnalysis Research总裁Bob O’Donnell告诉雅虎财经直播。</blockquote></p><p> Apple’s Services business, which includes its App Store, is one of the major sticking points the company has going for it. After all, if you own an iPhone, you’re going to buy apps, and when it’s time to get a new phone you’ll likely buy another iPhone to keep those apps.</p><p><blockquote>苹果的服务业务（包括其应用商店）是该公司发展的主要症结之一。毕竟，如果你有一部iPhone，你就会购买应用程序，当需要买一部新手机时，你可能会购买另一部iPhone来保留这些应用程序。</blockquote></p><p> The same idea would apply to the company’s AR/VR headset if Apple can wrangle the kind of third-party developer support it already enjoys on the iPhone.</p><p><blockquote>如果苹果能够争取到它在iPhone上已经享有的第三方开发者支持，同样的想法也适用于该公司的AR/VR耳机。</blockquote></p><p> “We see the potential for more Services monetization relative to iPad as use cases develop beyond gaming and remote servicing and evolve into a whole new way in which the world digitally interacts, which AR/VR experts we've spoken with view as the long-term killer AR/VR application,” Huberty wrote in a Dec. 7 analyst note.</p><p><blockquote>“随着用例超越游戏和远程服务的发展，并演变成一种全新的世界数字交互方式，我们看到了相对于iPad更多服务货币化的潜力，我们采访过的AR/VR专家将其视为长期杀手AR/VR应用，”Huberty在12月7日的分析师报告中写道。</blockquote></p><p> Of course, Apple’s iPhone is still the major driver of Apple’s revenue. And despite the supply chain problems that have upended nearly every industry around the world, Apple seems to be coming out of the crunch.</p><p><blockquote>当然，苹果的iPhone仍然是苹果营收的主要驱动力。尽管供应链问题颠覆了全球几乎所有行业，但苹果似乎正在走出困境。</blockquote></p><p> “Our checks indicate iPhone production is surprising to the upside as Apple hasn't experienced the same level of manufacturing disruptions as in the September quarter,” Huberty wrote. “While upward trending COVID cases are worth monitoring given they could create new production bottlenecks, we view supply upside as a driver of better December quarter iPhone results.”</p><p><blockquote>休伯蒂写道：“我们的检查表明，iPhone产量的增长令人惊讶，因为苹果并未经历与9月份季度相同程度的制造中断。”“虽然呈上升趋势的新冠病例值得监控，因为它们可能会造成新的生产瓶颈，但我们认为供应上升是iPhone 12月季度业绩更好的驱动因素。”</blockquote></p><p> Taken together, it’s clear analysts believe Apple’s new headset and related apps and services business, not to mention the iPhone, will serve as the catalysts that will not only push Apple over the $3 trillion mark, but send the company’s stock even higher.</p><p><blockquote>综上所述，分析师显然认为苹果的新耳机以及相关应用和服务业务（更不用说iPhone）将成为催化剂，不仅将推动苹果突破3万亿美元大关，还将推动该公司股价进一步走高。</blockquote></p><p> “Apple's rise is testament to its strong business model,” Santosh Rao, Manhattan Venture Partners’ head of research, told Yahoo Finance Live. “It's an amazing story.”</p><p><blockquote>Manhattan Venture Partners研究主管Santosh Rao告诉雅虎财经直播：“苹果的崛起证明了其强大的商业模式。”“这是一个惊人的故事。”</blockquote></p><p> “We have the cars coming up down the road, the 5G refresh, and so many other things, the services business, of course, is very strong,” he said. “So overall combined, this is a company that's well situated.”</p><p><blockquote>“我们有汽车上路、5G更新以及许多其他事情，当然，服务业务非常强劲，”他说。“所以总的来说，这是一家处于有利地位的公司。”</blockquote></p><p> Now Apple just has to prove the analysts’ optimism correct.</p><p><blockquote>现在苹果只需要证明分析师的乐观是正确的。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/why-analysts-love-apple-right-now-140655190.html\">Yahoo Finance</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://finance.yahoo.com/news/why-analysts-love-apple-right-now-140655190.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121295991","content_text":"Apple’s (AAPL) market capitalization is once again closing in on $3 trillion. If and when it hits the mark, which will require shares to reach $182.86, Apple will be in historic territory. And analysts are loving it.\nThis month alone, Katy Huberty of Morgan Stanley, Samik Chatterjee of JPMorgan, and Amit Daryanani of Evercore ISI have raised their price targets on the stock to $200. And on Tuesday BofA Global Research’s Wamsi Mohan upgraded the stock from neutral to buy and raised his price target for shares to $210.\nSeveral factors are spurring analysts to fawn over Apple: Optimism for Apple’s iPhone, its coming products including its rumored AR/VR headset, and the company’s ability to suck in consumers and keep them there through its services business.\n“We expect Apple to introduce an augmented reality/virtual reality (AR/VR) headset, either by the end of 2022 or early 2023,” Mohan wrote in a recent analyst note. “We view this technology as a game-changer as it will enable many new applications which will require high performance hardware and higher access speeds.”\nApple’s AR/VR headset,according to Bloomberg’s Mark Gurman, could cost upwards of $3,000 and be geared to gaming, entertainment, and communications. The headset has been rumored for some time, with Apple filing various patents related to the technology.\n“I think what a number of people and investors are thinking about is, ‘Hey, if they move to the glasses, the AR and VR glasses that a lot of people expect to see in '22, that's another opportunity to really build on this incredible ecosystem of device owners, and iOS, and Mac OS holders that really love their devices,’ ” TECHnalysis Research president Bob O’Donnell told Yahoo Finance Live.\nApple’s Services business, which includes its App Store, is one of the major sticking points the company has going for it. After all, if you own an iPhone, you’re going to buy apps, and when it’s time to get a new phone you’ll likely buy another iPhone to keep those apps.\nThe same idea would apply to the company’s AR/VR headset if Apple can wrangle the kind of third-party developer support it already enjoys on the iPhone.\n“We see the potential for more Services monetization relative to iPad as use cases develop beyond gaming and remote servicing and evolve into a whole new way in which the world digitally interacts, which AR/VR experts we've spoken with view as the long-term killer AR/VR application,” Huberty wrote in a Dec. 7 analyst note.\nOf course, Apple’s iPhone is still the major driver of Apple’s revenue. And despite the supply chain problems that have upended nearly every industry around the world, Apple seems to be coming out of the crunch.\n“Our checks indicate iPhone production is surprising to the upside as Apple hasn't experienced the same level of manufacturing disruptions as in the September quarter,” Huberty wrote. “While upward trending COVID cases are worth monitoring given they could create new production bottlenecks, we view supply upside as a driver of better December quarter iPhone results.”\nTaken together, it’s clear analysts believe Apple’s new headset and related apps and services business, not to mention the iPhone, will serve as the catalysts that will not only push Apple over the $3 trillion mark, but send the company’s stock even higher.\n“Apple's rise is testament to its strong business model,” Santosh Rao, Manhattan Venture Partners’ head of research, told Yahoo Finance Live. “It's an amazing story.”\n“We have the cars coming up down the road, the 5G refresh, and so many other things, the services business, of course, is very strong,” he said. “So overall combined, this is a company that's well situated.”\nNow Apple just has to prove the analysts’ optimism correct.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":2266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609123127,"gmtCreate":1638254172838,"gmtModify":1638254172928,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Vaccine stock rally tonight 🔥🙏💉","listText":"Vaccine stock rally tonight 🔥🙏💉","text":"Vaccine stock rally tonight 🔥🙏💉","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609123127","repostId":"1141430877","repostType":4,"repost":{"id":"1141430877","kind":"news","pubTimestamp":1638251771,"share":"https://www.laohu8.com/m/news/1141430877?lang=zh_CN&edition=full","pubTime":"2021-11-30 13:56","market":"us","language":"en","title":"Moderna CEO says vaccines likely less effective against Omicron<blockquote>Moderna首席执行官表示疫苗对奥密克戎病毒的效果可能较差</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141430877","media":"Reuters","summary":"SYDNEY, Nov 30 (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be a","content":"<p>SYDNEY, Nov 30 (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p><p><blockquote>路透悉尼11月30日-制药商Moderna负责人表示，COVID-19疫苗不太可能像以前那样有效对抗冠状病毒的奥密克戎变种，这引发了金融市场对疫情发展轨迹的新担忧。</blockquote></p><p> \"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times&nbsp;in an interview.</p><p><blockquote>Moderna首席执行官斯特凡·班塞尔(Stéphane Bancel)在接受英国《金融时报》采访时表示：“我认为，没有一个世界的（有效性）与我们与达美航空的水平相同。”</blockquote></p><p> \"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p><p><blockquote>“我认为这将是一次物质下降。我只是不知道有多少，因为我们需要等待数据。但我交谈过的所有科学家……都像‘这不会有好结果’。”</blockquote></p><p> Vaccine resistance could lead to more sickness and hospitalisations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks and the Australian dollar.</p><p><blockquote>疫苗耐药性可能会导致更多的疾病和住院，并延长疫情，他的言论引发了石油、股票和澳元等增长资产的抛售。</blockquote></p><p> Bancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified.</p><p><blockquote>Bancel补充说，病毒用于感染人类细胞的蛋白质刺突上的大量突变意味着当前的疫苗可能需要进行修改。</blockquote></p><p> He had earlier said on CNBC that it could take months to begin shipping a vaccine that does work against Omicron.</p><p><blockquote>他早些时候在CNBC上表示，可能需要几个月的时间才能开始运送针对奥密克戎病毒的疫苗。</blockquote></p><p> Fear of the new variant, despite a lack of information about its severity, has already triggered delays to some economic reopening plans and the reimposition of some travel and movement restrictions.</p><p><blockquote>尽管缺乏关于其严重性的信息，但对新变种的恐惧已经引发了一些经济重新开放计划的推迟，以及一些旅行和行动限制的重新实施。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says vaccines likely less effective against Omicron<blockquote>Moderna首席执行官表示疫苗对奥密克戎病毒的效果可能较差</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says vaccines likely less effective against Omicron<blockquote>Moderna首席执行官表示疫苗对奥密克戎病毒的效果可能较差</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-30 13:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p>SYDNEY, Nov 30 (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p><p><blockquote>路透悉尼11月30日-制药商Moderna负责人表示，COVID-19疫苗不太可能像以前那样有效对抗冠状病毒的奥密克戎变种，这引发了金融市场对疫情发展轨迹的新担忧。</blockquote></p><p> \"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times&nbsp;in an interview.</p><p><blockquote>Moderna首席执行官斯特凡·班塞尔(Stéphane Bancel)在接受英国《金融时报》采访时表示：“我认为，没有一个世界的（有效性）与我们与达美航空的水平相同。”</blockquote></p><p> \"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p><p><blockquote>“我认为这将是一次物质下降。我只是不知道有多少，因为我们需要等待数据。但我交谈过的所有科学家……都像‘这不会有好结果’。”</blockquote></p><p> Vaccine resistance could lead to more sickness and hospitalisations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks and the Australian dollar.</p><p><blockquote>疫苗耐药性可能会导致更多的疾病和住院，并延长疫情，他的言论引发了石油、股票和澳元等增长资产的抛售。</blockquote></p><p> Bancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified.</p><p><blockquote>Bancel补充说，病毒用于感染人类细胞的蛋白质刺突上的大量突变意味着当前的疫苗可能需要进行修改。</blockquote></p><p> He had earlier said on CNBC that it could take months to begin shipping a vaccine that does work against Omicron.</p><p><blockquote>他早些时候在CNBC上表示，可能需要几个月的时间才能开始运送针对奥密克戎病毒的疫苗。</blockquote></p><p> Fear of the new variant, despite a lack of information about its severity, has already triggered delays to some economic reopening plans and the reimposition of some travel and movement restrictions.</p><p><blockquote>尽管缺乏关于其严重性的信息，但对新变种的恐惧已经引发了一些经济重新开放计划的推迟，以及一些旅行和行动限制的重新实施。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/1-moderna-ceo-says-vaccines-055048321.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/1-moderna-ceo-says-vaccines-055048321.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141430877","content_text":"SYDNEY, Nov 30 (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.\n\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.\n\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"\nVaccine resistance could lead to more sickness and hospitalisations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks and the Australian dollar.\nBancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified.\nHe had earlier said on CNBC that it could take months to begin shipping a vaccine that does work against Omicron.\nFear of the new variant, despite a lack of information about its severity, has already triggered delays to some economic reopening plans and the reimposition of some travel and movement restrictions.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876551023,"gmtCreate":1637333835298,"gmtModify":1637334091344,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Holding on....especially with the opening of themeparks in the near future.","listText":"Holding on....especially with the opening of themeparks in the near future.","text":"Holding on....especially with the opening of themeparks in the near future.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876551023","repostId":"1157818316","repostType":4,"repost":{"id":"1157818316","kind":"news","pubTimestamp":1637331780,"share":"https://www.laohu8.com/m/news/1157818316?lang=zh_CN&edition=full","pubTime":"2021-11-19 22:23","market":"us","language":"en","title":"Disney Stock: Jim Cramer Says Selling Now Is Shortsighted<blockquote>迪士尼股票：吉姆·克莱默表示现在出售是短视的</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1157818316","media":"TheStreet","summary":"For CNBC’s Jim Cramer, investors are buying high and selling low by focusing on Disney’s short-term ","content":"<p>For CNBC’s Jim Cramer, investors are buying high and selling low by focusing on Disney’s short-term woes rather than on the company’s long-term potential.</p><p><blockquote>对于CNBC的吉姆·克莱默(Jim Cramer)来说，投资者通过关注迪士尼的短期困境而不是该公司的长期潜力来高买低卖。</blockquote></p><p> The market continues to witness softness in Disney stock. Investors seemed disappointed in last quarter’s results, particularly regarding the addition of Disney+ subscribers.On the day after the earnings report, share price fell 7%.</p><p><blockquote>市场继续见证迪士尼股票的疲软。投资者似乎对上个季度的业绩感到失望，特别是对于Disney+订阅者的增加。财报发布后的第二天，股价下跌7%。</blockquote></p><p> At the same time, other investors have remained optimistic about the company. One such example is CNBC’s Jim Cramer, host of Mad Money, whoseesreasons to bet on DIS for the long term. Among them are (1) the company's new content investments, (2) the reopening of the parks and (3) the contrarian view in the face of so much negative sentiment.</p><p><blockquote>与此同时，其他投资者也对公司保持乐观态度。CNBC的《Mad Money》主持人吉姆·克莱默(Jim Cramer)就是这样一个例子，他认为有理由长期押注DIS。其中包括（1）公司的新内容投资，（2）公园的重新开放，以及（3）面对如此多的负面情绪时的逆向观点。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fa43949a100665b5ceb4b8a647ee6f93\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: CNBC's Jim Cramer, host of Mad Money.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：CNBC的Jim Cramer，《Mad Money》主持人。</span></p></blockquote></p><p> <b>New content</b></p><p><blockquote><b>新内容</b></blockquote></p><p> One key criticism of Disney’s streaming business model are the high costs. The DTC (direct-to-consumer) approach entails large expenses with the production of exclusive content, which is arguably key in attracting and retaining the platform's subscribers.</p><p><blockquote>对迪士尼流媒体商业模式的一个关键批评是高成本。DTC（直接面向消费者）方法在制作独家内容方面需要大量费用，这可以说是吸引和留住平台订户的关键。</blockquote></p><p> But Cramer does not seem to view this as a problem, rather as a long-term investment that the market still misunderstands. Disney and peers like Netflix&nbsp;spend a large chunk of their operating income on content production, which often scares off investors and sends them to the exits. But after the content is available and it helps to drive new subscriptions, investors return to buy back the shares when the herd chooses to do the same.</p><p><blockquote>但克莱默似乎并不认为这是一个问题，而是一项市场仍然误解的长期投资。迪士尼和Netflix等同行将营业收入的很大一部分用于内容制作，这往往会吓跑投资者并迫使他们退出。但在内容可用并有助于推动新的订阅后，当投资者选择这样做时，投资者会回来回购股票。</blockquote></p><p> Therefore, by focusing on the short term and ignoring the long term, many investors continue to buy high and sell low – a recipe for disaster over time.</p><p><blockquote>因此，通过关注短期而忽视长期，许多投资者继续高买低卖——随着时间的推移，这将导致灾难。</blockquote></p><p> <b>Theme parks</b></p><p><blockquote><b>主题公园</b></blockquote></p><p> With the reopening of Disney's parks, the company’s financial results should start to resemble those of the pre-pandemic period. Therefore, looking only at the new streaming segment is a bit narrow, as it still represents a small slice of Disney’s revenue – although probably the fastest growing over the long haul.</p><p><blockquote>随着迪士尼乐园的重新开放，该公司的财务业绩应该会开始类似于大流行前的时期。因此，仅关注新的流媒体细分市场有点狭隘，因为它仍然只占迪士尼收入的一小部分——尽管从长远来看可能是增长最快的。</blockquote></p><p> <b>What analysts say</b></p><p><blockquote><b>分析师怎么说</b></blockquote></p><p> While many investors remain pessimistic about DIS, many investment banks continue to view the company's long-term growth potential as appealing. This is the case of Morgan Stanley, which&nbsp;reiterated&nbsp;its “overweight” rating of Disney:</p><p><blockquote>尽管许多投资者仍对DIS持悲观态度，但许多投行仍认为该公司的长期增长潜力具有吸引力。摩根士丹利就是如此，摩根士丹利重申了对迪斯尼的“跑赢大盘”评级：</blockquote></p><p>   “We continue to believe its guidance is achievable, that with streaming scale comes substantial earnings power, and that success is not priced in.”  <b>Our view</b></p><p><blockquote>“我们仍然相信其指导是可以实现的，流媒体规模带来了巨大的盈利能力，而且这种成功并未被定价。”<b>我们的观点</b></blockquote></p><p> We believe that Disney is still a major player in the so-called streaming wars, and one of the few that can effectively compete for market share with companies like Netflix and Amazon. Therefore, a smaller-than-expected addition of users in a single quarter, especially at an inflection point in the COVID-19 crisis, should not be extrapolated too far out into the future.</p><p><blockquote>我们认为，迪士尼仍然是所谓流媒体战争中的主要参与者，也是少数能够与Netflix和亚马逊等公司有效争夺市场份额的公司之一。因此，单季度用户增长低于预期，尤其是在新冠肺炎危机的拐点，不应外推到太远的未来。</blockquote></p><p> In our view, one must wait for a series of quarterly reports to understand how Disney+ may fare against its peers. Growth concerns should only come, if at all, after careful analysis of the longer-term trend.</p><p><blockquote>我们认为，必须等待一系列季度报告才能了解Disney+与同行相比的表现如何。只有在仔细分析长期趋势之后，才会出现增长担忧（如果有的话）。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney Stock: Jim Cramer Says Selling Now Is Shortsighted<blockquote>迪士尼股票：吉姆·克莱默表示现在出售是短视的</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney Stock: Jim Cramer Says Selling Now Is Shortsighted<blockquote>迪士尼股票：吉姆·克莱默表示现在出售是短视的</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-11-19 22:23</span>\n</p>\n</h4>\n</header>\n<article>\n<p>For CNBC’s Jim Cramer, investors are buying high and selling low by focusing on Disney’s short-term woes rather than on the company’s long-term potential.</p><p><blockquote>对于CNBC的吉姆·克莱默(Jim Cramer)来说，投资者通过关注迪士尼的短期困境而不是该公司的长期潜力来高买低卖。</blockquote></p><p> The market continues to witness softness in Disney stock. Investors seemed disappointed in last quarter’s results, particularly regarding the addition of Disney+ subscribers.On the day after the earnings report, share price fell 7%.</p><p><blockquote>市场继续见证迪士尼股票的疲软。投资者似乎对上个季度的业绩感到失望，特别是对于Disney+订阅者的增加。财报发布后的第二天，股价下跌7%。</blockquote></p><p> At the same time, other investors have remained optimistic about the company. One such example is CNBC’s Jim Cramer, host of Mad Money, whoseesreasons to bet on DIS for the long term. Among them are (1) the company's new content investments, (2) the reopening of the parks and (3) the contrarian view in the face of so much negative sentiment.</p><p><blockquote>与此同时，其他投资者也对公司保持乐观态度。CNBC的《Mad Money》主持人吉姆·克莱默(Jim Cramer)就是这样一个例子，他认为有理由长期押注DIS。其中包括（1）公司的新内容投资，（2）公园的重新开放，以及（3）面对如此多的负面情绪时的逆向观点。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fa43949a100665b5ceb4b8a647ee6f93\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: CNBC's Jim Cramer, host of Mad Money.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：CNBC的Jim Cramer，《Mad Money》主持人。</span></p></blockquote></p><p> <b>New content</b></p><p><blockquote><b>新内容</b></blockquote></p><p> One key criticism of Disney’s streaming business model are the high costs. The DTC (direct-to-consumer) approach entails large expenses with the production of exclusive content, which is arguably key in attracting and retaining the platform's subscribers.</p><p><blockquote>对迪士尼流媒体商业模式的一个关键批评是高成本。DTC（直接面向消费者）方法在制作独家内容方面需要大量费用，这可以说是吸引和留住平台订户的关键。</blockquote></p><p> But Cramer does not seem to view this as a problem, rather as a long-term investment that the market still misunderstands. Disney and peers like Netflix&nbsp;spend a large chunk of their operating income on content production, which often scares off investors and sends them to the exits. But after the content is available and it helps to drive new subscriptions, investors return to buy back the shares when the herd chooses to do the same.</p><p><blockquote>但克莱默似乎并不认为这是一个问题，而是一项市场仍然误解的长期投资。迪士尼和Netflix等同行将营业收入的很大一部分用于内容制作，这往往会吓跑投资者并迫使他们退出。但在内容可用并有助于推动新的订阅后，当投资者选择这样做时，投资者会回来回购股票。</blockquote></p><p> Therefore, by focusing on the short term and ignoring the long term, many investors continue to buy high and sell low – a recipe for disaster over time.</p><p><blockquote>因此，通过关注短期而忽视长期，许多投资者继续高买低卖——随着时间的推移，这将导致灾难。</blockquote></p><p> <b>Theme parks</b></p><p><blockquote><b>主题公园</b></blockquote></p><p> With the reopening of Disney's parks, the company’s financial results should start to resemble those of the pre-pandemic period. Therefore, looking only at the new streaming segment is a bit narrow, as it still represents a small slice of Disney’s revenue – although probably the fastest growing over the long haul.</p><p><blockquote>随着迪士尼乐园的重新开放，该公司的财务业绩应该会开始类似于大流行前的时期。因此，仅关注新的流媒体细分市场有点狭隘，因为它仍然只占迪士尼收入的一小部分——尽管从长远来看可能是增长最快的。</blockquote></p><p> <b>What analysts say</b></p><p><blockquote><b>分析师怎么说</b></blockquote></p><p> While many investors remain pessimistic about DIS, many investment banks continue to view the company's long-term growth potential as appealing. This is the case of Morgan Stanley, which&nbsp;reiterated&nbsp;its “overweight” rating of Disney:</p><p><blockquote>尽管许多投资者仍对DIS持悲观态度，但许多投行仍认为该公司的长期增长潜力具有吸引力。摩根士丹利就是如此，摩根士丹利重申了对迪斯尼的“跑赢大盘”评级：</blockquote></p><p>   “We continue to believe its guidance is achievable, that with streaming scale comes substantial earnings power, and that success is not priced in.”  <b>Our view</b></p><p><blockquote>“我们仍然相信其指导是可以实现的，流媒体规模带来了巨大的盈利能力，而且这种成功并未被定价。”<b>我们的观点</b></blockquote></p><p> We believe that Disney is still a major player in the so-called streaming wars, and one of the few that can effectively compete for market share with companies like Netflix and Amazon. Therefore, a smaller-than-expected addition of users in a single quarter, especially at an inflection point in the COVID-19 crisis, should not be extrapolated too far out into the future.</p><p><blockquote>我们认为，迪士尼仍然是所谓流媒体战争中的主要参与者，也是少数能够与Netflix和亚马逊等公司有效争夺市场份额的公司之一。因此，单季度用户增长低于预期，尤其是在新冠肺炎危机的拐点，不应外推到太远的未来。</blockquote></p><p> In our view, one must wait for a series of quarterly reports to understand how Disney+ may fare against its peers. Growth concerns should only come, if at all, after careful analysis of the longer-term trend.</p><p><blockquote>我们认为，必须等待一系列季度报告才能了解Disney+与同行相比的表现如何。只有在仔细分析长期趋势之后，才会出现增长担忧（如果有的话）。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/streaming/dis/jim-cramer-it-is-shortsighted-to-sell-disney-stock-now\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼"},"source_url":"https://www.thestreet.com/streaming/dis/jim-cramer-it-is-shortsighted-to-sell-disney-stock-now","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157818316","content_text":"For CNBC’s Jim Cramer, investors are buying high and selling low by focusing on Disney’s short-term woes rather than on the company’s long-term potential.\nThe market continues to witness softness in Disney stock. Investors seemed disappointed in last quarter’s results, particularly regarding the addition of Disney+ subscribers.On the day after the earnings report, share price fell 7%.\nAt the same time, other investors have remained optimistic about the company. One such example is CNBC’s Jim Cramer, host of Mad Money, whoseesreasons to bet on DIS for the long term. Among them are (1) the company's new content investments, (2) the reopening of the parks and (3) the contrarian view in the face of so much negative sentiment.\nFigure 1: CNBC's Jim Cramer, host of Mad Money.\nNew content\nOne key criticism of Disney’s streaming business model are the high costs. The DTC (direct-to-consumer) approach entails large expenses with the production of exclusive content, which is arguably key in attracting and retaining the platform's subscribers.\nBut Cramer does not seem to view this as a problem, rather as a long-term investment that the market still misunderstands. Disney and peers like Netflix spend a large chunk of their operating income on content production, which often scares off investors and sends them to the exits. But after the content is available and it helps to drive new subscriptions, investors return to buy back the shares when the herd chooses to do the same.\nTherefore, by focusing on the short term and ignoring the long term, many investors continue to buy high and sell low – a recipe for disaster over time.\nTheme parks\nWith the reopening of Disney's parks, the company’s financial results should start to resemble those of the pre-pandemic period. Therefore, looking only at the new streaming segment is a bit narrow, as it still represents a small slice of Disney’s revenue – although probably the fastest growing over the long haul.\nWhat analysts say\nWhile many investors remain pessimistic about DIS, many investment banks continue to view the company's long-term growth potential as appealing. This is the case of Morgan Stanley, which reiterated its “overweight” rating of Disney:\n\n “We continue to believe its guidance is achievable, that with streaming scale comes substantial earnings power, and that success is not priced in.”\n\nOur view\nWe believe that Disney is still a major player in the so-called streaming wars, and one of the few that can effectively compete for market share with companies like Netflix and Amazon. Therefore, a smaller-than-expected addition of users in a single quarter, especially at an inflection point in the COVID-19 crisis, should not be extrapolated too far out into the future.\nIn our view, one must wait for a series of quarterly reports to understand how Disney+ may fare against its peers. Growth concerns should only come, if at all, after careful analysis of the longer-term trend.","news_type":1,"symbols_score_info":{"DIS":0.9}},"isVote":1,"tweetType":1,"viewCount":2112,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878704212,"gmtCreate":1637228338741,"gmtModify":1637228338741,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Finally!!! Its time for it to shine!","listText":"Finally!!! Its time for it to shine!","text":"Finally!!! Its time for it to shine!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/878704212","repostId":"1168434077","repostType":4,"repost":{"id":"1168434077","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637227046,"share":"https://www.laohu8.com/m/news/1168434077?lang=zh_CN&edition=full","pubTime":"2021-11-18 17:17","market":"us","language":"en","title":"Novavax shares jumped 5% in premarket trading<blockquote>Novavax股价在盘前交易中上涨5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1168434077","media":"Tiger Newspress","summary":"Novavax shares jumped 5% in premarket trading as EU decision on Novavax COVID-19 shot could come 'wi","content":"<p>Novavax shares jumped 5% in premarket trading&nbsp;as&nbsp;EU decision on Novavax COVID-19 shot could come 'within weeks'.</p><p><blockquote>由于欧盟可能在“几周内”就Novavax COVID-19疫苗做出决定，Novavax股价在盘前交易中上涨5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/6082341ff6cf8c02e6284028a5ba5cd6\" tg-width=\"848\" tg-height=\"620\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The European Union’s drug regulator said on Wednesday it could decide on Novavax’s COVID-19 vaccine approval “within weeks” if the data it has received from the drugmaker was sufficient to prove the shot’s effectiveness.</p><p><blockquote>欧盟药品监管机构周三表示，如果从制药商那里收到的数据足以证明疫苗的有效性，它可能会在“几周内”决定批准Novavax的COVID-19疫苗。</blockquote></p><p> The protein-based vaccine, branded Nuvaxovid, has been under a rolling review since February, the European Medicines Agency (EMA) said. Such reviews allow for a speedy approval.</p><p><blockquote>欧洲药品管理局(EMA)表示，这种名为Nuvaxovid的蛋白质疫苗自2月份以来一直在接受滚动审查。这种审查允许快速批准。</blockquote></p><p> If approved by the EMA, the shot would be the region’s fifth coronavirus vaccine, joining those from Pfizer-BioNTech, Moderna, AstraZeneca and Johnson &amp; Johnson.</p><p><blockquote>如果获得EMA批准，该疫苗将成为该地区的第五种冠状病毒疫苗，加入辉瑞-BioNTech、Moderna、阿斯利康和强生公司的行列。</blockquote></p><p> The major approval could come much ahead of authorisation in the United States, where Novavax had to resolve manufacturing issues and expects to file for approval by the end of the year.</p><p><blockquote>重大批准可能会远远早于美国的授权，Novavax必须在美国解决制造问题，并预计在今年年底前申请批准。</blockquote></p><p> The EMA said two of its advisory panels were looking into various plans submitted by Novavax on risk management, and development and studies of the vaccine for use in children.</p><p><blockquote>EMA表示，其两个顾问小组正在研究Novavax提交的关于风险管理以及儿童疫苗开发和研究的各种计划。</blockquote></p><p> Novavax’s shot received its first emergency use approval earlier this month in Indonesia. The company has also sought backing from the World Health Organization. The Philippines on Wednesday authorised emergency use of a version made by India’s Serum Institute.</p><p><blockquote>Novavax的疫苗本月早些时候在印度尼西亚获得了首次紧急使用批准。该公司还寻求世界卫生组织的支持。菲律宾周三授权紧急使用印度血清研究所制造的版本。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares jumped 5% in premarket trading<blockquote>Novavax股价在盘前交易中上涨5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares jumped 5% in premarket trading<blockquote>Novavax股价在盘前交易中上涨5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-18 17:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Novavax shares jumped 5% in premarket trading&nbsp;as&nbsp;EU decision on Novavax COVID-19 shot could come 'within weeks'.</p><p><blockquote>由于欧盟可能在“几周内”就Novavax COVID-19疫苗做出决定，Novavax股价在盘前交易中上涨5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/6082341ff6cf8c02e6284028a5ba5cd6\" tg-width=\"848\" tg-height=\"620\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The European Union’s drug regulator said on Wednesday it could decide on Novavax’s COVID-19 vaccine approval “within weeks” if the data it has received from the drugmaker was sufficient to prove the shot’s effectiveness.</p><p><blockquote>欧盟药品监管机构周三表示，如果从制药商那里收到的数据足以证明疫苗的有效性，它可能会在“几周内”决定批准Novavax的COVID-19疫苗。</blockquote></p><p> The protein-based vaccine, branded Nuvaxovid, has been under a rolling review since February, the European Medicines Agency (EMA) said. Such reviews allow for a speedy approval.</p><p><blockquote>欧洲药品管理局(EMA)表示，这种名为Nuvaxovid的蛋白质疫苗自2月份以来一直在接受滚动审查。这种审查允许快速批准。</blockquote></p><p> If approved by the EMA, the shot would be the region’s fifth coronavirus vaccine, joining those from Pfizer-BioNTech, Moderna, AstraZeneca and Johnson &amp; Johnson.</p><p><blockquote>如果获得EMA批准，该疫苗将成为该地区的第五种冠状病毒疫苗，加入辉瑞-BioNTech、Moderna、阿斯利康和强生公司的行列。</blockquote></p><p> The major approval could come much ahead of authorisation in the United States, where Novavax had to resolve manufacturing issues and expects to file for approval by the end of the year.</p><p><blockquote>重大批准可能会远远早于美国的授权，Novavax必须在美国解决制造问题，并预计在今年年底前申请批准。</blockquote></p><p> The EMA said two of its advisory panels were looking into various plans submitted by Novavax on risk management, and development and studies of the vaccine for use in children.</p><p><blockquote>EMA表示，其两个顾问小组正在研究Novavax提交的关于风险管理以及儿童疫苗开发和研究的各种计划。</blockquote></p><p> Novavax’s shot received its first emergency use approval earlier this month in Indonesia. The company has also sought backing from the World Health Organization. The Philippines on Wednesday authorised emergency use of a version made by India’s Serum Institute.</p><p><blockquote>Novavax的疫苗本月早些时候在印度尼西亚获得了首次紧急使用批准。该公司还寻求世界卫生组织的支持。菲律宾周三授权紧急使用印度血清研究所制造的版本。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168434077","content_text":"Novavax shares jumped 5% in premarket trading as EU decision on Novavax COVID-19 shot could come 'within weeks'.\n\nThe European Union’s drug regulator said on Wednesday it could decide on Novavax’s COVID-19 vaccine approval “within weeks” if the data it has received from the drugmaker was sufficient to prove the shot’s effectiveness.\nThe protein-based vaccine, branded Nuvaxovid, has been under a rolling review since February, the European Medicines Agency (EMA) said. Such reviews allow for a speedy approval.\nIf approved by the EMA, the shot would be the region’s fifth coronavirus vaccine, joining those from Pfizer-BioNTech, Moderna, AstraZeneca and Johnson & Johnson.\nThe major approval could come much ahead of authorisation in the United States, where Novavax had to resolve manufacturing issues and expects to file for approval by the end of the year.\nThe EMA said two of its advisory panels were looking into various plans submitted by Novavax on risk management, and development and studies of the vaccine for use in children.\nNovavax’s shot received its first emergency use approval earlier this month in Indonesia. The company has also sought backing from the World Health Organization. The Philippines on Wednesday authorised emergency use of a version made by India’s Serum Institute.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889762920,"gmtCreate":1631180128360,"gmtModify":1631890825358,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>waiting for report to be released tmr. Hang in there!&nbsp;[吃瓜]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>waiting for report to be released tmr. Hang in there!&nbsp;[吃瓜]&nbsp;","text":"$Tiger Brokers(TIGR)$waiting for report to be released tmr. Hang in there! [吃瓜]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889762920","isVote":1,"tweetType":1,"viewCount":977,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889766003,"gmtCreate":1631180027002,"gmtModify":1631883559823,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[财迷]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[财迷]&nbsp;","text":"$Tesla Motors(TSLA)$[财迷]","images":[{"img":"https://static.tigerbbs.com/8e5acacbd5f146c0a6a10d8c719c1a46","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889766003","isVote":1,"tweetType":1,"viewCount":1335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":812596013,"gmtCreate":1630593348932,"gmtModify":1631890825361,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[财迷]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[财迷]&nbsp;","text":"$Tesla Motors(TSLA)$[财迷]","images":[{"img":"https://static.tigerbbs.com/791513175bb9ae21643cb6611407a8ed","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812596013","isVote":1,"tweetType":1,"viewCount":1089,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":812591614,"gmtCreate":1630593284338,"gmtModify":1631890825364,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"More more more","listText":"More more more","text":"More more more","images":[{"img":"https://static.tigerbbs.com/a912fe82c31f2472f4a003b31133e397","width":"720","height":"2143"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812591614","isVote":1,"tweetType":1,"viewCount":503,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":175649968,"gmtCreate":1627030371954,"gmtModify":1631890825368,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GOTU\">$Gaotu Techedu Inc.(GOTU)$</a>Can't even describe how I feel now. :( X 10000000","listText":"<a href=\"https://laohu8.com/S/GOTU\">$Gaotu Techedu Inc.(GOTU)$</a>Can't even describe how I feel now. :( X 10000000","text":"$Gaotu Techedu Inc.(GOTU)$Can't even describe how I feel now. :( X 10000000","images":[{"img":"https://static.tigerbbs.com/d93c31f6cedc6d06a9580a18b1e487d3","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":3,"link":"https://laohu8.com/post/175649968","isVote":1,"tweetType":1,"viewCount":1903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":145779375,"gmtCreate":1626250165197,"gmtModify":1631886369705,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>T.T from +25% profit to loss in a week. Ouchhhhhh.","listText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>T.T from +25% profit to loss in a week. Ouchhhhhh.","text":"$Stem Inc.(STEM)$T.T from +25% profit to loss in a week. Ouchhhhhh.","images":[{"img":"https://static.tigerbbs.com/0b3d4fba36c52eb193d8f62c526f41b0","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/145779375","isVote":1,"tweetType":1,"viewCount":660,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":121813326,"gmtCreate":1624458389665,"gmtModify":1631886369743,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","listText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","text":"$Stem Inc.(STEM)$[财迷] [财迷] [财迷]","images":[{"img":"https://static.tigerbbs.com/6b98ef2191be4e3fe8f302cee4c12644","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/121813326","isVote":1,"tweetType":1,"viewCount":977,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":163644616,"gmtCreate":1623884735035,"gmtModify":1631885748217,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>lets do it!&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>lets do it!&nbsp;","text":"$ChargePoint Holdings Inc.(CHPT)$lets do it!","images":[{"img":"https://static.tigerbbs.com/950bf86affe4ceeb525c4cd4d4f5ab35","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163644616","isVote":1,"tweetType":1,"viewCount":479,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":116796288,"gmtCreate":1622818075944,"gmtModify":1631890825371,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Let's go!","listText":"Let's go!","text":"Let's go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/116796288","repostId":"116443496","repostType":1,"repost":{"id":116443496,"gmtCreate":1622816867715,"gmtModify":1631884132357,"author":{"id":"3580359170890697","authorId":"3580359170890697","name":"ahong2706","avatar":"https://static.tigerbbs.com/0016ddf5c57401a3852f07709daabd2a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580359170890697","idStr":"3580359170890697"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$</a>Green Tea Frap x)","listText":"<a href=\"https://laohu8.com/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$</a>Green Tea Frap x)","text":"$Vanguard S&P 500 ETF(VOO)$Green Tea Frap x)","images":[{"img":"https://static.tigerbbs.com/e778f7ee341383ddc105cc95b3200821","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/116443496","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":485,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":175649968,"gmtCreate":1627030371954,"gmtModify":1631890825368,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GOTU\">$Gaotu Techedu Inc.(GOTU)$</a>Can't even describe how I feel now. :( X 10000000","listText":"<a href=\"https://laohu8.com/S/GOTU\">$Gaotu Techedu Inc.(GOTU)$</a>Can't even describe how I feel now. :( X 10000000","text":"$Gaotu Techedu Inc.(GOTU)$Can't even describe how I feel now. :( X 10000000","images":[{"img":"https://static.tigerbbs.com/d93c31f6cedc6d06a9580a18b1e487d3","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":3,"link":"https://laohu8.com/post/175649968","isVote":1,"tweetType":1,"viewCount":1903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":878704212,"gmtCreate":1637228338741,"gmtModify":1637228338741,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Finally!!! Its time for it to shine!","listText":"Finally!!! Its time for it to shine!","text":"Finally!!! Its time for it to shine!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/878704212","repostId":"1168434077","repostType":4,"repost":{"id":"1168434077","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637227046,"share":"https://www.laohu8.com/m/news/1168434077?lang=zh_CN&edition=full","pubTime":"2021-11-18 17:17","market":"us","language":"en","title":"Novavax shares jumped 5% in premarket trading<blockquote>Novavax股价在盘前交易中上涨5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1168434077","media":"Tiger Newspress","summary":"Novavax shares jumped 5% in premarket trading as EU decision on Novavax COVID-19 shot could come 'wi","content":"<p>Novavax shares jumped 5% in premarket trading&nbsp;as&nbsp;EU decision on Novavax COVID-19 shot could come 'within weeks'.</p><p><blockquote>由于欧盟可能在“几周内”就Novavax COVID-19疫苗做出决定，Novavax股价在盘前交易中上涨5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/6082341ff6cf8c02e6284028a5ba5cd6\" tg-width=\"848\" tg-height=\"620\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The European Union’s drug regulator said on Wednesday it could decide on Novavax’s COVID-19 vaccine approval “within weeks” if the data it has received from the drugmaker was sufficient to prove the shot’s effectiveness.</p><p><blockquote>欧盟药品监管机构周三表示，如果从制药商那里收到的数据足以证明疫苗的有效性，它可能会在“几周内”决定批准Novavax的COVID-19疫苗。</blockquote></p><p> The protein-based vaccine, branded Nuvaxovid, has been under a rolling review since February, the European Medicines Agency (EMA) said. Such reviews allow for a speedy approval.</p><p><blockquote>欧洲药品管理局(EMA)表示，这种名为Nuvaxovid的蛋白质疫苗自2月份以来一直在接受滚动审查。这种审查允许快速批准。</blockquote></p><p> If approved by the EMA, the shot would be the region’s fifth coronavirus vaccine, joining those from Pfizer-BioNTech, Moderna, AstraZeneca and Johnson &amp; Johnson.</p><p><blockquote>如果获得EMA批准，该疫苗将成为该地区的第五种冠状病毒疫苗，加入辉瑞-BioNTech、Moderna、阿斯利康和强生公司的行列。</blockquote></p><p> The major approval could come much ahead of authorisation in the United States, where Novavax had to resolve manufacturing issues and expects to file for approval by the end of the year.</p><p><blockquote>重大批准可能会远远早于美国的授权，Novavax必须在美国解决制造问题，并预计在今年年底前申请批准。</blockquote></p><p> The EMA said two of its advisory panels were looking into various plans submitted by Novavax on risk management, and development and studies of the vaccine for use in children.</p><p><blockquote>EMA表示，其两个顾问小组正在研究Novavax提交的关于风险管理以及儿童疫苗开发和研究的各种计划。</blockquote></p><p> Novavax’s shot received its first emergency use approval earlier this month in Indonesia. The company has also sought backing from the World Health Organization. The Philippines on Wednesday authorised emergency use of a version made by India’s Serum Institute.</p><p><blockquote>Novavax的疫苗本月早些时候在印度尼西亚获得了首次紧急使用批准。该公司还寻求世界卫生组织的支持。菲律宾周三授权紧急使用印度血清研究所制造的版本。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares jumped 5% in premarket trading<blockquote>Novavax股价在盘前交易中上涨5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares jumped 5% in premarket trading<blockquote>Novavax股价在盘前交易中上涨5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-18 17:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Novavax shares jumped 5% in premarket trading&nbsp;as&nbsp;EU decision on Novavax COVID-19 shot could come 'within weeks'.</p><p><blockquote>由于欧盟可能在“几周内”就Novavax COVID-19疫苗做出决定，Novavax股价在盘前交易中上涨5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/6082341ff6cf8c02e6284028a5ba5cd6\" tg-width=\"848\" tg-height=\"620\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The European Union’s drug regulator said on Wednesday it could decide on Novavax’s COVID-19 vaccine approval “within weeks” if the data it has received from the drugmaker was sufficient to prove the shot’s effectiveness.</p><p><blockquote>欧盟药品监管机构周三表示，如果从制药商那里收到的数据足以证明疫苗的有效性，它可能会在“几周内”决定批准Novavax的COVID-19疫苗。</blockquote></p><p> The protein-based vaccine, branded Nuvaxovid, has been under a rolling review since February, the European Medicines Agency (EMA) said. Such reviews allow for a speedy approval.</p><p><blockquote>欧洲药品管理局(EMA)表示，这种名为Nuvaxovid的蛋白质疫苗自2月份以来一直在接受滚动审查。这种审查允许快速批准。</blockquote></p><p> If approved by the EMA, the shot would be the region’s fifth coronavirus vaccine, joining those from Pfizer-BioNTech, Moderna, AstraZeneca and Johnson &amp; Johnson.</p><p><blockquote>如果获得EMA批准，该疫苗将成为该地区的第五种冠状病毒疫苗，加入辉瑞-BioNTech、Moderna、阿斯利康和强生公司的行列。</blockquote></p><p> The major approval could come much ahead of authorisation in the United States, where Novavax had to resolve manufacturing issues and expects to file for approval by the end of the year.</p><p><blockquote>重大批准可能会远远早于美国的授权，Novavax必须在美国解决制造问题，并预计在今年年底前申请批准。</blockquote></p><p> The EMA said two of its advisory panels were looking into various plans submitted by Novavax on risk management, and development and studies of the vaccine for use in children.</p><p><blockquote>EMA表示，其两个顾问小组正在研究Novavax提交的关于风险管理以及儿童疫苗开发和研究的各种计划。</blockquote></p><p> Novavax’s shot received its first emergency use approval earlier this month in Indonesia. The company has also sought backing from the World Health Organization. The Philippines on Wednesday authorised emergency use of a version made by India’s Serum Institute.</p><p><blockquote>Novavax的疫苗本月早些时候在印度尼西亚获得了首次紧急使用批准。该公司还寻求世界卫生组织的支持。菲律宾周三授权紧急使用印度血清研究所制造的版本。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168434077","content_text":"Novavax shares jumped 5% in premarket trading as EU decision on Novavax COVID-19 shot could come 'within weeks'.\n\nThe European Union’s drug regulator said on Wednesday it could decide on Novavax’s COVID-19 vaccine approval “within weeks” if the data it has received from the drugmaker was sufficient to prove the shot’s effectiveness.\nThe protein-based vaccine, branded Nuvaxovid, has been under a rolling review since February, the European Medicines Agency (EMA) said. Such reviews allow for a speedy approval.\nIf approved by the EMA, the shot would be the region’s fifth coronavirus vaccine, joining those from Pfizer-BioNTech, Moderna, AstraZeneca and Johnson & Johnson.\nThe major approval could come much ahead of authorisation in the United States, where Novavax had to resolve manufacturing issues and expects to file for approval by the end of the year.\nThe EMA said two of its advisory panels were looking into various plans submitted by Novavax on risk management, and development and studies of the vaccine for use in children.\nNovavax’s shot received its first emergency use approval earlier this month in Indonesia. The company has also sought backing from the World Health Organization. The Philippines on Wednesday authorised emergency use of a version made by India’s Serum Institute.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699706015,"gmtCreate":1639886846944,"gmtModify":1639886847065,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Nova!!!!","listText":"Nova!!!!","text":"Nova!!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/699706015","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","kind":"news","pubTimestamp":1639884070,"share":"https://www.laohu8.com/m/news/1122414343?lang=zh_CN&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir跻身医疗保健股涨幅之列，辉瑞(Pfizer)创下十年来最佳涨幅</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p><p><blockquote>标普500的医疗保健股表现优于大盘指数中的所有其他板块，涨幅约为2.5%，主要得益于并购前景。<a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>科技股以及与COVID-19死灰复燃作斗争的股票领涨，而整体指数下跌约1.9%。</blockquote></p><p> Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p><p><blockquote>在过去一周市值超过20亿美元、日均成交量超过10万的股票中，<a href=\"https://laohu8.com/S/ARNA\">Arena制药公司</a>之后上涨约83.8%<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>同意以约6.7 B美元的价格收购该生物技术公司，溢价100%。<a href=\"https://laohu8.com/S/CERN\">塞尔纳</a>也加入了并购推动的涨势，本周上涨约20.7%，有报道称来自<a href=\"https://laohu8.com/S/ORCL\">神谕</a>电子病历公司。</blockquote></p><p> Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p><p><blockquote>疫苗开发商、<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>由于投资者欢迎世界卫生组织批准该公司的COVID-19疫苗，股价上涨约30.5%。当欧洲监管机构的专家小组将于下周审查该疫苗的营销授权时，这家总部位于马里兰州的生物技术公司可能会进一步受益。</blockquote></p><p> <a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p><p><blockquote><a href=\"https://laohu8.com/S/BHVN\">Biohaven制药</a>在该公司宣布NURTEC ODT(rimegepant)在以色列获得批准后，该公司每周上涨约25.2%，使其成为该偏头痛药物在美国以外的首个监管胜利。与此同时，Vir Biotechnology（纳斯达克股票代码：VIR）飙升约23.7%，成为本月第二周涨幅最大的股票之一。本周出现的更多数据证实了该公司与葛兰素史克（纽约证券交易所股票代码：GSK）合作开发的COVID-19疗法具有奥密克戎中和作用。跻身涨幅前五名的还有，<a href=\"https://laohu8.com/S/ROIV\">Roivant科学</a>增加了约22.6%。</blockquote></p><p> Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p><p><blockquote>值得注意的赢家：<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE)本周成为头条新闻，再次提高了COVID-19疫苗的销售指引，因为迅速传播的奥密克戎变种凸显了加强注射的必要性。尽管周五突然结束了连续六天的涨势，<a href=\"https://laohu8.com/S/NWY\">纽约</a>总部位于美国的制药巨头股价上涨约12.7%，创下2009年3月以来的最佳单周涨幅。</blockquote></p><p> Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p><p><blockquote>在本周表现最差的公司中，两家新IPO的生物技术公司Instil Bio（纳斯达克股票代码：TIL）和Exscientia（纳斯达克股票代码：EXAI）脱颖而出，尽管它们在华尔街获得了良好的评级，但分别下跌了19.3%和约13.5%。与此同时，处方药比价平台运营商GoodRx Holdings（纳斯达克股票代码：GDRX）股价下跌约15.6%。</blockquote></p><p> Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p><p><blockquote>上周表现最好的，<a href=\"https://laohu8.com/S/BHG\">光明健康集团</a>，暴跌约13.1%，受到唯一卖出评级的伤害<a href=\"https://laohu8.com/S/GS\">高盛</a>尽管这家投资银行以基本积极的观点开始了对管理式医疗的报道。</blockquote></p><p> Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p><p><blockquote>Allogene Therapeutics（纳斯达克股票代码：ALLO）在ASH介绍实验性同种异体药物1期数据后股价下跌约12.3%<a href=\"https://laohu8.com/S/00699\">车</a>T疗法未能让投资者兴奋，其中包括Cathie Wood的Ark Investment Management，该公司几天后出售了约160万股该生物技术公司的股票。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir跻身医疗保健股涨幅之列，辉瑞(Pfizer)创下十年来最佳涨幅</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir跻身医疗保健股涨幅之列，辉瑞(Pfizer)创下十年来最佳涨幅</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-19 11:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p><p><blockquote>标普500的医疗保健股表现优于大盘指数中的所有其他板块，涨幅约为2.5%，主要得益于并购前景。<a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>科技股以及与COVID-19死灰复燃作斗争的股票领涨，而整体指数下跌约1.9%。</blockquote></p><p> Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p><p><blockquote>在过去一周市值超过20亿美元、日均成交量超过10万的股票中，<a href=\"https://laohu8.com/S/ARNA\">Arena制药公司</a>之后上涨约83.8%<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>同意以约6.7 B美元的价格收购该生物技术公司，溢价100%。<a href=\"https://laohu8.com/S/CERN\">塞尔纳</a>也加入了并购推动的涨势，本周上涨约20.7%，有报道称来自<a href=\"https://laohu8.com/S/ORCL\">神谕</a>电子病历公司。</blockquote></p><p> Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p><p><blockquote>疫苗开发商、<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>由于投资者欢迎世界卫生组织批准该公司的COVID-19疫苗，股价上涨约30.5%。当欧洲监管机构的专家小组将于下周审查该疫苗的营销授权时，这家总部位于马里兰州的生物技术公司可能会进一步受益。</blockquote></p><p> <a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p><p><blockquote><a href=\"https://laohu8.com/S/BHVN\">Biohaven制药</a>在该公司宣布NURTEC ODT(rimegepant)在以色列获得批准后，该公司每周上涨约25.2%，使其成为该偏头痛药物在美国以外的首个监管胜利。与此同时，Vir Biotechnology（纳斯达克股票代码：VIR）飙升约23.7%，成为本月第二周涨幅最大的股票之一。本周出现的更多数据证实了该公司与葛兰素史克（纽约证券交易所股票代码：GSK）合作开发的COVID-19疗法具有奥密克戎中和作用。跻身涨幅前五名的还有，<a href=\"https://laohu8.com/S/ROIV\">Roivant科学</a>增加了约22.6%。</blockquote></p><p> Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p><p><blockquote>值得注意的赢家：<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE)本周成为头条新闻，再次提高了COVID-19疫苗的销售指引，因为迅速传播的奥密克戎变种凸显了加强注射的必要性。尽管周五突然结束了连续六天的涨势，<a href=\"https://laohu8.com/S/NWY\">纽约</a>总部位于美国的制药巨头股价上涨约12.7%，创下2009年3月以来的最佳单周涨幅。</blockquote></p><p> Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p><p><blockquote>在本周表现最差的公司中，两家新IPO的生物技术公司Instil Bio（纳斯达克股票代码：TIL）和Exscientia（纳斯达克股票代码：EXAI）脱颖而出，尽管它们在华尔街获得了良好的评级，但分别下跌了19.3%和约13.5%。与此同时，处方药比价平台运营商GoodRx Holdings（纳斯达克股票代码：GDRX）股价下跌约15.6%。</blockquote></p><p> Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p><p><blockquote>上周表现最好的，<a href=\"https://laohu8.com/S/BHG\">光明健康集团</a>，暴跌约13.1%，受到唯一卖出评级的伤害<a href=\"https://laohu8.com/S/GS\">高盛</a>尽管这家投资银行以基本积极的观点开始了对管理式医疗的报道。</blockquote></p><p> Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p><p><blockquote>Allogene Therapeutics（纳斯达克股票代码：ALLO）在ASH介绍实验性同种异体药物1期数据后股价下跌约12.3%<a href=\"https://laohu8.com/S/00699\">车</a>T疗法未能让投资者兴奋，其中包括Cathie Wood的Ark Investment Management，该公司几天后出售了约160万股该生物技术公司的股票。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARNA":"阿里那","BK4533":"AQR资本管理(全球第二大对冲基金)","CERN":"美国塞纳","BK4007":"制药","BK4550":"红杉资本持仓","ORCL":"甲骨文","PFE":"辉瑞","BK4568":"美国抗疫概念","BK4534":"瑞士信贷持仓"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals  dominated with a ~83.8% rise after Pfizer  agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner  also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle  for the electronic-medical-records company.\nVaccine developer, Novavax  jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical  posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences  added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1,"symbols_score_info":{"ORCL":0.9,"CERN":0.9,"ARNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2324,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":116799900,"gmtCreate":1622817863200,"gmtModify":1631890825372,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Thank you. Thank you.","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Thank you. Thank you.","text":"$Tiger Brokers(TIGR)$Thank you. Thank you.","images":[{"img":"https://static.tigerbbs.com/57461042d2e8c4ae13af70e98202a45a","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/116799900","isVote":1,"tweetType":1,"viewCount":365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":696300104,"gmtCreate":1640612840415,"gmtModify":1640612840516,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Yes pleaseeeeeee.","listText":"Yes pleaseeeeeee.","text":"Yes pleaseeeeeee.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696300104","repostId":"1111088353","repostType":4,"repost":{"id":"1111088353","kind":"news","pubTimestamp":1640610579,"share":"https://www.laohu8.com/m/news/1111088353?lang=zh_CN&edition=full","pubTime":"2021-12-27 21:09","market":"us","language":"en","title":"Plug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla<blockquote>普拉格能源的交易就像一只故事股票，闻起来像早期的特斯拉</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111088353","media":"Seeking Alpha","summary":"Summary\n\nThe stock of Plug Power enjoyed some great appreciation during the last years, which seems ","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>The stock of Plug Power enjoyed some great appreciation during the last years, which seems hard to explain when purely looking at the fundamentals.</li>  <li>The stock performance of almost 2,000% over the last 5 years is an illustration of the increased momentum of the hydrogen market.</li>  <li>Plug Power shows some important parallels with Tesla, on which I will elaborate in this article.</li>  <li>If the sentiment can remain positive while growth continues, short-term fundamentals might not matter much.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80405c7f3988b402597ce18944c15c47\" tg-width=\"1536\" tg-height=\"683\" width=\"100%\" height=\"auto\"><span>http://www.fotogestoeber.de/iStock via Getty Images</span></p><p><blockquote><ul><li>普拉格能源的股票在过去几年中大幅升值，如果纯粹从基本面来看，这似乎很难解释。</li><li>过去5年近2,000%的股票表现说明了氢市场的增长势头。</li><li>普拉格能源与特斯拉有一些重要的相似之处，我将在本文中详细阐述。</li><li>如果在增长持续的同时，市场情绪能够保持积极，那么短期基本面可能并不重要。</li></ul><p class=\"t-img-caption\"><span>http://www.fotogestoeber.de/iStock来自Getty Images</span></p></blockquote></p><p> How can a company in a niche sector which has continuously burned cash over the years have a market capitalization of over $17B? Plug Power (PLUG) is a pure-play hydrogen company that has yet to run a profit. Still, the stock has returned a total of almost 2,000% over the last 5 years.</p><p><blockquote>一家多年来不断烧钱的利基行业公司，市值怎么可能超过170亿美元？普拉格能源（PLUG）是一家纯粹的氢能公司，尚未盈利。尽管如此，该股在过去5年中的总回报率仍接近2,000%。</blockquote></p><p> In this article, I will investigate the promises and expectations behind Plug Power and compare the stock to another stock with large promises: Tesla (TSLA).</p><p><blockquote>在本文中，我将调查普拉格能源背后的承诺和期望，并将该股票与另一只具有巨大承诺的股票：特斯拉（TSLA）进行比较。</blockquote></p><p> <b>Great stock performance, but a lofty valuation</b></p><p><blockquote><b>股票表现出色，但估值很高</b></blockquote></p><p> Plug Power has behaved somewhat like a battleground stock during the last couple of years. Ever since the&nbsp;2014 hydrogen rally, Plug Power has remained a stock that lured investors who believe in the technology, but also attracted quite some short-sellers, judged by its current short interest of almost 10 percent.</p><p><blockquote>过去几年，普拉格能源的表现有点像战场股票。自2014年氢能反弹以来，普拉格能源一直是一只吸引相信该技术的投资者的股票，但从其目前近10%的空头兴趣来看，也吸引了相当多的卖空者。</blockquote></p><p> More recently, the stock has experienced a huge liftoff, most likely fueled by the announcement of the&nbsp;Build Back Better Plan&nbsp;of president Biden. Since then, Plug Power's stock more or less came back to earth again, even though it is still trading at a very high price to sales ratio.</p><p><blockquote>最近，该股经历了大幅上涨，很可能是拜登总统宣布的重建更好计划推动的。从那时起，普拉格能源的股票或多或少又回到了现实，尽管它的市销率仍然非常高。</blockquote></p><p> Please review the following charts for illustration of these metrics:</p><p><blockquote>请查看以下图表，了解这些指标的说明：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3664f73c0fc1fcd1b2673c8df4701be5\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Plug Power development of share price, short interest, and price to sales ratio during the last 10 years. (source: YCharts)</i></p><p><blockquote><i>过去10年股价、空头权益和市销率的普拉格能源发展。（来源：YCharts）</i></blockquote></p><p> A true story stock</p><p><blockquote>真实故事股票</blockquote></p><p>   A story stock refers to a company's shares whose value reflects expected outperformance, the culmination of some new innovation, or favorable press coverage, rather than its market value being solely based on fundamentals like assets and income (Source:Investopedia)  A story can be a powerful backbone of stock performance. Though the hydrogen market is still somewhat of a niche, the story of Plug is one of great expectations.</p><p><blockquote>故事股票是指一家公司的股票，其价值反映了预期的优异表现、一些新创新的高潮或有利的新闻报道，而不是其市值仅基于资产和收入等基本面（来源：Investopedia）故事可以是股票表现的强大支柱。尽管氢市场在某种程度上仍然是一个利基市场，但Plug的故事却令人充满期待。</blockquote></p><p> Hydrogen is indeed a promising market. Let us explore the&nbsp;potential benefits and promises&nbsp;of hydrogen:</p><p><blockquote>氢确实是一个前景广阔的市场。让我们探索氢的潜在好处和前景：</blockquote></p><p> <ul>  <li>Green hydrogen can help to decarbonize multiple sectors in which it is difficult to reduce emissions, like long-haul transport, chemical industry, and iron and steel production.</li>  <li>Green hydrogen can contribute to improvements in air quality and energy security.</li>  <li>Hydrogen can be produced using a multitude of sources, such as renewables, nuclear energy, natural gas, oil, and even coal. Transportation can be done using pipelines or in liquefied form. It can be transformed into electricity very easily.</li>  <li>Hydrogen can play an important role in coping with the variable outputs of renewable energy sources. Wind and solar energy output are not always in sync with electricity demand, and hydrogen can be used as a store or energy in times when renewable energy production outpaces demand. These storages can be used in times when renewable energy output is lower than demand, and can be saved for days, weeks, or even months, and can even be transported over long distances if needed.</li>  <li>Clean hydrogen is currently used in an expanding number of projects worldwide, and it seems to be a matter of time before the technology is scaled up and costs are brought down.</li>  <li>Currently, hydrogen is mostly used in oil refining processes and for the production of fertilizers. Sectors in which it is still hardly used, like transport, buildings, and power generation seem large untapped markets.</li> </ul> As such, hydrogen could play an important supporting role in the renewable energy transition, supplying markets that are difficult or impractical to reach for batteries.</p><p><blockquote><ul><li>绿色氢可以帮助长途运输、化学工业和钢铁生产等难以减排的多个行业脱碳。</li><li>绿色氢能有助于改善空气质量和能源安全。</li><li>氢气可以使用多种来源生产，例如可再生能源、核能、天然气、石油甚至煤炭。运输可以使用管道或液化形式进行。它可以很容易地转化为电能。</li><li>氢可以在应对可再生能源的可变输出方面发挥重要作用。风能和太阳能输出并不总是与电力需求同步，当可再生能源产量超过需求时，氢可以用作储存或能源。这些存储可以在可再生能源输出低于需求的时候使用，可以保存几天、几周甚至几个月，如果需要，甚至可以长距离运输。</li><li>清洁氢目前在全球越来越多的项目中使用，该技术的扩大和成本的降低似乎只是时间问题。</li><li>目前，氢气主要用于炼油过程和化肥生产。交通、建筑和发电等仍然很少使用它的行业似乎是巨大的未开发市场。</li></ul>因此，氢可以在可再生能源转型中发挥重要的支持作用，供应电池难以或不切实际的市场。</blockquote></p><p> Plug Power has a focused strategy, is already an established business in the hydrogen market, and has a large growing number of commercial relationships. This might mean that the company has the potential to become one of the first pure-play hydrogen companies which&nbsp;could transition&nbsp;from a story stock to a large positive cash flow company.</p><p><blockquote>普拉格能源拥有专注的战略，已经是氢市场的成熟企业，并且拥有大量不断增长的商业关系。这可能意味着该公司有潜力成为首批纯氢公司之一，可以从故事股票转型为大型正现金流公司。</blockquote></p><p></p><p> The commercial relationships and collaborations which Plug is undertaking are among the most important future drivers of growth for the company, among which are collaborations with&nbsp;Airbus(OTCPK:EADSF),Phillips66(PSX),Acciona(OTCPK:ACXIF),BAE Systems(OTCPK:BAESF),Baker Hughes(BKR), and&nbsp;Brookfield Renewable(BEP).</p><p><blockquote>Plug正在开展的商业关系和合作是公司未来最重要的增长动力之一，其中包括与空中客车公司(OTCPK：EADSF)、Phillips66(PSX)、Acciona(OTCPK：ACXIF)、BAE Systems(OTCPK：BAESF)、贝克休斯(BKR)和布鲁克菲尔德可再生能源公司(BEP)的合作。</blockquote></p><p> <b>Parallels with early-stage Tesla</b></p><p><blockquote><b>与早期特斯拉的相似之处</b></blockquote></p><p> I think it is very interesting to compare Plug Power with Tesla. This seems to make sense since they were both one of the largest first movers in big markets: EV for Tesla and hydrogen for Plug. Tesla also was (and might still be) a good example of a story stock, with their large promises of electrifying the automotive sector.</p><p><blockquote>我认为将普拉格能源与特斯拉进行比较是非常有趣的。这似乎是有道理的，因为他们都是大市场中最大的先行者之一：电动汽车代表特斯拉，氢能代表插电式汽车。特斯拉也是（并且可能仍然是）故事股票的一个很好的例子，他们在汽车行业电气化方面有着巨大的前景。</blockquote></p><p> Let us look at the share price development, short percentage, and PS ratio of Tesla during the period from 2010 to the end of 2019:</p><p><blockquote>让我们看看2010年至2019年底期间特斯拉的股价发展、空头百分比和PS比率：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d9911b4514f3c0a566dffcd28c188e1c\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Tesla's development of share price, short interest, and price to sales ratio between 2010 and the end of 2019. (source: YCharts)</i></p><p><blockquote><i>2010年至2019年底特斯拉股价、空头权益和市销率的发展情况。（来源：YCharts）</i></blockquote></p><p> There are some noticeable differences between the share price development of Plug Power and an earlier-stage Tesla. First of all, from 2012 to 2019, the percentage of Tesla's stock sold short has consistently oscillated around 20%. Plug Power is already under 10% and has moved around 15% for the largest part of the last couple of years. But the biggest difference between the two stocks is probably that the price to sales ratio of Tesla has trended down quickly between 2010 and the end of 2019. Since Plug Power's price to sales ratio is heavily influenced by its recent outlier, let us take a look at a graph comparing the two between 2010 and September of this year:</p><p><blockquote>普拉格能源的股价发展与早期特斯拉有一些明显的差异。首先，从2012年到2019年，特斯拉股票被卖空的比例一直在20%左右振荡。普拉格能源已经低于10%，并且在过去几年的大部分时间里一直在15%左右波动。但两只股票最大的区别可能是，特斯拉的市销率在2010年至2019年底期间呈快速下降趋势。由于普拉格能源的市销率受到近期异常值的严重影响，让我们看一下2010年至今年9月两者的比较图表：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d46be5e658002b2f45b8c5ca43559b93\" tg-width=\"635\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Tesla and Plug Power development price to sales ratio between 2010 and September 2021. (source: YCharts)</i></p><p><blockquote><i>2010年至2021年9月期间特斯拉和普拉格能源开发的市销率。（来源：YCharts）</i></blockquote></p><p> These two ratios look to have a lot more in common. But as we can already see, after the end of 2019, Tesla's price to sales ratio went sharply up again. The reason for this was, of course, the almost unprecedented skyrocketing of the Tesla stock starting from the end of 2019. This is illustrated in the following graph of what happened to Tesla shares from September 2019 until now:</p><p><blockquote>这两个比率看起来有更多的共同点。但正如我们已经看到的，2019年底后，特斯拉的市销率再次大幅上升。其原因当然是特斯拉股价从2019年底开始几乎史无前例的暴涨。下图显示了从2019年9月至今特斯拉股票的情况：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d29232b1b3d9ff99e1edb6e4eac33901\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Development of Tesla share price, short interest, and price to sales ratio between September 2019 and now. (source: YCharts)</i></p><p><blockquote><i>2019年9月至今特斯拉股价、空头利息和市销率的发展。（来源：YCharts）</i></blockquote></p><p> As the stock price of Tesla skyrocketed, the short percentage went down sharply and the PS ratio went up.</p><p><blockquote>随着特斯拉股价暴涨，空头百分比大幅下降，PS比率上升。</blockquote></p><p> The million-dollar question is of course, could this happen to Plug Power as well? Technically, if we look solely at the metrics of Plug compared with the metrics of Tesla just before the stock price exploded, the P/S ratio of Plug is still much too high to expect that the stock could go in the same direction in short order. I also believe that fundamentally, Plug would need to experience some serious growth for the stock to be able to regain its recent upward momentum.</p><p><blockquote>当然，最重要的问题是，这种情况也会发生在普拉格能源身上吗？从技术上讲，如果我们仅将Plug的指标与股价爆炸前特斯拉的指标进行比较，Plug的市盈率仍然太高，无法预期该股在短期内会朝着同样的方向发展。我还认为，从根本上讲，Plug需要经历一些大幅增长，该股才能恢复近期的上涨势头。</blockquote></p><p> Another similarity between Plug and Tesla is that negative earnings surprises have been many at Plug recently, this happened to Tesla as well&nbsp;in 2019. At the time, Tesla's stock price was not negatively impacted by those surprises. Currently, the market seems to shake off Plug Power's results as well, though the stock did drop by more than 50% since last year.</p><p><blockquote>Plug和特斯拉之间的另一个相似之处是，最近Plug的盈利出现了很多负面意外，2019年特斯拉也发生了这种情况。当时，特斯拉的股价并未受到这些意外的负面影响。目前，市场似乎也摆脱了普拉格能源的业绩，尽管该股自去年以来确实下跌了50%以上。</blockquote></p><p> <b>Currently, expectations still beat metrics</b></p><p><blockquote><b>目前，预期仍然超过指标</b></blockquote></p><p> Like Tesla, Plug's share price seems to be governed more by growth expectations than by current stock metrics. This<i>could</i>mean that Plug would be able to go in the same direction as Tesla if enough investors remain convinced that their business model is profitable for the future and if growth can be expected to continue. Also, as for Tesla, in the long term, fundamental metrics will need to correspond with their lofty valuations. This means that the companies will need to deliver on their expectations.</p><p><blockquote>与特斯拉一样，Plug的股价似乎更多地取决于增长预期，而不是当前的股票指标。这个<i>可以</i>这意味着，如果有足够多的投资者仍然相信他们的商业模式在未来是有利可图的，并且可以预期增长将继续下去，那么Plug将能够朝着与特斯拉相同的方向发展。此外，对于特斯拉来说，从长远来看，基本面指标需要与其高估值相对应。这意味着公司需要实现他们的期望。</blockquote></p><p> <b>These are some very large ifs.</b></p><p><blockquote><b>这些都是非常大的假设。</b></blockquote></p><p> Of course, the hydrogen market is different from the EV market. Since the energy density of hydrogen is very high, it will likely be able to compete in markets where batteries still have issues, like long-haul transport. On the other hand, on an energy efficiency level, batteries have some large benefits over hydrogen for smaller transport purposes. On aggregate, I am skeptical about hydrogen being able to be a strong competitor in the EV space, but it will likely play a large role in other modes of transport, as in energy storage.</p><p><blockquote>当然，氢市场不同于电动汽车市场。由于氢的能量密度非常高，它很可能能够在电池仍然存在问题的市场中竞争，例如长途运输。另一方面，在能源效率水平上，对于较小的运输目的，电池比氢气有一些很大的好处。总的来说，我对氢能否成为电动汽车领域的强有力竞争对手持怀疑态度，但它可能会在其他交通方式中发挥重要作用，例如在储能方面。</blockquote></p><p></p><p> Plug Power has been trading like a stock for believers, which shows some strong parallels with Tesla. Theoretically, the stock could follow the same direction as Tesla did, but this is anyone's guess and I believe it would take more growth to continue its upward momentum.</p><p><blockquote>普拉格能源的交易就像信徒的股票一样，这与特斯拉有一些很强的相似之处。理论上，该股可能会遵循与特斯拉相同的方向，但这是任何人的猜测，我相信需要更多的增长才能继续其上涨势头。</blockquote></p><p> Plug Power is a promising business, but the company had some bad results recently. This did not impact the stock much during the last 2 years. In the short term, the stock price seems to be most impacted by sentiment and not by fundamentals. This makes it a wonderful stock for traders, but as a long-term investor, I am staying on the sidelines.</p><p><blockquote>普拉格能源是一项有前途的业务，但该公司最近业绩不佳。在过去的两年里，这对股票没有太大影响。短期内，股价似乎受情绪影响最大，而不是基本面。这使得它成为交易者的绝佳股票，但作为长期投资者，我仍持观望态度。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Plug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla<blockquote>普拉格能源的交易就像一只故事股票，闻起来像早期的特斯拉</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPlug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla<blockquote>普拉格能源的交易就像一只故事股票，闻起来像早期的特斯拉</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-27 21:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>The stock of Plug Power enjoyed some great appreciation during the last years, which seems hard to explain when purely looking at the fundamentals.</li>  <li>The stock performance of almost 2,000% over the last 5 years is an illustration of the increased momentum of the hydrogen market.</li>  <li>Plug Power shows some important parallels with Tesla, on which I will elaborate in this article.</li>  <li>If the sentiment can remain positive while growth continues, short-term fundamentals might not matter much.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80405c7f3988b402597ce18944c15c47\" tg-width=\"1536\" tg-height=\"683\" width=\"100%\" height=\"auto\"><span>http://www.fotogestoeber.de/iStock via Getty Images</span></p><p><blockquote><ul><li>普拉格能源的股票在过去几年中大幅升值，如果纯粹从基本面来看，这似乎很难解释。</li><li>过去5年近2,000%的股票表现说明了氢市场的增长势头。</li><li>普拉格能源与特斯拉有一些重要的相似之处，我将在本文中详细阐述。</li><li>如果在增长持续的同时，市场情绪能够保持积极，那么短期基本面可能并不重要。</li></ul><p class=\"t-img-caption\"><span>http://www.fotogestoeber.de/iStock来自Getty Images</span></p></blockquote></p><p> How can a company in a niche sector which has continuously burned cash over the years have a market capitalization of over $17B? Plug Power (PLUG) is a pure-play hydrogen company that has yet to run a profit. Still, the stock has returned a total of almost 2,000% over the last 5 years.</p><p><blockquote>一家多年来不断烧钱的利基行业公司，市值怎么可能超过170亿美元？普拉格能源（PLUG）是一家纯粹的氢能公司，尚未盈利。尽管如此，该股在过去5年中的总回报率仍接近2,000%。</blockquote></p><p> In this article, I will investigate the promises and expectations behind Plug Power and compare the stock to another stock with large promises: Tesla (TSLA).</p><p><blockquote>在本文中，我将调查普拉格能源背后的承诺和期望，并将该股票与另一只具有巨大承诺的股票：特斯拉（TSLA）进行比较。</blockquote></p><p> <b>Great stock performance, but a lofty valuation</b></p><p><blockquote><b>股票表现出色，但估值很高</b></blockquote></p><p> Plug Power has behaved somewhat like a battleground stock during the last couple of years. Ever since the&nbsp;2014 hydrogen rally, Plug Power has remained a stock that lured investors who believe in the technology, but also attracted quite some short-sellers, judged by its current short interest of almost 10 percent.</p><p><blockquote>过去几年，普拉格能源的表现有点像战场股票。自2014年氢能反弹以来，普拉格能源一直是一只吸引相信该技术的投资者的股票，但从其目前近10%的空头兴趣来看，也吸引了相当多的卖空者。</blockquote></p><p> More recently, the stock has experienced a huge liftoff, most likely fueled by the announcement of the&nbsp;Build Back Better Plan&nbsp;of president Biden. Since then, Plug Power's stock more or less came back to earth again, even though it is still trading at a very high price to sales ratio.</p><p><blockquote>最近，该股经历了大幅上涨，很可能是拜登总统宣布的重建更好计划推动的。从那时起，普拉格能源的股票或多或少又回到了现实，尽管它的市销率仍然非常高。</blockquote></p><p> Please review the following charts for illustration of these metrics:</p><p><blockquote>请查看以下图表，了解这些指标的说明：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3664f73c0fc1fcd1b2673c8df4701be5\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Plug Power development of share price, short interest, and price to sales ratio during the last 10 years. (source: YCharts)</i></p><p><blockquote><i>过去10年股价、空头权益和市销率的普拉格能源发展。（来源：YCharts）</i></blockquote></p><p> A true story stock</p><p><blockquote>真实故事股票</blockquote></p><p>   A story stock refers to a company's shares whose value reflects expected outperformance, the culmination of some new innovation, or favorable press coverage, rather than its market value being solely based on fundamentals like assets and income (Source:Investopedia)  A story can be a powerful backbone of stock performance. Though the hydrogen market is still somewhat of a niche, the story of Plug is one of great expectations.</p><p><blockquote>故事股票是指一家公司的股票，其价值反映了预期的优异表现、一些新创新的高潮或有利的新闻报道，而不是其市值仅基于资产和收入等基本面（来源：Investopedia）故事可以是股票表现的强大支柱。尽管氢市场在某种程度上仍然是一个利基市场，但Plug的故事却令人充满期待。</blockquote></p><p> Hydrogen is indeed a promising market. Let us explore the&nbsp;potential benefits and promises&nbsp;of hydrogen:</p><p><blockquote>氢确实是一个前景广阔的市场。让我们探索氢的潜在好处和前景：</blockquote></p><p> <ul>  <li>Green hydrogen can help to decarbonize multiple sectors in which it is difficult to reduce emissions, like long-haul transport, chemical industry, and iron and steel production.</li>  <li>Green hydrogen can contribute to improvements in air quality and energy security.</li>  <li>Hydrogen can be produced using a multitude of sources, such as renewables, nuclear energy, natural gas, oil, and even coal. Transportation can be done using pipelines or in liquefied form. It can be transformed into electricity very easily.</li>  <li>Hydrogen can play an important role in coping with the variable outputs of renewable energy sources. Wind and solar energy output are not always in sync with electricity demand, and hydrogen can be used as a store or energy in times when renewable energy production outpaces demand. These storages can be used in times when renewable energy output is lower than demand, and can be saved for days, weeks, or even months, and can even be transported over long distances if needed.</li>  <li>Clean hydrogen is currently used in an expanding number of projects worldwide, and it seems to be a matter of time before the technology is scaled up and costs are brought down.</li>  <li>Currently, hydrogen is mostly used in oil refining processes and for the production of fertilizers. Sectors in which it is still hardly used, like transport, buildings, and power generation seem large untapped markets.</li> </ul> As such, hydrogen could play an important supporting role in the renewable energy transition, supplying markets that are difficult or impractical to reach for batteries.</p><p><blockquote><ul><li>绿色氢可以帮助长途运输、化学工业和钢铁生产等难以减排的多个行业脱碳。</li><li>绿色氢能有助于改善空气质量和能源安全。</li><li>氢气可以使用多种来源生产，例如可再生能源、核能、天然气、石油甚至煤炭。运输可以使用管道或液化形式进行。它可以很容易地转化为电能。</li><li>氢可以在应对可再生能源的可变输出方面发挥重要作用。风能和太阳能输出并不总是与电力需求同步，当可再生能源产量超过需求时，氢可以用作储存或能源。这些存储可以在可再生能源输出低于需求的时候使用，可以保存几天、几周甚至几个月，如果需要，甚至可以长距离运输。</li><li>清洁氢目前在全球越来越多的项目中使用，该技术的扩大和成本的降低似乎只是时间问题。</li><li>目前，氢气主要用于炼油过程和化肥生产。交通、建筑和发电等仍然很少使用它的行业似乎是巨大的未开发市场。</li></ul>因此，氢可以在可再生能源转型中发挥重要的支持作用，供应电池难以或不切实际的市场。</blockquote></p><p> Plug Power has a focused strategy, is already an established business in the hydrogen market, and has a large growing number of commercial relationships. This might mean that the company has the potential to become one of the first pure-play hydrogen companies which&nbsp;could transition&nbsp;from a story stock to a large positive cash flow company.</p><p><blockquote>普拉格能源拥有专注的战略，已经是氢市场的成熟企业，并且拥有大量不断增长的商业关系。这可能意味着该公司有潜力成为首批纯氢公司之一，可以从故事股票转型为大型正现金流公司。</blockquote></p><p></p><p> The commercial relationships and collaborations which Plug is undertaking are among the most important future drivers of growth for the company, among which are collaborations with&nbsp;Airbus(OTCPK:EADSF),Phillips66(PSX),Acciona(OTCPK:ACXIF),BAE Systems(OTCPK:BAESF),Baker Hughes(BKR), and&nbsp;Brookfield Renewable(BEP).</p><p><blockquote>Plug正在开展的商业关系和合作是公司未来最重要的增长动力之一，其中包括与空中客车公司(OTCPK：EADSF)、Phillips66(PSX)、Acciona(OTCPK：ACXIF)、BAE Systems(OTCPK：BAESF)、贝克休斯(BKR)和布鲁克菲尔德可再生能源公司(BEP)的合作。</blockquote></p><p> <b>Parallels with early-stage Tesla</b></p><p><blockquote><b>与早期特斯拉的相似之处</b></blockquote></p><p> I think it is very interesting to compare Plug Power with Tesla. This seems to make sense since they were both one of the largest first movers in big markets: EV for Tesla and hydrogen for Plug. Tesla also was (and might still be) a good example of a story stock, with their large promises of electrifying the automotive sector.</p><p><blockquote>我认为将普拉格能源与特斯拉进行比较是非常有趣的。这似乎是有道理的，因为他们都是大市场中最大的先行者之一：电动汽车代表特斯拉，氢能代表插电式汽车。特斯拉也是（并且可能仍然是）故事股票的一个很好的例子，他们在汽车行业电气化方面有着巨大的前景。</blockquote></p><p> Let us look at the share price development, short percentage, and PS ratio of Tesla during the period from 2010 to the end of 2019:</p><p><blockquote>让我们看看2010年至2019年底期间特斯拉的股价发展、空头百分比和PS比率：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d9911b4514f3c0a566dffcd28c188e1c\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Tesla's development of share price, short interest, and price to sales ratio between 2010 and the end of 2019. (source: YCharts)</i></p><p><blockquote><i>2010年至2019年底特斯拉股价、空头权益和市销率的发展情况。（来源：YCharts）</i></blockquote></p><p> There are some noticeable differences between the share price development of Plug Power and an earlier-stage Tesla. First of all, from 2012 to 2019, the percentage of Tesla's stock sold short has consistently oscillated around 20%. Plug Power is already under 10% and has moved around 15% for the largest part of the last couple of years. But the biggest difference between the two stocks is probably that the price to sales ratio of Tesla has trended down quickly between 2010 and the end of 2019. Since Plug Power's price to sales ratio is heavily influenced by its recent outlier, let us take a look at a graph comparing the two between 2010 and September of this year:</p><p><blockquote>普拉格能源的股价发展与早期特斯拉有一些明显的差异。首先，从2012年到2019年，特斯拉股票被卖空的比例一直在20%左右振荡。普拉格能源已经低于10%，并且在过去几年的大部分时间里一直在15%左右波动。但两只股票最大的区别可能是，特斯拉的市销率在2010年至2019年底期间呈快速下降趋势。由于普拉格能源的市销率受到近期异常值的严重影响，让我们看一下2010年至今年9月两者的比较图表：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d46be5e658002b2f45b8c5ca43559b93\" tg-width=\"635\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Tesla and Plug Power development price to sales ratio between 2010 and September 2021. (source: YCharts)</i></p><p><blockquote><i>2010年至2021年9月期间特斯拉和普拉格能源开发的市销率。（来源：YCharts）</i></blockquote></p><p> These two ratios look to have a lot more in common. But as we can already see, after the end of 2019, Tesla's price to sales ratio went sharply up again. The reason for this was, of course, the almost unprecedented skyrocketing of the Tesla stock starting from the end of 2019. This is illustrated in the following graph of what happened to Tesla shares from September 2019 until now:</p><p><blockquote>这两个比率看起来有更多的共同点。但正如我们已经看到的，2019年底后，特斯拉的市销率再次大幅上升。其原因当然是特斯拉股价从2019年底开始几乎史无前例的暴涨。下图显示了从2019年9月至今特斯拉股票的情况：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d29232b1b3d9ff99e1edb6e4eac33901\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> <i>Development of Tesla share price, short interest, and price to sales ratio between September 2019 and now. (source: YCharts)</i></p><p><blockquote><i>2019年9月至今特斯拉股价、空头利息和市销率的发展。（来源：YCharts）</i></blockquote></p><p> As the stock price of Tesla skyrocketed, the short percentage went down sharply and the PS ratio went up.</p><p><blockquote>随着特斯拉股价暴涨，空头百分比大幅下降，PS比率上升。</blockquote></p><p> The million-dollar question is of course, could this happen to Plug Power as well? Technically, if we look solely at the metrics of Plug compared with the metrics of Tesla just before the stock price exploded, the P/S ratio of Plug is still much too high to expect that the stock could go in the same direction in short order. I also believe that fundamentally, Plug would need to experience some serious growth for the stock to be able to regain its recent upward momentum.</p><p><blockquote>当然，最重要的问题是，这种情况也会发生在普拉格能源身上吗？从技术上讲，如果我们仅将Plug的指标与股价爆炸前特斯拉的指标进行比较，Plug的市盈率仍然太高，无法预期该股在短期内会朝着同样的方向发展。我还认为，从根本上讲，Plug需要经历一些大幅增长，该股才能恢复近期的上涨势头。</blockquote></p><p> Another similarity between Plug and Tesla is that negative earnings surprises have been many at Plug recently, this happened to Tesla as well&nbsp;in 2019. At the time, Tesla's stock price was not negatively impacted by those surprises. Currently, the market seems to shake off Plug Power's results as well, though the stock did drop by more than 50% since last year.</p><p><blockquote>Plug和特斯拉之间的另一个相似之处是，最近Plug的盈利出现了很多负面意外，2019年特斯拉也发生了这种情况。当时，特斯拉的股价并未受到这些意外的负面影响。目前，市场似乎也摆脱了普拉格能源的业绩，尽管该股自去年以来确实下跌了50%以上。</blockquote></p><p> <b>Currently, expectations still beat metrics</b></p><p><blockquote><b>目前，预期仍然超过指标</b></blockquote></p><p> Like Tesla, Plug's share price seems to be governed more by growth expectations than by current stock metrics. This<i>could</i>mean that Plug would be able to go in the same direction as Tesla if enough investors remain convinced that their business model is profitable for the future and if growth can be expected to continue. Also, as for Tesla, in the long term, fundamental metrics will need to correspond with their lofty valuations. This means that the companies will need to deliver on their expectations.</p><p><blockquote>与特斯拉一样，Plug的股价似乎更多地取决于增长预期，而不是当前的股票指标。这个<i>可以</i>这意味着，如果有足够多的投资者仍然相信他们的商业模式在未来是有利可图的，并且可以预期增长将继续下去，那么Plug将能够朝着与特斯拉相同的方向发展。此外，对于特斯拉来说，从长远来看，基本面指标需要与其高估值相对应。这意味着公司需要实现他们的期望。</blockquote></p><p> <b>These are some very large ifs.</b></p><p><blockquote><b>这些都是非常大的假设。</b></blockquote></p><p> Of course, the hydrogen market is different from the EV market. Since the energy density of hydrogen is very high, it will likely be able to compete in markets where batteries still have issues, like long-haul transport. On the other hand, on an energy efficiency level, batteries have some large benefits over hydrogen for smaller transport purposes. On aggregate, I am skeptical about hydrogen being able to be a strong competitor in the EV space, but it will likely play a large role in other modes of transport, as in energy storage.</p><p><blockquote>当然，氢市场不同于电动汽车市场。由于氢的能量密度非常高，它很可能能够在电池仍然存在问题的市场中竞争，例如长途运输。另一方面，在能源效率水平上，对于较小的运输目的，电池比氢气有一些很大的好处。总的来说，我对氢能否成为电动汽车领域的强有力竞争对手持怀疑态度，但它可能会在其他交通方式中发挥重要作用，例如在储能方面。</blockquote></p><p></p><p> Plug Power has been trading like a stock for believers, which shows some strong parallels with Tesla. Theoretically, the stock could follow the same direction as Tesla did, but this is anyone's guess and I believe it would take more growth to continue its upward momentum.</p><p><blockquote>普拉格能源的交易就像信徒的股票一样，这与特斯拉有一些很强的相似之处。理论上，该股可能会遵循与特斯拉相同的方向，但这是任何人的猜测，我相信需要更多的增长才能继续其上涨势头。</blockquote></p><p> Plug Power is a promising business, but the company had some bad results recently. This did not impact the stock much during the last 2 years. In the short term, the stock price seems to be most impacted by sentiment and not by fundamentals. This makes it a wonderful stock for traders, but as a long-term investor, I am staying on the sidelines.</p><p><blockquote>普拉格能源是一项有前途的业务，但该公司最近业绩不佳。在过去的两年里，这对股票没有太大影响。短期内，股价似乎受情绪影响最大，而不是基本面。这使得它成为交易者的绝佳股票，但作为长期投资者，我仍持观望态度。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4476789-plug-power-stock-promising-business-parallels-with-tesla\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLUG":"普拉格能源"},"source_url":"https://seekingalpha.com/article/4476789-plug-power-stock-promising-business-parallels-with-tesla","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111088353","content_text":"Summary\n\nThe stock of Plug Power enjoyed some great appreciation during the last years, which seems hard to explain when purely looking at the fundamentals.\nThe stock performance of almost 2,000% over the last 5 years is an illustration of the increased momentum of the hydrogen market.\nPlug Power shows some important parallels with Tesla, on which I will elaborate in this article.\nIf the sentiment can remain positive while growth continues, short-term fundamentals might not matter much.\n\nhttp://www.fotogestoeber.de/iStock via Getty Images\nHow can a company in a niche sector which has continuously burned cash over the years have a market capitalization of over $17B? Plug Power (PLUG) is a pure-play hydrogen company that has yet to run a profit. Still, the stock has returned a total of almost 2,000% over the last 5 years.\nIn this article, I will investigate the promises and expectations behind Plug Power and compare the stock to another stock with large promises: Tesla (TSLA).\nGreat stock performance, but a lofty valuation\nPlug Power has behaved somewhat like a battleground stock during the last couple of years. Ever since the 2014 hydrogen rally, Plug Power has remained a stock that lured investors who believe in the technology, but also attracted quite some short-sellers, judged by its current short interest of almost 10 percent.\nMore recently, the stock has experienced a huge liftoff, most likely fueled by the announcement of the Build Back Better Plan of president Biden. Since then, Plug Power's stock more or less came back to earth again, even though it is still trading at a very high price to sales ratio.\nPlease review the following charts for illustration of these metrics:\nData by YCharts\nPlug Power development of share price, short interest, and price to sales ratio during the last 10 years. (source: YCharts)\nA true story stock\n\n A story stock refers to a company's shares whose value reflects expected outperformance, the culmination of some new innovation, or favorable press coverage, rather than its market value being solely based on fundamentals like assets and income (Source:Investopedia)\n\nA story can be a powerful backbone of stock performance. Though the hydrogen market is still somewhat of a niche, the story of Plug is one of great expectations.\nHydrogen is indeed a promising market. Let us explore the potential benefits and promises of hydrogen:\n\nGreen hydrogen can help to decarbonize multiple sectors in which it is difficult to reduce emissions, like long-haul transport, chemical industry, and iron and steel production.\nGreen hydrogen can contribute to improvements in air quality and energy security.\nHydrogen can be produced using a multitude of sources, such as renewables, nuclear energy, natural gas, oil, and even coal. Transportation can be done using pipelines or in liquefied form. It can be transformed into electricity very easily.\nHydrogen can play an important role in coping with the variable outputs of renewable energy sources. Wind and solar energy output are not always in sync with electricity demand, and hydrogen can be used as a store or energy in times when renewable energy production outpaces demand. These storages can be used in times when renewable energy output is lower than demand, and can be saved for days, weeks, or even months, and can even be transported over long distances if needed.\nClean hydrogen is currently used in an expanding number of projects worldwide, and it seems to be a matter of time before the technology is scaled up and costs are brought down.\nCurrently, hydrogen is mostly used in oil refining processes and for the production of fertilizers. Sectors in which it is still hardly used, like transport, buildings, and power generation seem large untapped markets.\n\nAs such, hydrogen could play an important supporting role in the renewable energy transition, supplying markets that are difficult or impractical to reach for batteries.\nPlug Power has a focused strategy, is already an established business in the hydrogen market, and has a large growing number of commercial relationships. This might mean that the company has the potential to become one of the first pure-play hydrogen companies which could transition from a story stock to a large positive cash flow company.\nThe commercial relationships and collaborations which Plug is undertaking are among the most important future drivers of growth for the company, among which are collaborations with Airbus(OTCPK:EADSF),Phillips66(PSX),Acciona(OTCPK:ACXIF),BAE Systems(OTCPK:BAESF),Baker Hughes(BKR), and Brookfield Renewable(BEP).\nParallels with early-stage Tesla\nI think it is very interesting to compare Plug Power with Tesla. This seems to make sense since they were both one of the largest first movers in big markets: EV for Tesla and hydrogen for Plug. Tesla also was (and might still be) a good example of a story stock, with their large promises of electrifying the automotive sector.\nLet us look at the share price development, short percentage, and PS ratio of Tesla during the period from 2010 to the end of 2019:\nData by YCharts\nTesla's development of share price, short interest, and price to sales ratio between 2010 and the end of 2019. (source: YCharts)\nThere are some noticeable differences between the share price development of Plug Power and an earlier-stage Tesla. First of all, from 2012 to 2019, the percentage of Tesla's stock sold short has consistently oscillated around 20%. Plug Power is already under 10% and has moved around 15% for the largest part of the last couple of years. But the biggest difference between the two stocks is probably that the price to sales ratio of Tesla has trended down quickly between 2010 and the end of 2019. Since Plug Power's price to sales ratio is heavily influenced by its recent outlier, let us take a look at a graph comparing the two between 2010 and September of this year:\nData by YCharts\nTesla and Plug Power development price to sales ratio between 2010 and September 2021. (source: YCharts)\nThese two ratios look to have a lot more in common. But as we can already see, after the end of 2019, Tesla's price to sales ratio went sharply up again. The reason for this was, of course, the almost unprecedented skyrocketing of the Tesla stock starting from the end of 2019. This is illustrated in the following graph of what happened to Tesla shares from September 2019 until now:\nData by YCharts\nDevelopment of Tesla share price, short interest, and price to sales ratio between September 2019 and now. (source: YCharts)\nAs the stock price of Tesla skyrocketed, the short percentage went down sharply and the PS ratio went up.\nThe million-dollar question is of course, could this happen to Plug Power as well? Technically, if we look solely at the metrics of Plug compared with the metrics of Tesla just before the stock price exploded, the P/S ratio of Plug is still much too high to expect that the stock could go in the same direction in short order. I also believe that fundamentally, Plug would need to experience some serious growth for the stock to be able to regain its recent upward momentum.\nAnother similarity between Plug and Tesla is that negative earnings surprises have been many at Plug recently, this happened to Tesla as well in 2019. At the time, Tesla's stock price was not negatively impacted by those surprises. Currently, the market seems to shake off Plug Power's results as well, though the stock did drop by more than 50% since last year.\nCurrently, expectations still beat metrics\nLike Tesla, Plug's share price seems to be governed more by growth expectations than by current stock metrics. Thiscouldmean that Plug would be able to go in the same direction as Tesla if enough investors remain convinced that their business model is profitable for the future and if growth can be expected to continue. Also, as for Tesla, in the long term, fundamental metrics will need to correspond with their lofty valuations. This means that the companies will need to deliver on their expectations.\nThese are some very large ifs.\nOf course, the hydrogen market is different from the EV market. Since the energy density of hydrogen is very high, it will likely be able to compete in markets where batteries still have issues, like long-haul transport. On the other hand, on an energy efficiency level, batteries have some large benefits over hydrogen for smaller transport purposes. On aggregate, I am skeptical about hydrogen being able to be a strong competitor in the EV space, but it will likely play a large role in other modes of transport, as in energy storage.\nPlug Power has been trading like a stock for believers, which shows some strong parallels with Tesla. Theoretically, the stock could follow the same direction as Tesla did, but this is anyone's guess and I believe it would take more growth to continue its upward momentum.\nPlug Power is a promising business, but the company had some bad results recently. This did not impact the stock much during the last 2 years. In the short term, the stock price seems to be most impacted by sentiment and not by fundamentals. This makes it a wonderful stock for traders, but as a long-term investor, I am staying on the sidelines.","news_type":1,"symbols_score_info":{"PLUG":0.9}},"isVote":1,"tweetType":1,"viewCount":2941,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609123127,"gmtCreate":1638254172838,"gmtModify":1638254172928,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Vaccine stock rally tonight 🔥🙏💉","listText":"Vaccine stock rally tonight 🔥🙏💉","text":"Vaccine stock rally tonight 🔥🙏💉","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609123127","repostId":"1141430877","repostType":4,"repost":{"id":"1141430877","kind":"news","pubTimestamp":1638251771,"share":"https://www.laohu8.com/m/news/1141430877?lang=zh_CN&edition=full","pubTime":"2021-11-30 13:56","market":"us","language":"en","title":"Moderna CEO says vaccines likely less effective against Omicron<blockquote>Moderna首席执行官表示疫苗对奥密克戎病毒的效果可能较差</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141430877","media":"Reuters","summary":"SYDNEY, Nov 30 (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be a","content":"<p>SYDNEY, Nov 30 (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p><p><blockquote>路透悉尼11月30日-制药商Moderna负责人表示，COVID-19疫苗不太可能像以前那样有效对抗冠状病毒的奥密克戎变种，这引发了金融市场对疫情发展轨迹的新担忧。</blockquote></p><p> \"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times&nbsp;in an interview.</p><p><blockquote>Moderna首席执行官斯特凡·班塞尔(Stéphane Bancel)在接受英国《金融时报》采访时表示：“我认为，没有一个世界的（有效性）与我们与达美航空的水平相同。”</blockquote></p><p> \"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p><p><blockquote>“我认为这将是一次物质下降。我只是不知道有多少，因为我们需要等待数据。但我交谈过的所有科学家……都像‘这不会有好结果’。”</blockquote></p><p> Vaccine resistance could lead to more sickness and hospitalisations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks and the Australian dollar.</p><p><blockquote>疫苗耐药性可能会导致更多的疾病和住院，并延长疫情，他的言论引发了石油、股票和澳元等增长资产的抛售。</blockquote></p><p> Bancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified.</p><p><blockquote>Bancel补充说，病毒用于感染人类细胞的蛋白质刺突上的大量突变意味着当前的疫苗可能需要进行修改。</blockquote></p><p> He had earlier said on CNBC that it could take months to begin shipping a vaccine that does work against Omicron.</p><p><blockquote>他早些时候在CNBC上表示，可能需要几个月的时间才能开始运送针对奥密克戎病毒的疫苗。</blockquote></p><p> Fear of the new variant, despite a lack of information about its severity, has already triggered delays to some economic reopening plans and the reimposition of some travel and movement restrictions.</p><p><blockquote>尽管缺乏关于其严重性的信息，但对新变种的恐惧已经引发了一些经济重新开放计划的推迟，以及一些旅行和行动限制的重新实施。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says vaccines likely less effective against Omicron<blockquote>Moderna首席执行官表示疫苗对奥密克戎病毒的效果可能较差</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says vaccines likely less effective against Omicron<blockquote>Moderna首席执行官表示疫苗对奥密克戎病毒的效果可能较差</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-30 13:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p>SYDNEY, Nov 30 (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p><p><blockquote>路透悉尼11月30日-制药商Moderna负责人表示，COVID-19疫苗不太可能像以前那样有效对抗冠状病毒的奥密克戎变种，这引发了金融市场对疫情发展轨迹的新担忧。</blockquote></p><p> \"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times&nbsp;in an interview.</p><p><blockquote>Moderna首席执行官斯特凡·班塞尔(Stéphane Bancel)在接受英国《金融时报》采访时表示：“我认为，没有一个世界的（有效性）与我们与达美航空的水平相同。”</blockquote></p><p> \"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p><p><blockquote>“我认为这将是一次物质下降。我只是不知道有多少，因为我们需要等待数据。但我交谈过的所有科学家……都像‘这不会有好结果’。”</blockquote></p><p> Vaccine resistance could lead to more sickness and hospitalisations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks and the Australian dollar.</p><p><blockquote>疫苗耐药性可能会导致更多的疾病和住院，并延长疫情，他的言论引发了石油、股票和澳元等增长资产的抛售。</blockquote></p><p> Bancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified.</p><p><blockquote>Bancel补充说，病毒用于感染人类细胞的蛋白质刺突上的大量突变意味着当前的疫苗可能需要进行修改。</blockquote></p><p> He had earlier said on CNBC that it could take months to begin shipping a vaccine that does work against Omicron.</p><p><blockquote>他早些时候在CNBC上表示，可能需要几个月的时间才能开始运送针对奥密克戎病毒的疫苗。</blockquote></p><p> Fear of the new variant, despite a lack of information about its severity, has already triggered delays to some economic reopening plans and the reimposition of some travel and movement restrictions.</p><p><blockquote>尽管缺乏关于其严重性的信息，但对新变种的恐惧已经引发了一些经济重新开放计划的推迟，以及一些旅行和行动限制的重新实施。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/1-moderna-ceo-says-vaccines-055048321.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/1-moderna-ceo-says-vaccines-055048321.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141430877","content_text":"SYDNEY, Nov 30 (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.\n\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.\n\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"\nVaccine resistance could lead to more sickness and hospitalisations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks and the Australian dollar.\nBancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified.\nHe had earlier said on CNBC that it could take months to begin shipping a vaccine that does work against Omicron.\nFear of the new variant, despite a lack of information about its severity, has already triggered delays to some economic reopening plans and the reimposition of some travel and movement restrictions.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":121813326,"gmtCreate":1624458389665,"gmtModify":1631886369743,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","listText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","text":"$Stem Inc.(STEM)$[财迷] [财迷] [财迷]","images":[{"img":"https://static.tigerbbs.com/6b98ef2191be4e3fe8f302cee4c12644","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/121813326","isVote":1,"tweetType":1,"viewCount":977,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":876551023,"gmtCreate":1637333835298,"gmtModify":1637334091344,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Holding on....especially with the opening of themeparks in the near future.","listText":"Holding on....especially with the opening of themeparks in the near future.","text":"Holding on....especially with the opening of themeparks in the near future.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876551023","repostId":"1157818316","repostType":4,"repost":{"id":"1157818316","kind":"news","pubTimestamp":1637331780,"share":"https://www.laohu8.com/m/news/1157818316?lang=zh_CN&edition=full","pubTime":"2021-11-19 22:23","market":"us","language":"en","title":"Disney Stock: Jim Cramer Says Selling Now Is Shortsighted<blockquote>迪士尼股票：吉姆·克莱默表示现在出售是短视的</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1157818316","media":"TheStreet","summary":"For CNBC’s Jim Cramer, investors are buying high and selling low by focusing on Disney’s short-term ","content":"<p>For CNBC’s Jim Cramer, investors are buying high and selling low by focusing on Disney’s short-term woes rather than on the company’s long-term potential.</p><p><blockquote>对于CNBC的吉姆·克莱默(Jim Cramer)来说，投资者通过关注迪士尼的短期困境而不是该公司的长期潜力来高买低卖。</blockquote></p><p> The market continues to witness softness in Disney stock. Investors seemed disappointed in last quarter’s results, particularly regarding the addition of Disney+ subscribers.On the day after the earnings report, share price fell 7%.</p><p><blockquote>市场继续见证迪士尼股票的疲软。投资者似乎对上个季度的业绩感到失望，特别是对于Disney+订阅者的增加。财报发布后的第二天，股价下跌7%。</blockquote></p><p> At the same time, other investors have remained optimistic about the company. One such example is CNBC’s Jim Cramer, host of Mad Money, whoseesreasons to bet on DIS for the long term. Among them are (1) the company's new content investments, (2) the reopening of the parks and (3) the contrarian view in the face of so much negative sentiment.</p><p><blockquote>与此同时，其他投资者也对公司保持乐观态度。CNBC的《Mad Money》主持人吉姆·克莱默(Jim Cramer)就是这样一个例子，他认为有理由长期押注DIS。其中包括（1）公司的新内容投资，（2）公园的重新开放，以及（3）面对如此多的负面情绪时的逆向观点。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fa43949a100665b5ceb4b8a647ee6f93\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: CNBC's Jim Cramer, host of Mad Money.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：CNBC的Jim Cramer，《Mad Money》主持人。</span></p></blockquote></p><p> <b>New content</b></p><p><blockquote><b>新内容</b></blockquote></p><p> One key criticism of Disney’s streaming business model are the high costs. The DTC (direct-to-consumer) approach entails large expenses with the production of exclusive content, which is arguably key in attracting and retaining the platform's subscribers.</p><p><blockquote>对迪士尼流媒体商业模式的一个关键批评是高成本。DTC（直接面向消费者）方法在制作独家内容方面需要大量费用，这可以说是吸引和留住平台订户的关键。</blockquote></p><p> But Cramer does not seem to view this as a problem, rather as a long-term investment that the market still misunderstands. Disney and peers like Netflix&nbsp;spend a large chunk of their operating income on content production, which often scares off investors and sends them to the exits. But after the content is available and it helps to drive new subscriptions, investors return to buy back the shares when the herd chooses to do the same.</p><p><blockquote>但克莱默似乎并不认为这是一个问题，而是一项市场仍然误解的长期投资。迪士尼和Netflix等同行将营业收入的很大一部分用于内容制作，这往往会吓跑投资者并迫使他们退出。但在内容可用并有助于推动新的订阅后，当投资者选择这样做时，投资者会回来回购股票。</blockquote></p><p> Therefore, by focusing on the short term and ignoring the long term, many investors continue to buy high and sell low – a recipe for disaster over time.</p><p><blockquote>因此，通过关注短期而忽视长期，许多投资者继续高买低卖——随着时间的推移，这将导致灾难。</blockquote></p><p> <b>Theme parks</b></p><p><blockquote><b>主题公园</b></blockquote></p><p> With the reopening of Disney's parks, the company’s financial results should start to resemble those of the pre-pandemic period. Therefore, looking only at the new streaming segment is a bit narrow, as it still represents a small slice of Disney’s revenue – although probably the fastest growing over the long haul.</p><p><blockquote>随着迪士尼乐园的重新开放，该公司的财务业绩应该会开始类似于大流行前的时期。因此，仅关注新的流媒体细分市场有点狭隘，因为它仍然只占迪士尼收入的一小部分——尽管从长远来看可能是增长最快的。</blockquote></p><p> <b>What analysts say</b></p><p><blockquote><b>分析师怎么说</b></blockquote></p><p> While many investors remain pessimistic about DIS, many investment banks continue to view the company's long-term growth potential as appealing. This is the case of Morgan Stanley, which&nbsp;reiterated&nbsp;its “overweight” rating of Disney:</p><p><blockquote>尽管许多投资者仍对DIS持悲观态度，但许多投行仍认为该公司的长期增长潜力具有吸引力。摩根士丹利就是如此，摩根士丹利重申了对迪斯尼的“跑赢大盘”评级：</blockquote></p><p>   “We continue to believe its guidance is achievable, that with streaming scale comes substantial earnings power, and that success is not priced in.”  <b>Our view</b></p><p><blockquote>“我们仍然相信其指导是可以实现的，流媒体规模带来了巨大的盈利能力，而且这种成功并未被定价。”<b>我们的观点</b></blockquote></p><p> We believe that Disney is still a major player in the so-called streaming wars, and one of the few that can effectively compete for market share with companies like Netflix and Amazon. Therefore, a smaller-than-expected addition of users in a single quarter, especially at an inflection point in the COVID-19 crisis, should not be extrapolated too far out into the future.</p><p><blockquote>我们认为，迪士尼仍然是所谓流媒体战争中的主要参与者，也是少数能够与Netflix和亚马逊等公司有效争夺市场份额的公司之一。因此，单季度用户增长低于预期，尤其是在新冠肺炎危机的拐点，不应外推到太远的未来。</blockquote></p><p> In our view, one must wait for a series of quarterly reports to understand how Disney+ may fare against its peers. Growth concerns should only come, if at all, after careful analysis of the longer-term trend.</p><p><blockquote>我们认为，必须等待一系列季度报告才能了解Disney+与同行相比的表现如何。只有在仔细分析长期趋势之后，才会出现增长担忧（如果有的话）。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney Stock: Jim Cramer Says Selling Now Is Shortsighted<blockquote>迪士尼股票：吉姆·克莱默表示现在出售是短视的</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney Stock: Jim Cramer Says Selling Now Is Shortsighted<blockquote>迪士尼股票：吉姆·克莱默表示现在出售是短视的</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-11-19 22:23</span>\n</p>\n</h4>\n</header>\n<article>\n<p>For CNBC’s Jim Cramer, investors are buying high and selling low by focusing on Disney’s short-term woes rather than on the company’s long-term potential.</p><p><blockquote>对于CNBC的吉姆·克莱默(Jim Cramer)来说，投资者通过关注迪士尼的短期困境而不是该公司的长期潜力来高买低卖。</blockquote></p><p> The market continues to witness softness in Disney stock. Investors seemed disappointed in last quarter’s results, particularly regarding the addition of Disney+ subscribers.On the day after the earnings report, share price fell 7%.</p><p><blockquote>市场继续见证迪士尼股票的疲软。投资者似乎对上个季度的业绩感到失望，特别是对于Disney+订阅者的增加。财报发布后的第二天，股价下跌7%。</blockquote></p><p> At the same time, other investors have remained optimistic about the company. One such example is CNBC’s Jim Cramer, host of Mad Money, whoseesreasons to bet on DIS for the long term. Among them are (1) the company's new content investments, (2) the reopening of the parks and (3) the contrarian view in the face of so much negative sentiment.</p><p><blockquote>与此同时，其他投资者也对公司保持乐观态度。CNBC的《Mad Money》主持人吉姆·克莱默(Jim Cramer)就是这样一个例子，他认为有理由长期押注DIS。其中包括（1）公司的新内容投资，（2）公园的重新开放，以及（3）面对如此多的负面情绪时的逆向观点。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fa43949a100665b5ceb4b8a647ee6f93\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: CNBC's Jim Cramer, host of Mad Money.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：CNBC的Jim Cramer，《Mad Money》主持人。</span></p></blockquote></p><p> <b>New content</b></p><p><blockquote><b>新内容</b></blockquote></p><p> One key criticism of Disney’s streaming business model are the high costs. The DTC (direct-to-consumer) approach entails large expenses with the production of exclusive content, which is arguably key in attracting and retaining the platform's subscribers.</p><p><blockquote>对迪士尼流媒体商业模式的一个关键批评是高成本。DTC（直接面向消费者）方法在制作独家内容方面需要大量费用，这可以说是吸引和留住平台订户的关键。</blockquote></p><p> But Cramer does not seem to view this as a problem, rather as a long-term investment that the market still misunderstands. Disney and peers like Netflix&nbsp;spend a large chunk of their operating income on content production, which often scares off investors and sends them to the exits. But after the content is available and it helps to drive new subscriptions, investors return to buy back the shares when the herd chooses to do the same.</p><p><blockquote>但克莱默似乎并不认为这是一个问题，而是一项市场仍然误解的长期投资。迪士尼和Netflix等同行将营业收入的很大一部分用于内容制作，这往往会吓跑投资者并迫使他们退出。但在内容可用并有助于推动新的订阅后，当投资者选择这样做时，投资者会回来回购股票。</blockquote></p><p> Therefore, by focusing on the short term and ignoring the long term, many investors continue to buy high and sell low – a recipe for disaster over time.</p><p><blockquote>因此，通过关注短期而忽视长期，许多投资者继续高买低卖——随着时间的推移，这将导致灾难。</blockquote></p><p> <b>Theme parks</b></p><p><blockquote><b>主题公园</b></blockquote></p><p> With the reopening of Disney's parks, the company’s financial results should start to resemble those of the pre-pandemic period. Therefore, looking only at the new streaming segment is a bit narrow, as it still represents a small slice of Disney’s revenue – although probably the fastest growing over the long haul.</p><p><blockquote>随着迪士尼乐园的重新开放，该公司的财务业绩应该会开始类似于大流行前的时期。因此，仅关注新的流媒体细分市场有点狭隘，因为它仍然只占迪士尼收入的一小部分——尽管从长远来看可能是增长最快的。</blockquote></p><p> <b>What analysts say</b></p><p><blockquote><b>分析师怎么说</b></blockquote></p><p> While many investors remain pessimistic about DIS, many investment banks continue to view the company's long-term growth potential as appealing. This is the case of Morgan Stanley, which&nbsp;reiterated&nbsp;its “overweight” rating of Disney:</p><p><blockquote>尽管许多投资者仍对DIS持悲观态度，但许多投行仍认为该公司的长期增长潜力具有吸引力。摩根士丹利就是如此，摩根士丹利重申了对迪斯尼的“跑赢大盘”评级：</blockquote></p><p>   “We continue to believe its guidance is achievable, that with streaming scale comes substantial earnings power, and that success is not priced in.”  <b>Our view</b></p><p><blockquote>“我们仍然相信其指导是可以实现的，流媒体规模带来了巨大的盈利能力，而且这种成功并未被定价。”<b>我们的观点</b></blockquote></p><p> We believe that Disney is still a major player in the so-called streaming wars, and one of the few that can effectively compete for market share with companies like Netflix and Amazon. Therefore, a smaller-than-expected addition of users in a single quarter, especially at an inflection point in the COVID-19 crisis, should not be extrapolated too far out into the future.</p><p><blockquote>我们认为，迪士尼仍然是所谓流媒体战争中的主要参与者，也是少数能够与Netflix和亚马逊等公司有效争夺市场份额的公司之一。因此，单季度用户增长低于预期，尤其是在新冠肺炎危机的拐点，不应外推到太远的未来。</blockquote></p><p> In our view, one must wait for a series of quarterly reports to understand how Disney+ may fare against its peers. Growth concerns should only come, if at all, after careful analysis of the longer-term trend.</p><p><blockquote>我们认为，必须等待一系列季度报告才能了解Disney+与同行相比的表现如何。只有在仔细分析长期趋势之后，才会出现增长担忧（如果有的话）。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/streaming/dis/jim-cramer-it-is-shortsighted-to-sell-disney-stock-now\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼"},"source_url":"https://www.thestreet.com/streaming/dis/jim-cramer-it-is-shortsighted-to-sell-disney-stock-now","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157818316","content_text":"For CNBC’s Jim Cramer, investors are buying high and selling low by focusing on Disney’s short-term woes rather than on the company’s long-term potential.\nThe market continues to witness softness in Disney stock. Investors seemed disappointed in last quarter’s results, particularly regarding the addition of Disney+ subscribers.On the day after the earnings report, share price fell 7%.\nAt the same time, other investors have remained optimistic about the company. One such example is CNBC’s Jim Cramer, host of Mad Money, whoseesreasons to bet on DIS for the long term. Among them are (1) the company's new content investments, (2) the reopening of the parks and (3) the contrarian view in the face of so much negative sentiment.\nFigure 1: CNBC's Jim Cramer, host of Mad Money.\nNew content\nOne key criticism of Disney’s streaming business model are the high costs. The DTC (direct-to-consumer) approach entails large expenses with the production of exclusive content, which is arguably key in attracting and retaining the platform's subscribers.\nBut Cramer does not seem to view this as a problem, rather as a long-term investment that the market still misunderstands. Disney and peers like Netflix spend a large chunk of their operating income on content production, which often scares off investors and sends them to the exits. But after the content is available and it helps to drive new subscriptions, investors return to buy back the shares when the herd chooses to do the same.\nTherefore, by focusing on the short term and ignoring the long term, many investors continue to buy high and sell low – a recipe for disaster over time.\nTheme parks\nWith the reopening of Disney's parks, the company’s financial results should start to resemble those of the pre-pandemic period. Therefore, looking only at the new streaming segment is a bit narrow, as it still represents a small slice of Disney’s revenue – although probably the fastest growing over the long haul.\nWhat analysts say\nWhile many investors remain pessimistic about DIS, many investment banks continue to view the company's long-term growth potential as appealing. This is the case of Morgan Stanley, which reiterated its “overweight” rating of Disney:\n\n “We continue to believe its guidance is achievable, that with streaming scale comes substantial earnings power, and that success is not priced in.”\n\nOur view\nWe believe that Disney is still a major player in the so-called streaming wars, and one of the few that can effectively compete for market share with companies like Netflix and Amazon. Therefore, a smaller-than-expected addition of users in a single quarter, especially at an inflection point in the COVID-19 crisis, should not be extrapolated too far out into the future.\nIn our view, one must wait for a series of quarterly reports to understand how Disney+ may fare against its peers. Growth concerns should only come, if at all, after careful analysis of the longer-term trend.","news_type":1,"symbols_score_info":{"DIS":0.9}},"isVote":1,"tweetType":1,"viewCount":2112,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889762920,"gmtCreate":1631180128360,"gmtModify":1631890825358,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>waiting for report to be released tmr. Hang in there!&nbsp;[吃瓜]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>waiting for report to be released tmr. Hang in there!&nbsp;[吃瓜]&nbsp;","text":"$Tiger Brokers(TIGR)$waiting for report to be released tmr. Hang in there! [吃瓜]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889762920","isVote":1,"tweetType":1,"viewCount":977,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699454604,"gmtCreate":1639881638280,"gmtModify":1639881638376,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574086622886620","idStr":"3574086622886620"},"themes":[],"htmlText":"Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?","listText":"Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?","text":"Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699454604","repostId":"1109831591","repostType":4,"repost":{"id":"1109831591","kind":"news","pubTimestamp":1639804463,"share":"https://www.laohu8.com/m/news/1109831591?lang=zh_CN&edition=full","pubTime":"2021-12-18 13:14","market":"us","language":"en","title":"Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109831591","media":"Motley Fool","summary":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnso","content":"<p>What happened</p><p><blockquote>发生了什么</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>当日均跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的看法。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师Chris Shibutani周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性推荐。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司开发的Comirnaty冠状病毒疫苗取得了巨大成功，但涩谷对他认为辉瑞的未来有些阴云密布感到担忧<b>BioNTech</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对[辉瑞]的看法归结为，我们估计其当前估值的三分之一左右归因于COVID-19疫苗和治疗[产品]，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预言家认为该股的估值也相当合理。然而，他对公司的潜力持更为乐观的态度。</blockquote></p><p> \"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着[强生]正处于组织多个领域的转型之中……我们看到了可能性——即使是在[强生]规模和范围的组织内——开发更多潜在的颠覆性机会在我们看来，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p><p><blockquote>Shibutani对辉瑞股票的目标价为每股51美元，强生公司的目标价为每股161美元。</blockquote></p><p> Now what</p><p><blockquote>现在怎么办</blockquote></p><p> Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞和强生公司无疑正在进入一些不确定的水域——无论是冠状病毒，还是后者公司显然迫在眉睫的分拆。不过，在我看来，这两家公司在各自疫苗之外的众多产品领域都拥有雄厚的实力，因此投资者不应因高盛的最新评估而过于气馁。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-18 13:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>What happened</p><p><blockquote>发生了什么</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>当日均跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的看法。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师Chris Shibutani周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性推荐。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司开发的Comirnaty冠状病毒疫苗取得了巨大成功，但涩谷对他认为辉瑞的未来有些阴云密布感到担忧<b>BioNTech</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对[辉瑞]的看法归结为，我们估计其当前估值的三分之一左右归因于COVID-19疫苗和治疗[产品]，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预言家认为该股的估值也相当合理。然而，他对公司的潜力持更为乐观的态度。</blockquote></p><p> \"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着[强生]正处于组织多个领域的转型之中……我们看到了可能性——即使是在[强生]规模和范围的组织内——开发更多潜在的颠覆性机会在我们看来，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p><p><blockquote>Shibutani对辉瑞股票的目标价为每股51美元，强生公司的目标价为每股161美元。</blockquote></p><p> Now what</p><p><blockquote>现在怎么办</blockquote></p><p> Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞和强生公司无疑正在进入一些不确定的水域——无论是冠状病毒，还是后者公司显然迫在眉睫的分拆。不过，在我看来，这两家公司在各自疫苗之外的众多产品领域都拥有雄厚的实力，因此投资者不应因高盛的最新评估而过于气馁。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109831591","content_text":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnson & Johnson both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.\n\nSo what\nGoldman Sachs analyst Chris Shibutani initiated coverage on Pfizer and Johnson & Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.\nShibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech BioNTech.\n\"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.\nAs for Johnson & Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.\n\"With [Johnson & Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson & Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.\nLast month, Johnson & Johnson announced plans to spin off its sprawlingconsumer healthcare division.\nShibutani's price target on Pfizer stock is $51 per share, and that for Johnson & Johnson is $161.\nNow what\nPfizer and Johnson & Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.","news_type":1,"symbols_score_info":{"PFE":0.9,"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":3235,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}